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ABSTRACT 
Sun Hee Rim:  Ovarian Cancer Treatment Decisions: Accessing Gynecologic Oncology Care 
(Under the direction of Stephanie Wheeler) 
 
Ovarian cancer is the most fatal gynecologic malignancy and the fifth leading cause of 
cancer-related deaths among women in the U.S (USCS 2015).  The majority (>80%) of women 
is diagnosed at late stages (III or IV), often when the prognosis is poor and the 5-year survival 
rate is 37-45% (Howlader et al. 2015; USCS 2015).  Poor prognosis has been attributed to a lack 
of an early detection strategy, lack of access of specialist care, variations in surgical and 
chemotherapeutic treatment and patient variability in uptake, as well as healthcare systems 
characteristics that may contribute to variable quality of care and delays (Bristow et al. 2014b; 
Carney et al. 2002; Cliby et al. 2015; Thrall et al. 2011).  While earlier research efforts have 
shown treatment from a gynecologic oncologist (GO) to be associated with improved survival, 
studies have suggested that a substantial number of women with ovarian cancer still do not 
receive care from a GO at any point during their care (Vernooij et al. 2007).  Less is known 
about when women are accessing the care from a GO (i.e. preoperative/consult only, 
intraoperatively, postoperatively, or continuous involvement at all phases) and how accessing a 
GO at different phases of care (i.e. timing) impacts survival.  Furthermore, gaps still exist in the 
literature on the role of a patient’s psychosocial experience and voice in ovarian cancer care 
(Erwin 2010; Herzog et al. 2014).  The overall objective of this research was to understand the 
effect of timing of GO involvement on mortality (Aim 1 and 2) and explore the patient-level 
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preferences and roles around decision-making and decisional self-efficacy among women with 
ovarian cancer (Aim 3).  Through use of cancer registries supplemented with medical record 
abstraction (n=2,162) and survey data (n=170), this research examined different aspects around 
when and where ovarian cancer patients accessed a GO and among those largely seen by a GO, 
we explored patient-centered factors associated with having greater decisional efficacy and/or 
decisional support needs.  Based on our findings, differences in GO involvement were evident by 
patient age, race, and place of care.  The patient’s perception of a GO as the most important 
physician in treatment decisions about care did not affect decisional efficacy, but other 
psychosocial domains did.  Though our results likely reflects the confluence of clinical 
management processes, patient- and provider treatment preferences, and the complexities of the 
patient-provider clinical interaction that determine the extent of care, it underscores the 
importance of further examining equitable care delivery to all subgroups of women, particularly 
those whom may be vulnerable to decisional support needs.  We expect that our research 
findings will help future efforts to identify, understand, and implement interventions to improve 
receipt of continuous, quality care associated with increased survival and consistent with patient 
needs.     
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To Mom. 
Who lived with and died from ovarian cancer. 
You are always Young in our hearts. 
 
 
  
vi 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 Though my name solely appears on the cover of this dissertation work, there are many 
people to acknowledge and thank on this journey.  First, my committee members: I am indebted 
to your timely responses and in many cases, prioritization of me even through your holidays, 
vacations, maternity leave, surgeries, and countless other competing demands.  Without you, 
completion of this final product (and thus, this phase of my life) would not have been possible.  
Also to my professors and colleagues at the University of North Carolina at Chapel Hill, 
colleagues and collaborators at the University of Alabama at Birmingham, and the many 
individuals who worked on data collection that enabled me to analyze the data for research: I 
owe my sincerest appreciation and thanks.  To my esteemed mentors, colleagues, and friends at 
the Centers for Disease Control and Prevention:  I am infinitely grateful and honored for the 
support and guidance offered to me through the years.  I am privileged and blessed to know you.  
And last, but not least, to my family members and friends, whom have walked with me through 
many of life’s trials and joys and have never been short of encouragement and support: your 
devotion and love are as certain as anything I have ever known and I am so thankful for that.  
“Because you are my help…I sing” (Psalm 63:7).      
vii 
 
  
 
 
 
 
 
TABLE OF CONTENTS 
LIST OF TABLES ...........................................................................................................................x 
LIST OF FIGURES ...................................................................................................................... xii 
LIST OF ABBREVIATIONS ...................................................................................................... xiii 
CHAPTER 1:  INTRODUCTION ...................................................................................................1 
CHAPTER 2:  LITERATURE REVIEW ......................................................................................10 
     Burden of Ovarian Cancer ........................................................................................................13 
     Basic Epidemiology and Risk Factors ......................................................................................14 
     NCCN Treatment Guidelines and Standard of Care .................................................................15 
     Treatment Receipt from a Gynecologic Oncologist .................................................................17 
     Barriers to Treatment Receipt from a Gynecologic Oncologist and  
     the Role of Treatment Preferences for Women with Ovarian Cancer ......................................18 
     Age and Race Disparities in Incidence, Mortality, and 
     Treatment Receipt .....................................................................................................................20 
     Age and Race Disparities and Treatment Variation by Place of Care ......................................21 
CHAPTER 3:  STUDY DESIGN AND METHODS ....................................................................24 
     Overview and rationale .............................................................................................................24 
     Conceptual Model .....................................................................................................................25 
     Research Question and Hypotheses ..........................................................................................30 
     Data ...........................................................................................................................................31 
     Study population and criteria for inclusion ...............................................................................33 
     Variables and Measurement ......................................................................................................35 
viii 
 
             Dependent variables ..........................................................................................................35 
             Key independent variables ................................................................................................36 
             Covariates .........................................................................................................................37 
     Statistical Analysis by Aim .......................................................................................................38 
CHAPTER 4: PATIENT- AND HEALTHCARE SYSTEMS-LEVEL FACTORS 
ASSOCIATED WITH THE TIMING AND INVOLVEMENT OF GYNECOLOGIC 
ONCOLOGISTS IN PERIOPERATIVE OVARIAN CANCER CARE ......................................43 
     Overview ...................................................................................................................................43 
     Introduction ...............................................................................................................................45 
     Methods.....................................................................................................................................47 
     Results .......................................................................................................................................53 
     Discussion .................................................................................................................................55 
CHAPTER 5: ASSOCIATIONS OF TIMING AND INVOLVEMENT 
OF GYNECOLOGIC ONCOLOGISTS IN PERIOPERATIVE OVARIAN 
CANCER CARE WITH OVERAL SURVIVAL  .........................................................................69 
     Overview ...................................................................................................................................69 
     Introduction ...............................................................................................................................71 
     Methods.....................................................................................................................................73 
     Results .......................................................................................................................................77 
     Discussion .................................................................................................................................79 
CHAPTER 6:  TREATMENT DECISIONAL ROLE AND PSYCHOSOCIAL 
RESPONSE DURING AND AFTER AN OVARIAN CANCER DIAGNOSIS: 
A CDC-Funded Study on Research to Understand Treatment Choices in Ovarian 
Cancer ............................................................................................................................................90 
     Overview ...................................................................................................................................90 
     Introduction ...............................................................................................................................92 
     Methods.....................................................................................................................................95 
ix 
 
     Results .....................................................................................................................................104 
     Discussion ...............................................................................................................................107 
CHAPTER 7:  SUMMARY OF FINDINGS AND IMPLICATIONS FOR 
POLICY, PRACTICE, AND RESEARCH .................................................................................121 
     Summary of Findings and Implications for Policy, Practice, 
     and Research ...........................................................................................................................121 
     Future Research ......................................................................................................................130 
     Conclusion ..............................................................................................................................134 
APPENDIX 1: DISTRIBUTION OF PATIENT-LEVEL AND HEALTHCARE- 
LEVEL CHARACTERISTICS BY GYNECOLOGIC ONCOLOGIST 
INVOLVEMENT IN OVARIAN CANCER CARE ...................................................................137 
      
APPENDIX 2a: SURVIVAL PROBABILITIES OF WOMEN IN THE   
OVARIAN CANCER TREATMENT, SUBSPECIALIST CARE, AND  
OUTCOMES STUDY BY GYNECOLOGIC ONCOLOGIST INVOLVEMENT  
IN PERIOPERATIVE CARE ......................................................................................................139 
      
APPENDIX 2b: SURVIVAL PROBABILITIES OF WOMEN IN THE 
OVARIAN CANCER TREATMENT, SUBSPECIALIST CARE, AND 
OUTCOMES STUDY BY GYNECOLOGIC ONCOLOGIST INVOLVEMENT   
IN PERIOPERATIVE CARE AND BY CARE AT NCI vs. NON-NCI- 
DESIGNATED CANCER CENTERS ........................................................................................139 
APPENDIX 3: DESCRIPTIVE STATISTICS OF THE ANALYTIC SAMPLE 
OF WOMEN IN THE OVARIAN CANCER TREATMENT, SUBSPECIALIST 
CARE, AND OUTCOMES STUDY BY GYNECOLOGIC ONCOLOGIST 
INVOLVEMENT ........................................................................................................................140 
APPENDIX 4: FREQUENCY OF RUTH SURVEY ITEM-LEVEL RESPONSE 
FOR SOCIAL SUPPORT AND DECISIONAL PERCEIVED SELF-EFFICACY ...................142 
APPENDIX 5: 1- to 4- FACTOR ANALYSIS OF RUTH WORRY SCALE ITEMS ...............144 
APPENDIX 6: MULTIVARIABLE LOGISTIC REGRESSION OF PATIENT- 
LEVEL WORRIES DURING CANCER TREATMENT DECISION-MAKING  
REPORTING AVERAGE MARGINAL (OR DIFFERENTIAL) EFFECTS ............................145  
APPENDIX 7:  SELECTED RUTH SURVEY ITEMS (Aim 3)  ...............................................146 
REFERENCES ............................................................................................................................151  
x 
 
LIST OF TABLES 
Table 
     1:  Outcome Variables and Measures .......................................................................................35 
     2:  Independent Variables and Measures for Aim 1, Aim 2, Aim 3 .........................................37 
     3:  Descriptive Statistics of Ovarian Cancer Disease in the Cancer 
          Registry Sample ...................................................................................................................62 
     4:  Characteristics of Women Treated by a Gynecologic Oncologist .......................................64 
     5a: Logistic Regression Model of Gynecologic Oncologist Involvement 
           in Ovarian Cancer Care Among Women in the Cancer Registry Sample ..........................65 
     5b: Predictive Probability of Ever Receiving GO Care by Race- and 
           and NCI-designated Cancer Center Interaction ..................................................................66 
     6a: Multinomial Logistic Regression Model on Timing of Involvement 
           Among Women Who Had Seen a Gynecologic Oncologist ...............................................67 
     6b: Predictive Probability of Race- and NCI-designated Cancer Center 
           Interaction and GO Timing .................................................................................................68 
     7:  Descriptive Statistics of the Analytic Sample of Women in the Ovarian 
           Cancer Treatment, Subspecialist Care, and Outcomes Study (n=2,137) ............................85 
     8:  Kaplan-Meir Median (unadjusted) Time (in days) from Diagnosis to 
           Death by Individual Subgroups ..........................................................................................87 
     9a: Cox Proportional Hazard Model Regression Results of Time from 
           Diagnosis to Death Among Women in the Ovarian Cancer Treatment, 
           Subspecialist Care, and Outcomes Study............................................................................88 
     9b: Cox Proportional Hazard Model Regression Results of Time from 
           Diagnosis to Death Among Women in the Ovarian Cancer Treatment, 
           Subspecialist Care, and Outcomes Study–Interaction of Race and 
           Place of Care (NCI-designated Cancer Center) ..................................................................89 
     10:  Characteristics of Women in the RUTH Sample .............................................................115 
     11a: Unadjusted Frequencies of Decisional Role by Race .....................................................117 
     11b: Decisional Regret by Race, Adjusting for Age, Stage, and Comorbidities ....................117 
xi 
 
     12:  Unadjusted Mean and Adjusted Marginal (or Differential) Effects from 
           Multivariable Linear Regression of RUTH Participants’ Perceived Self-Efficacy ..........118 
     13:  Unadjusted Mean and Adjusted Marginal (or Differential) Effects from 
           Multivariable Linear Regression of Patient Worries 
           During Cancer Treatment Decision-Making ....................................................................119 
 
 
 
  
xii 
 
LIST OF FIGURES 
Figure 
     1:  U.S. Cancer Statistics Top 10 Cancer Sites: 2011, Female, United States ..........................12 
     2:  Opportunities to Optimize Cancer Care Across the Cancer Care Continuum .....................12 
     3a: Estimates of the National Expenditure for Cancer Care in the U.S. in  
           2010 (in billions of dollars) by Cancer Site and Phase of Care ..........................................13 
     3b: Estimates of the Proportion of National Expenditures for Cancer Care  
           in the U.S. in 2010 (in billions) by Cancer Site and Phase of Care ....................................13 
     4:  Conceptual Model for Assessing Quality: Health Care Structure,  
           Process of GO Care, and Survival Outcome for Aims 1 and 2 ...........................................27 
     5:  Conceptual Model of Transactional Model of Stress and Coping  
           Constructs for Aim 3 ...........................................................................................................29 
 
 
 
  
xiii 
 
LIST OF ABBREVIATIONS 
CA-125 Cancer antigen – 125 
CanCORS Cancer Care Outcomes Research and Surveillance Consortium 
CDC  Centers for Disease Control and Prevention 
CI  Confidence Interval 
FIGO  International Federation of Gynecology and Obstetrics 
GA  Georgia 
GO  Gynecologic Oncologist 
HR  Hazard Ratio 
ICD  International Classification of Diseases for Oncology 
IRB  Institutional Review Board 
NCCN  National Comprehensive Cancer Network 
NCI             National Cancer Institute 
NOS  Not Otherwise Specified 
OR  Odds Ratio 
RUTH  Research to Understand Treatment Choices in Ovarian Cancer  
SC  South Carolina 
SEER  Surveillance Epidemiology and End Results  
SGO  Society for Gynecologic Oncology 
SOC  Standard of Care 
UAB  University of Alabama at Birmingham 
UNC  University of North Carolina at Chapel Hill   
1 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1:  INTRODUCTION 
Ovarian cancer is the leading cause of death among gynecologic cancers (USCS 2015).  
Three out of four ovarian cancer diagnoses occur at late (regional & distant) stages, generally 
when the clinical prognosis is poor and the 5-year survival rate is approximately 30% (Howlader 
et al. 2015). Without an adequate early detection strategy, ensuring that women receive 
appropriate treatment (concordant with standard of care) and treatment from a gynecologic 
oncologist (GO) are the only known interventions that have been shown to improve survival 
from ovarian cancer.  As such, the National Comprehensive Cancer Network (NCCN) 
recommends that all women undergo clinical evaluation prior to chemotherapy and surgical 
treatment by a GO (NCCN 2014).       
Women with suspected ovarian cancer—based on a palpable pelvic mass or recognition 
of symptoms (such as abdominal pain, early satiety, urinary symptoms, etc. (Ryerson et al. 
2007))—receive a workup that includes an ultrasound and a blood test for tumor marker CA-125; 
however ovarian cancer is mainly a surgically staged and surgically treated disease (Goff et al. 
2006; NCCN 2014).  The prognosis is generally dependent on the histologic type and operative 
extent of the tumor.  Current standard of care treatment approaches for women with advanced 
ovarian cancers include both surgery (to assess the extent of disease and attain maximal 
cytoreduction/minimal residual tumor) and chemotherapy (NCCN 2014).  Important prognostic 
indicators include optimal surgical cytoreduction (residual tumor of less than 1cm in maximum 
diameter or thickness) and as prior studies have shown, receipt of treatment from a gynecologic 
oncologist (Chan et al. 2007b; du Bois et al. 2005; Earle et al. 2006; NCCN 2014; Vergote et al. 
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2011).  Women who received care from a gynecologic oncologist were more frequently (58-
60%) appropriately staged compared to those staged by general surgeons and tended to have 
better survival outcomes (Chan et al. 2007b; Earle et al. 2006; Goff et al. 2006; Vergote et al. 
2011).  Prior studies have also shown that women who received surgical treatment from a GO 
had lower rates of recurrences after comprehensive surgical staging (Le et al. 2002) and 
improved median survival associated with cytoreduction (Hunter, Alexander, and Soutter 1992).  
In a recent study of women diagnosed with ovarian cancer in the Medicare population, those who 
“ever” obtained surgery from a GO had approximately 2.35 times the odds of receiving the 
surgical standard of care and 1.25 times the odds of receiving chemotherapeutic standard of care 
than women who obtained treatment from a non-GO (p < 0.01) (Rim, et al in press).  Women 
who had ever received surgical treatment from a GO had a statistically significant lower risk of 
dying from ovarian cancer, even after controlling for age, race, comorbidities, and receipt of 
surgical standard of care (Rim, et al in press).    
Given the surgical expertise and skilled comprehensive management that fellowship-
trained GOs offer, continuous care from a GO has been suggested to be important for women 
with ovarian cancer.  Thus, the 2014 NCCN Clinical Practice Guidelines for women with ovarian 
cancer recommend that GOs provide the primary assessment, debulking surgery (also known as 
cytoreductive surgery where the goal is to leave no tumor nodule behind that measures more than 
one centimeter), and follow-up care (NCCN 2014).  While earlier studies acknowledge that 
gynecologic oncologist involvement is associated with improved outcomes, the timing and extent 
of involvement and its relationship on positive outcomes has not been well-examined.  Within 
the literature on treatment receipt from a GO, little is known about what proportion of women at 
the population-level are accessing GO care preoperatively/consult only, intraoperatively, 
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postoperatively, or continuously at all phases and whether GO involvement at different phases of 
care (i.e. timing) impacts survival.  And though the NCCN and Society of Gynecologic 
Oncology (SGO) recommend the early involvement of subspecialist care in consult and surgery, 
the specific timing of involvement has not been rigorously examined as a quality process 
measure associated with improved survival.   
Despite the noted benefits and recommendations to seek treatment from a GO, only an 
estimated 30-40% of women with ovarian cancer are treated by a GO (Vernooij et al. 2007).  
There is a dearth of information on why women with ovarian cancer do not receive care from a 
GO at any point during their care.  Though some studies have suggested the lack of access to be 
related to the availability of GOs across the U.S. (Stewart, Rim, and Richards 2011), the 
decisions for accessing skilled subspecialist care and receiving guideline-based treatment are 
likely to be more complex, as these decisions involve the underlying patient-level condition as 
well as the socio-behavioral-environmental factors that may affect healthcare utilization and 
treatment receipt.  Improving survival from ovarian cancer is critically dependent on the 
interplay of both patient characteristics (including demographic, tumor biology, early recognition 
of symptoms, and psychosocial treatment-seeking behavior) as well as healthcare system factors 
(i.e. type of hospital—National Cancer Institute designed, teaching facility, etc.—or high-volume 
hospitals), provider-level factors (i.e. high-volume physicians), and measures of the quality of 
treatment received (e.g. surgical and chemotherapeutic standard of care) (Bristow et al. 2014a; 
Bristow et al. 2014b; Bristow et al. 2010; Bristow et al. 2009; Chan et al. 2008; Earle et al. 2006; 
Mercado et al. 2010). These simultaneous influences of patient-level conditions, including 
barriers/promoters for accessing care and factors that affect decision-making, are thought to 
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account for the variation in treatment patterns and subsequently, the survival differences in this 
population and across different subgroups of ovarian cancer patients (Shavers and Brown 2002).   
For ovarian cancer patients, the majority of whom are diagnosed at advanced stages, the 
period occuring prior to and post-surgical treatment (i.e. the perioperative period) can be critical.  
Having timely, continuous, quality care during this time period can be important not only in 
terms of improving survival, but also the patients’ psychosocial needs and well-being, which is 
an endpoint of comparable significance in delivering quality care.   
The central objective of this dissertation was two-fold.  First, the objective was to 
understand the impact of perioperative timing and continuity of GO involvement on mortality 
outcomes and second, to explore patient-level perspectives on treatment decision-making during 
the perioperative period and the impact that a GO and other psychosocial factors have on 
decisional self-efficacy and worries during treatment.   
The specific aims included:  
Aim 1: Examine the association between patient- (i.e. age, race/ethnicity) and healthcare 
systems- level characteristics (i.e. NCI designation, teaching hospital status) with the 
timing and involvement of gynecologic oncologists a) preoperative/consult only, b) 
intraoperatively/postoperatively only, c) at all phases (e.g. preoperative/consult, 
intraoperatively, and postoperatively) and d) no involvement. 
Aim 2: Examine the associations of timing and involvement of gynecologic oncologists 
with overall survival.  
a. Examine variations in timing and involvement of GO and survival by race and 
healthcare facility where care was received (i.e. NCI-designated cancer center 
vs. non-NCI-designated cancer center). 
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Aim 3: Explore ovarian cancer patient-level beliefs and psychosocial concerns during 
perioperative treatment decision-making, perspectives of GO involvement, and factors 
associated with decisional self-efficacy during perioperative care to identify women with 
potential decisional support needs for survivorship care.   
Data for Aims 1 and 2 of the dissertation was from the Ovarian Cancer Treatment, 
Subspecialist Care, and Outcomes Study, a follow-up study to the initial patterns of care study 
(2001) funded by the Centers for Disease Control and Prevention (CDC) through the National 
Program of Cancer Registries’ unique collaboration with individual state population-based 
cancer registries (http://www.cdc.gov/cancer/npcr/research/poc_studies/index.htm).   The 
Ovarian Cancer Treatment, Subspecialist Care, and Outcomes Study is the most recent of the 
series of specially-funded studies and was conducted by the South Carolina and Georgia Cancer 
Registries.  Retrospective medical record abstraction was completed for approximately 2,162 
incident ovarian cancer cases within the South Carolina and Georgia cancer registry.  Briefly, the 
analytic approach for Aim 1 included binary and multinomial logistic reression models with 
dependent variables defined in two ways as categorically distinct and temporally ordered phase 
of care.  Key independent variables included patient- (i.e. age, race/ethnicity) and healthcare- 
systems (i.e. NCI-designated cancer center) characteristics.  For Aim 2, the methodologic 
approach included Cox proportional hazard models controlling for demographic and tumor 
characteristics, comorbidities, and healthcare systems characteristics.  The dependent variable 
was a count from date of diagnosis to death from any underlying cause.  In addition to the key 
independent variables examined in Aim 1, GO timing was included as a key independent 
variable in Aim 2.     
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Findings from Aims 1 and Aim 2 indicated that younger women and women seen at an 
NCI-designated cancer center were more likely to see a GO.  Younger women had statistically 
significantly greater odds of having a GO involved in intra/postoperative care and all phases of 
care.  While White/non-White women differentially saw a GO within NCI-designated cancer 
centers—with White women seen at an NCI-designated cancer center more likely to receive 
intra/post operative care than non-White women—no statistically significant difference was 
observed by race among non-NCI-designated cancer centers.  Overall, three-year survival 
probabilities were best observed among women receiving GO care at all phases at NCI-
designated cancer centers.  Among White women, those seen at NCI-designated cancer centers 
had better survival outcomes.  Poorer outcomes were observed among those with advancing age, 
stage, and greater comorbidities.       
Data for Aim 3 of the dissertation was from the Research to Understand Treatment 
Choices in Ovarian Cancer (RUTH) Study, a Centers for Disease Control and Prevention’s 
Cooperative Agreement (Special Interest Project #11-42) with the University of Alabama at 
Birmingham (UAB).  This study included patient surveys collected from approximately 170 
ovarian cancer patients to explore the domains (e.g. patient’s choice, access, beliefs about 
treatment and doctor) that may contribute to a patient’s treatment decision-making, receipt of 
treatment from a gynecologic oncologist, and quality of life during and after the cancer 
diagnosis. 
The analytic approach for Aim 3 included both descriptive and analytic statistics.  
Summary statistics were used to characterize the sample and also provide some context for the 
patient-level perspectives of GO involvement, their beliefs about what the doctor’s role would be 
in treatment and decision-making.  Linear regression (univariate and multivariate) were used to 
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examine the associations between key demographic, clinical, and psychosocial factors on 
perceived self-efficacy and worry scores.  The decisional self-efficacy dependent variable was 
computed by summing item scores and then linearly transforming on a 0-100 scale, per user’s 
manual (higher scores indicating greater self-efficacy) (O'Connor 1995).  Similarly, composite 
scores for worry were calculated to a range of 0 to 36, with higher scores indicating greater 
worry.  Due to concerns for heteroscedasticity, the final modeling approach used was a feasible 
generalized least square model.      
Findings from Aim 3 indicated that a high proportion of women received surgical and 
chemotherapeutic care from a GO.  However, in general, women were not aware of the GO 
specialty of their doctors.  Our results suggested an apparent disconnect in women knowing that 
they saw/received care from a GO.  Treating physician specialty had no significant effect on a 
patient’s decisional self-efficacy and cancer worries during/after treatment.  Furthermore, most 
women had high confidence in their ability to get the facts about their treatment choices, ask 
questions, and figure out choices that best suited them.  Yet, subgroups of African American 
women and older aged women had an expected decisional self-efficacy score that was lower than 
their respective White and younger aged counterparts.  Our findings highlighted a clear need for 
and opportunity to educate patients and improve patient experience and supportive needs during 
treatment/perioperative period.     
While there has been moderate improvement in treatment and survival over the past three 
decades (Barnholtz-Sloan et al. 2002), there are still significant gaps in knowledge regarding 
disparities in treatment, outcome, and patient-level factors that affect care (Erwin 2010).  This 
research advanced previous research with two important contributions.  First, this dissertation 
provided insight on the impact of the timing and extent of gynecologic oncology care.  The 
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findings underscored the importance of GO subspecialty in delivering quality ovarian cancer care 
and healthcare system characteristics (i.e. where patient care is received) as relevant to survival.  
Second, the research provided important patient-level psychosocial and behavioral domains in 
treatment-relevant decision-making that offer avenues for improving the delivery of patient-
centered ovarian cancer care.   
This dissertation research was timely under the current transformations in the healthcare 
system.  As a result of the U.S. Patient Protection and Affordable Care Act (HR3590), there have 
been renewed interest in and the prioritization of the “triple aims” of improving quality, reducing 
costs, and enhancing the patient and provider experience (Peikes et al.).  With these changes in 
health policy, the goals of healthcare have shifted towards delivering person-centered, team-
based, coordinated care (Peikes et al.).  These goals complement the Institute of Medicine 
(IOM)’s aim of providing high-quality health care: effective, safe, timely, efficient, equitable, 
and patient-centered (Medicine 2001).  Not only does this research have implications for 
improving quality, but it also has broader implications for cancer survivorship and the process of 
care as potential intervention points across the cancer care continuum (Figure 2) (Fennell et al. 
2010).   
No studies to date have attempted to examine the timing of access to GO specialist care 
for ovarian cancer.  The results of this study provides important information on the predictors of 
how patients access the care (for example, timing and extent of the GO care) (Aim 1) and the 
effect of this timing on survival (Aim 2); lastly, it identifies important psychosocial domains 
among women receiving treatment for ovarian cancer.  It is a national priority research area 
under the Patient Protection and Affordable Care Act of 2010 to understand how to improve 
quality of care and survival while examining patient concerns to making informed decisions 
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about cancer treatment options.  It is also a recommended research priority as defined by the 
Institute of Medicine’s Committee on the State of the Science in Ovarian Cancer Research (IOM 
2016).  The goals of the research are consistent with national initiatives and efforts to prioritize 
patient-centered outcomes research and registry-supplemented studies that will help translate 
research into practical and effective public health prevention strategies. 
In the subsequent chapters of this dissertation, Chapter 2 provides background literature 
on ovarian cancer, current treatment guidelines and standard of care (including treatment receipt 
from a GO), disparities in treatment and survival, and the potential role of patient-level attributes 
in decision-making and preferences for care among women with ovarian cancer.  Chapter 3 
provides an overview of the methods including the study design, data sources, research question, 
hypothesis, and analytic approach.  Chapters 4 – 6 correspond respectively to Aims 1 – 3, and are 
intended for submission for peer-reviewed publication.  Lastly, Chapter 7 summarizes the 
findings and implications for policy, practice, and future research.  References are provided in a 
complete bibliography at the conclusion of the dissertation.    
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CHAPTER 2:  LITERATURE REVIEW 
Overview 
More women die of ovarian cancer than any other gynecologic cancer (USCS 2015). 
Each year in the U.S., over 20,000 women are newly diagnosed and nearly 15,000 die from the 
disease (USCS 2015).  Ovarian cancer is the eighth most commonly diagnosed cancer and the 
fifth leading cause of death among all cancers that affect women (Figure 1) (USCS 2015).  In 
2012, the year for which the most recent data are available, the incidence rate of ovarian cancer 
was 11.3 per 100,000 women and the mortality rate was 7.4 per 100,000 (USCS 2015).  All 
women, regardless of age or race/ethnicity, are at risk of getting the disease.  The mean age at 
diagnosis is 63 years; and the risk of disease increases with advancing age (Howlader et al. 
2015).  Risk factors also include family history, or personal history of endometrial, colon, breast, 
or ovarian cancer which may be related to a genetic predisposition (e.g. through mutations in the 
BRCA 1 and BRCA2 genes or other familial conditions such as hereditary non-polyposis 
colorectal cancer or hereditary breast and ovarian cancer syndrome) (Hankinson and Danforth 
2006; Hennessy, Coleman, and Markman 2009).  Although oral contraceptive use is a recognized 
chemo-preventive agent, evidence on primary prevention strategies is otherwise limited for 
average risk women (Havrilesky 2013).  There are several hypotheses on the etiology and 
pathogenesis of ovarian cancer (Hankinson and Danforth 2006), but the cause is unknown.   
Over the last three decades, women with advanced stage ovarian cancer have experienced 
only a two-year improvement in the median overall survival (Herzog et al. 2014; Howlader et al. 
2015).  While marginal improvements in short-term survival might be attributed to progress in 
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surgical and perioperative management (Herzog et al. 2014), there is a clear need for improved 
therapeutic approaches and interventions, as long-term survival has not significantly changed 
over time.  At present, with the shortcomings in primary prevention and screening (Jacobs et al. 
2015), the focus for improving ovarian cancer prognoses continues to lie in understanding how 
to increase early diagnosis of ovarian cancer and provide quality perioperative care (pre-, intra-, 
and post-operatively) from a GO following diagnosis and during the tertiary care stages of the 
disease. Much of the care happens at the later stages on the cancer care continuum (Figure 2).   
While identifying ways of prolonging survival are important, addressing preference-
sensitive components of the care process, to stop/continue treatment, palliate disease-related 
symptoms, and maintain/improve quality of life are also critical (Havrilesky et al. 2014).  This is 
particularly relevant for women with ovarian cancer as the psychosocial burden of disease is 
high.  Given that women with an ovarian cancer diagnosis face a high mortality rate and/or high 
risk of recurrence (du Bois et al. 2003; Havrilesky et al. 2014; Lowery et al. 2013), the threat of 
an early death and/or the fear of recurrence are potential realities.  The actual and perceived 
barriers for accessing care and a woman’s cognitive preferences can influence decisions to seek 
care and receive treatment (Thewes et al. 2012).  Specifically, for the 20% of ovarian cancer 
patients with platinum-resistant disease (defined according to the time-to-recurrence as within 6 
months of receiving platinum-based therapy), treatment preferences often involve careful 
consideration on an individual-basis with consideration as to the extent and severity of the 
disease and the patient’s tolerance to treatment side-effects, drug toxicity, and management of 
disease-related symptoms (Jelovac and Armstrong 2011; Pfisterer and Ledermann 2006).  
Understanding patient-level preferences and psychological factors in treatment decisions are thus 
important areas for further exploration.      
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Figure 1. U.S. Cancer Statistics Top 10 Cancer Sites: 2012, Female, United States
 
Source:  http://www.cdc.gov/cancer/npcr/. Age-adjusted Invasive Cancer Incidence and 
Mortality Rates for the Ten Primary Sites. Rates are per 100,000 persons and are age-adjusted to 
the 2000 U.S. Standard Population. 
 
Figure 2.  Opportunities to Optimize Cancer Care Across the Cancer Care Continuum 
Reprinted from Taplin, et al. 2012. Journal of the National Cancer Institute. Monographs 
2012(44): 2-10. 
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Burden of Ovarian Cancer 
 
Ovarian cancer is a disease of high economic and social burden.  The estimated national 
cost of ovarian cancer care was approximately $5 billion (Mariotto et al. 2011).  Ovarian cancer 
ranks 7th highest among estimates of national cancer-related expenditures.  Unlike most other 
cancers which follow in a pattern of a “u-shaped” curve with higher costs generally at the 
beginning and end of life, (Yabroff et al. 2011) the proportion of national cancer care 
expenditures for ovarian cancer is relatively equi-distributed at all phases of care (See Figure 3a 
and 3a) (Mariotto et al. 2011; Yabroff et al. 2011).  Indirect costs such as patient morbidity costs 
and lost productivity from premature deaths are also high.  The literature on the psychosocial 
domains of ovarian cancer survivors suggest that many of these women fear recurrence, 
death/dying, experience concerns about spirituality/hopelessness, and symptoms/toxicity (Roland 
et al. 2013).  However, there is likely to be other unexplored psychosocial domains that may be 
important factors contributing to the decisions about treatment choices in this population.  
Examining the cancer care continuum and identifying potential clinical and patient-level 
strategies for addressing the disease burden, while maintaining quality, can be an important 
contribution to guideline-issuing organizations, practitioners, or policy-makers (Taplin et al. 
2012). 
 
Figure 3a and 3b  - Reprinted from Yabroff, K. R., J. Lund, D. Kepka, and A. Mariotto. 2011. 
Cancer Epidemiology, Biomarkers and Prevention 20(10): 2006-14. 
 
a.  Estimates of the National Expenditures for Cancer Care in the U.S. in 2010 (in billions 
of dollars) by Cancer Site and Phase of Care 
b. Estimates of the Proportion of National Expenditures for Cancer Care in the U.S. in 2010 
(in billions) by Cancer Site and Phase of Care 
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Basic Epidemiology and Risk Factors 
 
Long-term (> 5-year) survival is expected in less than 20% of ovarian cancers patients 
(Herzog et al. 2014; Howlader et al. 2015; USCS 2015).  At localized stage disease, ovarian 
cancer patients have a 5-year survival rate of 92%, however only about 15% of new cases are 
diagnosed with localized disease (Howlader et al. 2015).  The majority (>80%) of women treated 
for ovarian cancer are diagnosed at regional or distant stage disease when the prognosis is poorer 
and the relative 5-year survival rate decreases markedly from 71% and 30% for regional and 
distant stage disease, respectively (Howlader et al. 2015).   
Ovarian cancer is a heterogeneous disease that consists of many different histologic 
types, which have been shown to have important prognostic significance (DiSaia and Creasman 
2007). Ovarian tumors largely fall into two main categories: epithelial and non-epithelial tumors.  
Epithelial tumors (serous, mucinous, endometrioid, and clear-cell being the most common) 
account for most (90%) of the incident cases, and much of ovarian cancer research is focused on 
this tumor type, likely given the high incidence with which they occur.  Non-epithelial cancers, 
such as germ cell and sex-cord stromal tumors, represent a fairly small proportion of ovarian 
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cancer cases but have been shown to have much better prognoses (DiSaia and Creasman 2007).  
Non-epithelial cancers have 5-year survival rates of up to 90% (DiSaia and Creasman 2007). 
There are a number of other factors that differentiate epithelial vs. non-epithelial ovarian 
cancers.  First, the anatomic structures from which the tumors presumably originate are different 
(DiSaia and Creasman 2007).  Epithelial tumors are histologically similar to the mesothelium, or 
the epithelium that lines the interior of pelvic and abdominal cavities, from which they may share 
a common origin (DiSaia and Creasman 2007; Hankinson and Danforth 2006).  Sex cord-stromal 
tumors, such as granulosa, theca cells, Sertoli and Leydig tumors, are thought to originate from 
ovarian stromal and support cells (DiSaia and Creasman 2007).  Germ cell tumors arise from the 
pathogenetic transformation of ovarian germ cells, and include dysgerminomas, embryonal 
carcinomas, choriocarcinomas, yolk sac tumors, and teratomas (DiSaia and Creasman 2007).  
Second, while epithelial tumors most often occur in post-menopausal women, non-epithelial 
tumors (both ovarian sex cord-stromal and germ cell tumors) tend to happen at a younger age at 
diagnosis (DiSaia and Creasman 2007; Hankinson and Danforth 2006).  As such, women with 
non-epithelial cancers are likely to have differing patterns of care (as different tumor histologies 
respond differently to standard therapy and treatment regimens) and concerns about treatment 
(e.g. fertility sparing concerns).      
 
National Comprehensive Cancer Network (NCCN) Treatment Guidelines and Standard of 
Care  
Surgery is integral to the initial management, staging, and treatment for ovarian cancer. 
Treatment guidelines differ by tumor histology (NCCN 2014).  However, for women with 
epithelial or non-epithelial tumors (who do not wish to preserve fertility), initial surgery with 
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comprehensive staging is recommended.  Since most incident ovarian cancer cases are epithelial 
(90%), the standard initial treatment in most cases is optimal tumor debulking (including total 
hysterectomy and bilateral salpingo-oophorectomy, with residual disease less than 1cm in 
diameter or thickness) and six cycles of chemotherapy administration with carboplatin and 
paclitaxel (Hennessy et al. 2009; NCCN 2014; Stewart et al. 2011). Surgical management 
options, however, can depend upon several factors including patient and tumor characteristics, 
histologic type, extent of disease, and the overall patient condition to ensure appropriate 
treatment and optimized survival (Morgan et al. 2008).  Although most women benefit from 
first-line therapy (~ 80%), ovarian cancer survivors have a high probability of experiencing a 
recurrence.  Second-line therapies may improve quality of life and prolong survival, but can be 
individually-based on several patient-level factors and considerations (Havrilesky et al. 2014; 
Morgan et al. 2008; Stewart et al. 2011). 
According to the NCCN guidelines (NCCN 2014), “it is recommended that a gynecologic 
oncologist perform the appropriate surgery.”  Standard recommendations also involves a patient 
evaluation by a gynecologic oncologist before initiating surgery and chemotherapy, particularly 
if the patient is under consideration for neoadjuvant chemotherapy (NCCN 2014).  Per 
recommendation, a gynecologic oncologist should evaluate these patients before they are 
considered to be a “poor surgical candidate”  (NCCN 2014).  Additionally, after primary 
treatment (e.g. surgery/6 cycles of chemotherapy), recommendations call for patient follow-up, 
clinical re-evaluation, and monitoring (NCCN 2014). 
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Treatment Receipt from a Gynecologic Oncologist  
Gynecologic oncologists (GOs) are skilled surgeons who are trained to provide 
comprehensive care management from diagnosis, to surgery, prescribing appropriate 
chemotherapy, through survivorship and palliative/end-of-life care (Society for Gynecologic 
Oncology White Paper, 2013) (Minig, Padilla-Iserte, and Zorrero 2015; Stewart et al. 2011).  
Their training equips them to serve as the physician who coordinates all aspects of a woman’s 
care and recovery from ovarian cancer and “minimize hazards related to undertreatment (failure 
to cancer control) and overtreatment (avoidable expenses and complications)” (SGO 2000). 
Numerous studies have demonstrated that women with ovarian cancer treated by GOs have 
better clinical outcomes than those who are not (Chan et al. 2007b; Cliby et al. 2015; Earle et al. 
2006; Vergote et al. 2011).  This is largely due to the fact that patients operated on by a GO tend 
to more often receive optimal debulking or better rates of complete removal of disease (du Bois 
et al. 2005; Vernooij et al. 2007).  Furthermore, prior studies have shown that patients treated by 
a GO had nearly four times the probability of receiving all recommended surgical staging 
procedures than those who were not (Cress et al. 2011).  Additionally, clinical procedures, such 
as lymph node dissection for stage I patients and debulking surgery, were performed more often 
by GOs than by gynecologists or general surgeons (Earle et al. 2006; Goff et al. 2006; Stewart et 
al. 2011).  Lastly, ovarian cancer patients seen by a GO had more often received standard 
chemotherapy than those not treated by a GO (Chan et al. 2008).  It has been suggested that the 
guideline-based subspecialty care that ovarian cancer patients receive from a GO could translate 
into a 6–10-month median survival advantage for women with this disease (du Bois et al. 2009; 
Giede et al. 2005; Minig et al. 2015). 
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The current guidance from the American College of Obstetricians and Gynecologists, the 
Society of Gynecologic Oncologists, the National Comprehensive Cancer Network as well as the 
U.S. Centers for Disease Control and Prevention (CDC) and National Institutes of Health is such 
that women with ovarian cancer are suggested to obtain treatment from a GO (ACOG 2011; 
NCCN 2014). 
 
Barriers to Treatment Receipt from a Gynecologic Oncologist and the Role of Treatment 
Preferences for Women with Ovarian Cancer 
Despite the noted benefits, a SEER-Medicare study (2000-2002) of ovarian cancer 
patients showed that only an estimated 42% of women accessed a GO at any time during their 
care (Austin et al. 2013).  Furthermore, use of GO varied by demographic subgroups—with 
African American women among the lowest to access GO specialists at any point; and use of GO 
services also differed by phase of care (51% during the 12 months after diagnosis, 29% during 
the last 12 months of life, and 42% during the time in between) (Austin et al. 2013).  In addition 
to the low utilization of GOs, several SEER-Medicare or large population-based studies have 
also examined the surgical and/or chemotherapeutic treatment patterns among ovarian cancer 
patients (Cress et al. 2003; Du et al. 2008; Earle et al. 2006; Fairfield et al. 2010; Goff et al. 
2006; Harlan, Clegg, and Trimble 2003; Howell et al. 2013; Jordan et al. 2013; Thrall et al. 
2011); these findings also note the underuse of cancer-directed surgeries and the variable receipt 
of chemotherapy and combined surgical and chemotherapy care.   
While patient knowledge about GO specialty care and availability of GO are suspected to 
be likely barriers to accessing GOs/treatment (Austin et al. 2013; Fairfield et al. 2010; Stewart et 
al. 2014), for some women there is a potential role for patient preference in choosing to care.  
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For example, although there is little existing information on ovarian cancer treatment-seeking 
behaviors (and how it may differ by different subgroups), research among breast cancer patients 
has speculated that older patients may have differing treatment decisions that affect some aspects 
of their care, including chemotherapy treatment receipt (Siminoff et al. 2000).  In a study among 
approximately 900 older women with newly diagnosed breast cancer (Mandelblatt et al. 2010), 
women who “very much” believed that by having chemotherapy, cancer was “less likely to come 
back” more commonly received chemotherapy; and similarly, women who “very much” believed 
that the “adverse effects of chemotherapy [were] worse than the disease,” less frequently 
received chemotherapy.  In the same study, women who indicated that they would “prefer” 
chemotherapy, even for the smallest gain (i.e. one week) in life, had 3.9 times the odds of 
receiving chemotherapy, adjusting for other covariates (Mandelblatt et al. 2010).  
The patient voice is important in understanding the variations in surgical and 
chemotherapeutic treatment receipt, care delivery, and subsequent mortality from cancer.  The 
literature on cancer disparities and utilization of healthcare services (e.g. screening and 
treatment) has highlighted several patient-level concerns including cost/inability to afford out-of-
pocket co-payments, lack of transportation, barriers to time off from work, beliefs on the 
effectiveness of the screening/treatment, and having a fatalistic view (that nothing can be done to 
prevent what will happen) that can affect uptake (Champion and Skinner 2003; Lopez et al. 
2009; Menon et al. 2007; Price et al. 1988).  Although there is much variability by demographic 
subgroups in how these factors affect utilization, identification of the issues have enabled 
targeted inventions for specific subgroups over the years.      
Similarly, the literature on treatment preferences of cancer patients is growing given that 
addressing patient-relevant treatment goals (and endpoints) have been noted to be an important 
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part of delivering quality care (Herzog et al. 2014; IOM 2001).  Briefly, in a discrete choice 
experiment of a woman’s willingness to trade clinical benefit (progression free survival (PFS)) 
for reduced toxicity from chemotherapy, there was a clear preference for PFS (Havrilesky et al. 
2014).  However, other studies from in-clinic surveys have shown a relatively even split in 
preference with regards to quality of life vs. length of life (Meropol et al. 2008).  Furthermore, 
when asked to make decisions about a hypothetical illness, approximately 84% of a sample of 
Medicare beneficiaries did not want potentially life-prolonging drugs at the cost of feeling worse 
all the time (quality of life), although about 16% did; this study was not able to map how these 
preferences related to treatment receipt (Barnato et al. 2007).  The literature on patient 
preferences in treatment/decision-making is difficult to synthesize given that patient preferences, 
the patient sample, the measurement, and the measures/context of such can differ widely.  The 
studies do, however, provide a glimpse of the variability of responses and preferences as well as 
possible gaps in the literature.   
 
Age and Race Disparities in Incidence, Mortality, and Treatment Receipt   
Ovarian cancer is predominately a disease of older women.  Treatment among older 
adults vary considerably.  Physician biases for treatment (Duska, Tew, and Moore 2015; Harder 
et al. 2013; Tew and Fleming 2015) and individual-level preferences of older adults (Puts et al. 
2015) have been suggested among the many reasons for the observed variation.  According to a 
recent systematic review of older adults, there were notable psychosocial reasons for 
accepting/declining treatment including trust in the physician, dynamics of the patient-physician 
relationship/discussions, as well as physician recommendations (Duska et al. 2015; Tew and 
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Fleming 2015).  The influence of comorbidities at advanced age (Leroy et al. 2014) can also 
have significant effects on treatment receipt and disease-related survival (O'Malley et al. 2012).   
Racial/ethnic disparities in ovarian cancer have been previously documented in the 
scientific literature and particularly examined with respect to stage at diagnosis, treatment, and 
survival (Barnholtz-Sloan et al. 2002; Bristow et al. 2013; Bristow, Zahurak, and Ibeanu 2011; 
Collins et al. 2014; Du et al. 2008; Howlader et al. 2015; Liu et al. 2014; Merrill, Anderson, and 
Merrill 2010; USCS 2015). Although incidence of ovarian cancer is lower among African 
American women than in White women (8.8 vs. 11.7/100,000 respectively), a greater proportion 
of African Americans and American Indian/Alaska Native are diagnosed at later stage disease 
than White and Hispanic women (Goodman and Shvetsov 2009).  The 5-year relative survival is 
considerably lower for African American women than their White counterparts at all ages 
(USCS 2015).  
 The reasons for survival disparities among African American women are largely 
unknown and still being explored (Barnholtz-Sloan et al. 2002; Bristow et al. 2013; Collins et al. 
2014).  However, there is likely to be an interplay of many nuanced differences in access to 
treatment/specialists, differences in quality of care received, as well as patient-level factors 
including tumor characteristics and preferences for care, by race/ethnicity, that account for the 
racial disparities in ovarian cancer care.   
 
Age and Race Disparities and Treatment Variation by Place of Care 
There are differences in where patients seek care.  Patients have differential access to 
cancer care that are both geographically determined (such as distance to care facilities, travel 
time, provider shortage areas) as well as by demographically driven (for example, race/ethnicity, 
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income, health insurance status, and patient choice) (Collins et al. 2014; Onega et al. 2009b; 
Onega et al. 2008; Stewart et al. 2014; Su et al. 2010).  Regardless of the reasons, studies have 
shown that patient outcomes for some cancers are better when cancer care is provided at high-
volume, centralized facilities (for example National Cancer Institute (NCI)-designated cancer 
centers) and from specialized, high case-volume providers (Birkmeyer et al. 2005; Bristow et al. 
2010; Bristow et al. 2009; Friese et al. 2010; Onega et al. 2009b; Woo et al. 2012).  At present 
(at the time of this dissertation), there are 69 NCI-designated cancer centers dispersed within 35 
U.S. states and the District of Columbia (http://www.cancer.gov/research/nci-role/cancer-
centers).  Given that designation required extensive peer- and site- reviewed evaluation of basic 
and population science research programs as well as high standards of comprehensive clinical 
research and practice (http://www.cancer.gov/research/nci-role/cancer-centers), these centers 
have an influence within the cancer community as leaders in cancer care (at the forefront of new 
surgical methods and therapies) and often “serve as de facto regionalized facilities” of care 
(Onega et al. 2009b).  It is expected that favorable outcomes in these institutions are, in part, due 
to greater adherence to evidence based-care, access to clinical (sub)specialists, and thus, delivery 
of better quality care (Bilimoria et al. 2008; Birkmeyer et al. 2005; Bristow et al. 2015; Onega et 
al. 2010b).          
Despite the comprehensive, multi-disciplinary care that these facilities offer (Gomella et 
al. 2010; Hui et al. 2010), studies have also shown differential accessing of such specialized 
facilities like the NCI-designated cancer centers, particularly among specific subgroups such as 
older patients and ethnic minorities (Huang et al. 2014; Onega et al. 2009a).  Attendence at NCI-
designated facilities was low particularly among persons of older age (i.e. Medicare 
beneficiaries) (Onega et al. 2009a), earlier staged disease (Onega et al. 2009a), and specified race 
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(i.e. African Americans (Onega et al. 2010a)) and Hispanic ethnicities (Huang et al. 2014).  
Access to specialists and specialized health facilties have also been noted to be low particularly 
in rural populations (Chan, Hart, and Goodman 2006; Onega et al. 2010a).  While proximity to 
care facilities has been noted to be one reason for underutilization (Bristow et al. 2014a; Onega 
et al. 2008; Su et al. 2010), other reasons for differences in the appropriate utilization of 
specialists/specialized cancer facilities are speculative or unknown.  On-going and emerging 
research in patient-level characteristics and preference for care may contribute to a better 
understanding of its role in attendance at specialized facilities.    
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CHAPTER 3:  STUDY DESIGN AND METHODS 
Overview and Rationale 
Aim 1 and Aim 2 employed primary data from two independent cancer registries (South 
Carolina and Georgia) collected via a contracting, non-federal organization.  The cancer registry-
collected data were supplemented with manually abstracted data from medical records of women 
with ovarian cancer diagnoses from two states within the U.S. South Atlantic census division 
(http://www.census.gov); this region has the second highest tertile of ovarian cancer incident 
rates within the United States, particularly among African American women 
(http://wonder.cdc.gov/cancer.html).  Aims 1 and 2 analyzed ovarian cancer cases from a 
retrospective cohort of women in the Ovarian Cancer Treatment, Subspecialist Care, and 
Outcomes Study, derived from the registry, using binary and multinomial logistic regression 
(Aim 1) and survival analysis (Aim 2).  For Aim 1, the dependent variables of interest were the 
timing of gynecologic oncologist involvement operationalized as 1) no GO involvement vs. ever 
involved for binary logistic regression models and 2) for multinomial logistic regression: no GO 
involvement, preoperative/consult only, some involvement (i.e. intraoperatively/post-operatively 
only), and GO involvement at all phases (e.g. preoperatively, intraoperatively, and 
postoperatively).  For Aim 2, the dependent variable was a count variable of all-cause mortality.  
Independent variables of interest for Aim 1 included patient-level characteristics (e.g. age, 
race/ethnicity) and healthcare systems-level characteristics (e.g. NCI cancer center designation).  
The key independent variable for Aim 2 was the timing of GO involvement a) continuously at all 
phases (pre-operatively/consult, intraoperatively, and post-operatively), b) at some phases 
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(intraoperatively/post-operatively only), c) preoperative/consult only, and d) no GO 
involvement. 
The analysis in Aim 3 utilized patient surveys (Alabama and Georgia) of women newly 
diagnosed with ovarian cancer, collected as part of a Special Interest Project, titled “Research to 
Understand Treatment Choices in Ovarian Cancer” (hereafter referred to as RUTH), with the 
Centers for Disease Control and Prevention (CDC).  Aim 3 explored the patient-level concerns 
during treatment decision-making and factors associated with decisional self-efficacy during 
perioperative care.  The dependent variables of interest were 1) self-reported perceived self-
efficacy and 2) cancer-related worry/well-being.  The key independent variable for Aim 3 was 
gynecologic oncologist being the important physician in treatment decision-making, age, race, 
social support measure, and perceived self-efficacy (for regression of the cancer worry 
dependent variable).   
 
Conceptual Model 
Conceptual Model: Aim 1 and Aim 2 
Figure 4 presents the conceptual framework illustrating the interwoven relationship of 
patient-level, provider-level, and healthcare systems-level interactions.  The model adapts 
Donabedian’s widely used approach for assessing quality (Donabedian 1980; Donabedian 1992), 
which considers three components of structure, process, and outcome.  Structure is defined as the 
“physical and organizational properties of the setting in which care is provided” (Donabedian 
1992).  These include academic affiliation (teaching hospital status), hospital volume of ovarian 
cancer cases, and NCI cancer center designation/accreditation.  Process is defined as “what is 
done for patients” (Donabedian 1992), which is defined according to the timing and extent of GO 
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care (as previously described, continuous involvement pre-operatively/consult only, 
intraoperatively, and post-operatively; some involvement pre-operatively/intraoperatively; and 
no involvement).  Lastly, outcome is defined as “what is accomplished for patients” (Donabedian 
1992), which is measured in terms of survival (time to death) in this model.  As Donabedian 
points out, outcome measures can only make inferences about the quality of the process rather 
than direct statements about quality (Donabedian 1992).  They are also integrative in that they 
are the summation of all of the collective efforts of structure and process and all of the 
individuals, systems, and resources involved (Donabedian 1992).  Ideally, efforts to improve 
quality should incorporate all three (i.e. multiple) domains.  
This adaptation of the Donabedian model also loosely incorporates parts of Andersen and 
Aday’s Behavioral Model of Health Service Use (Andersen 1995) to better categorize elements 
within a person’s characteristics that influence the inclusion into the structure, process of care, 
and outcome.  According to the Andersen and Aday’s Behavioral Model, there are factors that 
predispose individuals to access or seek care (i.e. age, race, socioeconomic status); enabling 
factors such as income, insurance, comorbidities, education, urban/rural region; and lastly, need 
factors which entail the perceived need based on stage of diagnosis, and histologic type.  See 
Figure 4. 
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Figure 4.  Conceptual Model for Assessing Quality: Health Care Structure, Process of GO Care, 
and Survival Outcome for Aims 1 and 2. 
 
 
Note:  Model adapted and modified from Donabedian Framework for Assessing Quality and 
Behavioral Model of Health Service Use (Andersen 1995; Donabedian 1992) 
 
 Theory can be a useful tool when attempting to disentangle complex human behaviors, 
given that it provides an organized structure for examining issues, identifies and relates various 
components, and helps to explicate important assumptions (Brundage, Feldman Stewart, and 
Tishelman 2010).  To more carefully examine the patient-level constructs and treatment 
preferences (i.e. knowledge, attitudes, beliefs, preference for care, etc.), Aim 3 borrows from the 
structural framework of the Health Belief Model and key constructs from the Transactional 
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Model of Stress and Coping within a sample of women diagnosed with ovarian cancer (Figure 
5).  
Conceptual Model: Aim 3 
 
The Health Belief Model is one of the most commonly used conceptual frameworks for 
understanding health behavior.  The model, originally developed in the 1950s to predict 
behaviors related to disease prevention, has been successful applied to understanding the 
relationship of health behaviors, practices, and healthcare utilization (Hochbaum 1958; 
Rosenstock and Kirscht 1974).  According to the Health Belief Model, an individual’s 
motivation to assume a health-related action, is based on three main categories: modifying 
factors, individual beliefs/behaviors, and the health action/intention/outcome.  The modifying 
factors are the patient-level demographics such as the age, race/ethnicity, and socioeconomic 
status. The individual perceptions are factors that affect “why people will take action;” these 
include susceptibility, seriousness, benefits and barriers, as well as self-efficacy (Glanz, Rimer, 
and Viswanath 2008).  Lastly, the health action of interest is the woman’s treatment seeking 
outcome, intention or behavior.    
According to the Transactional Model of Stress and Coping, in the primary appraisal 
phase, a woman initially assesses the potential significance of the threat (i.e. her perceived 
susceptibility and perceived severity of signs/symptoms).  Secondary appraisal involves the 
perceived ability to control/cope with the “stressor” (i.e. cancer diagnosis) (Glanz et al. 2008), 
for example, their decisional self-efficacy and role in decision-making.  Coping efforts mediate 
these appraisals, but involve complexities of both a problem-management and an emotionally- 
/meaning-based focus.  This encompasses both the perceived physical and emotional benefits 
and barriers to treatment.  According to this model, coping strategies may be affected further by 
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a sense of meaning or purpose (i.e. spiritual beliefs and religion) and the presence/type of social 
support in the individuals’ life.   
Figure 5.  Conceptual Model of Transactional Model of Stress and Coping Constructs for Aim 3 
 
 
 
 Construct Definition 
Primary Appraisal   
 Perceived susceptibility   Belief about the chances of experiencing 
a risk 
 Perceived severity   Belief about how serious a condition and 
its sequelae  
Secondary Appraisal   
 Perceived self-efficacy  Confidence in one’s ability to take action 
Coping Effort   
Problem management Perceived benefits  Beliefs in efficacy of the advised action 
to reduce risk or seriousness of impact 
 Perceived barriers  Beliefs about the tangible and 
psychological costs of the advised action 
Emotional/meaning-
based coping 
  Spiritual beliefs 
Outcome   Emotional well-being, health behaviors, 
positive or negative adaptation 
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Note:  Revised and reprinted from Glanz K, Rimer BK, Viswanath V (Eds.)  Health Behavior 
and Health Education:  Theory, Research, and Practice.  Fourth Edition. San Francisco: Jossey-
Bass, Inc. 2008 (Glanz et al. 2008).  Adapted to items specific for the RUTH Study. 
 
---Dotted lines represent key constructs examined in this analysis.  First, we examine decisional 
self-efficacy and factors associated with perceived self-efficacy. Second, we examine impact of 
perceived self-efficacy and social support on cancer worries.    
 
The conceptual framework presented informs variable selection for analytic models and 
demonstrates how theory is operationalized and provides insight into the potential impact of 
these pathways on observed disparities in ovarian cancer outcomes. 
 
Research Question and Hypotheses 
 
Research Question 1:  Examine the association between patient- (i.e. age, race/ethnicity) and 
healthcare systems- level characteristics (i.e. NCI designation, teaching hospital status) with 
the timing and involvement of gynecologic oncologists a) preoperative/consult only, b) 
intraoperatively/postoperatively only, c) at all phases (e.g. preoperative/consult, 
intraoperatively, and postoperatively) and d) no involvement, controlling for known covariates. 
Hypothesis 1: African American compared to White women and older women compared to 
younger women will have lower odds of continuous GO involvement in care.   
Hypothesis 2: NCI hospital designation compared to non-NCI-designated hospitals and those 
with teaching affiliation will have greater odds of providing patients with continuous GO care (at 
all phases preoperatively, intraoperatively, and postoperatively).  
 
Research Question 2:  Examine the associations of timing and involvement of gynecologic 
oncologists with all-cause mortality outcomes, controlling for known covariates.   
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a. Examine variations in timing and involvement of GO and survival by race and 
healthcare facility where care was received (i.e. NCI-designated cancer center vs. 
non-NCI-designated cancer center). 
Hypothesis 1: Women who received GO care continuously (preoperatively, intraoperatively, and 
postoperatively) will have better survival outcomes than those who did not.    
Hypothesis 2:  Women who received GO care at NCI-designated cancer centers, regardless of 
race, will have better survival outcomes than those who did not.   
 
Research Question 3:  Explore ovarian cancer patient-level beliefs and psychosocial concerns 
during perioperative treatment decision-making, perspectives of GO involvement, and factors 
associated with decisional self-efficacy during perioperative care to identify women with 
potential decisional support needs for survivorship care. 
Hypothesis 1: Older aged women and those of lower income/socioeconomic status may have 
potential decisional support needs.   
Hypothesis 2: Women with stronger (more confident) perceived self-efficacy and stronger (more 
reliable) social support will be associated with lower cancer-related worries/better well-being.   
 
Data Sources 
This dissertation relied on data from several sources collected from the southeast region 
of the United States, including primary data collected through a subcontract (of the Ovarian 
Cancer Treatment, Subspecialist Care, and Outcomes Study) and cooperative agreement (RUTH 
Study) with the Centers for Disease Control and Prevention (CDC).   An explanation of each 
dataset is provided below. 
32 
 
Aims 1 and 2 were addressed through use of an enhanced cancer registry dataset 
supplemented with manually abstracted medical records of women with invasive epithelial 
ovarian cancer from two states (South Carolina and Georgia); Aim 3 utilized primary data 
collected from the University of Alabama at Birmingham (UAB) RUTH Study from 170 ovarian 
cancer patients, recruited through cancer registry, hospital and local gynecologic 
oncology/oncology practices.   
The Ovarian Cancer Treatment, Subspecialist Care, and Outcomes Study (2010-2014) 
was funded by the CDC and conducted by the South Carolina and Georgia Cancer Registries.  
Both registries conduct high-quality, population-based cancer surveillance per standards of the 
United States Cancer Statistics (USCS), and are both certified by the North American 
Association of Central Cancer Registries (NAACCR).  These registries routinely review medical 
records to abstract demographics, tumor characteristics and treatment data as part of state-
mandated cancer surveillance. However, for the Ovarian Cancer Treatment, Subspecialist Care, 
and Outcomes Study, staff from these respective registries collected more detailed treatment data 
(e.g. timing of GO involvement, chemotherapeutic agents received, results of cytoreductive 
surgery) from various sources including hospital, outpatient facility and physician records.  All 
data were abstracted by specially-trained certified tumor registrars using standard practices 
[NAACCR dictionary 2006].  A contracting, non-federal organization coordinated the data 
collection efforts from both states.  
 The Research to Understand Treatment Choices in Ovarian Cancer (RUTH) Study was a 
Special Interest Project (contract #11-42), funded by the CDC that surveyed women diagnosed 
with ovarian cancer on treatment-seeking behavior and care.  Similar to the Cancer Care 
Outcomes Research and Surveillance Consortium (CanCORS) survey 
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(http://appliedresearch.cancer.gov/cancors/) (Malin et al. 2006), which purports to examine the 
characteristics and beliefs of cancer patients as possible reasons for disparities in cancer care, the 
RUTH survey also collected information (during 2013-2014) on patient  demographics, 
symptoms that led to the diagnosis, initial treatment offered and received, medical decision 
making, goals of treatment and prognosis, and other financial/coverage-related information.  The 
survey additionally included questions directly related to ovarian cancer, as identified from the 
literature, including cancer-related expenses as tradeoffs for family needs (Darby et al. 2009; 
Sherwood et al. 2008) and topics related to fertility sparing surgery or sexual concerns that may 
be important domains for women with ovarian cancer (Grzankowski and Carney 2011; 
Mirabeau-Beale et al. 2009; Sun et al. 2005).  The RUTH study was approved by the University 
of Alabama at Birmingham Institutional Review Board (protocol # X120914008) and the CDC 
Institutional Review Board.  Access to the data was granted to the doctoral student (presently at 
the University of North Carolina at Chapel Hill) through a data-use agreement with the doctoral 
student and an existing collegial partnership between the CDC/UNC and UAB. 
 
Study Population and Criteria for Inclusion 
 The general inclusion criteria for both datasets were that women must have had at least a 
primary diagnosis of ovarian cancer (defined by International Classification of Diseases (ICD) 
classification code C56).  Although the Ovarian Cancer Treatment, Subspecialist Care, and 
Outcomes Study sample included all patients with invasive, histologically-confirmed epithelial, 
germ cell, or sex-cord stromal ovarian cancers, the analytic sample was restricted to epithelial 
tumors only given differences in prognosis by histologic type.  Based on prior studies from 
Californian and New York cancer registries, ovarian cancer cases were likely to be 95% 
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epithelial tumors, 3% germ cell, and 2% sex-cord stromal tumors (Rim, et al. poster presentation, 
October 2010).  Benign and low malignant potential tumors, primary peritoneal and fallopian 
tube cancer cases (ICD-O codes 8442, 8451, 8462, 8472, and 8473) were not included in the 
Ovarian Cancer Treatment, Subspecialist Care, and Outcomes Study population (Goodman and 
Shvetsov 2009).  Persons diagnosed at autopsy or by death certificate only were ineligible. Vital 
status was determined by linkage with the National Death Index.   
 Patients in the RUTH Study included newly diagnosed women (within the first year of 
cancer diagnosis) who were recruited from several different sources:  1) partnership with the 
Alabama Statewide Cancer Registry (ASCR), 2) existing contracts with the University of South 
Alabama/Mitchell Cancer Institute in Mobile, AL and Northside Hospital in Atlanta, GA and 3) 
in-reach recruitment efforts through the University of Alabama at Birmingham hospitals.  
Eligible patients included women who 1) were age 21 years or older 2) had a recent diagnosis of 
ovarian cancer (stage I-IV or unstaged) 3) were proficient in the English language and 
able/willing to provide their consent to participate in the telephone-based survey.  Women were 
specifically excluded if they were currently being treated for another primary cancer or were 
institutionalized (such as being on hospice).  Patients who did not participate in the study were 
documented as to the reasons for non-eligibility (e.g. disconnected phone/could not be reached, 
non-English speaker, etc.), or personal preference in declining participation.    
Only women who met the RUTH study inclusion criteria were recruited and interviewed 
in the study (n=170).  Survey recruitment strategies had minor variations by site.  Study 
coordinators at each site reviewed a list of newly diagnosed ovarian cancer patients and assessed 
eligibility.  When appropriate, physicians were consented for permission to contact their patients.  
Potential participants were then initially contacted by a letter providing detailed information 
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about the study and the option to decline participation at any time via dialing a 1-800 phone 
number or by email.  Within several days (usually three days), the potential participant was 
contacted by phone for an eligibility screen, verbal consent, and to schedule a date/time for the 
60-minute structured, phone-based interview.            
 
Variables and Measurement by Aim 
Dependent variable 
 For Aim 1, the outcome variable of interest was an ordinal/nominal variable, whether the 
patient received a) no GO involvement (no GO), b) involvement preoperative/consult only, c) 
intraoperatively/postoperatively or d) at all phases (e.g. preoperative/consult, intraoperatively, 
and postoperatively) (all GO).  See Table 1. 
 The Aim 2 focus was on all-cause survival, where the outcome variable was a count 
(number of days between events) from date of diagnosis to death.  Survival time was calculated 
from the date of diagnosis to the date of death.  Death was defined as death from any underlying 
cause.     
 For Aim 3, the dependent variable was a continuous score measure for 1) perceived 
decisional self-efficacy, with values ranging from 0 (not at all confident/extremely low self-
efficacy) to 100 (very confident/extremely high self-efficacy) and 2) cancer worry, with values 
ranging from 0 to 36 (higher scores indicating greater worry).      
Table 1. Outcome Variables and Measures 
 
Aim  Outcome Measure Variable 
Aim 1 GO timing Ordered 0=no GO; 
1=preoperative; 
2=intra/postoperative; 3=all 
GO 
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Aim 2 Survival time (date of diagnosis to date of 
death) 
Count (number of days 
between events) 
Aim 3 Perceived self-efficacy score 
Cancer worry score 
Continuous (range 0 – 100) 
Continuous (range 0 – 36) 
 
Key independent variable 
 For Aims 1 and 2, the key independent variables included age, race/ethnicity (defined as 
White, African American/Other races).  Although we initially aimed to examine mutually 
exclusive race/ethnicity categories, data on race and ethnicity were inconsistently collected 
across states (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/interpreting/race.htm) and 
some state registries (for example, South Carolina) opted not to report Hispanic ethnicity case 
counts and rates to the U.S. Cancer Statistics for state-specific analyses, although they are 
included in aggregate national data.  Based on the data available, the majority of cases in our 
analytic dataset were non-Hispanic; only about 1.8% were of Hispanic origin.  In sensitivity 
analyses, removing Hispanic women did not significantly alter regression results.  However, 
given the concerns with records of ethnicity at the state-specific level (as noted above), in these 
analyses, the race variable was retained as originally collected by the respective state registries 
(i.e. as non-mutually exclusive categories).  For the healthcare systems-level characteristics, the 
main independent variables included was NCI cancer center designation.  See Table 2 for 
detailed information on how these variables were measured and coded, per NAACCR standards 
and/or the research protocol.   
 For Aim 3, the main independent variables included treating physician specialty (i.e. 
gynecologic oncologist as the most important physician in treatment decision-making), age, race, 
social support scale (with values ranging from 0=low social support to 100=high social support), 
and perceived self-efficacy scale items (with values ranging from 0=not at all 
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confident/extremely low self-efficacy to 100=very confident/extremely high self-efficacy).  
RUTH survey items that mapped to the constructs of the conceptual model were incorporated for 
background descriptive statistics. 
Table 2.  Independent Variables and Measures for Aim 1, Aim 2, Aim 3. 
 
Construct Variable Variable Type Source (by Aims) 
Aims 1 and 2    
Patient characteristics Age Categorical Registry 
 Race/ethnicity Categorical Registry 
Healthcare system 
characteristic 
NCI designation Binary Registry 
Timing of GO  Timing of GO 
involvement (no GO,  
preoperative/consult 
only, intra/ 
postoperative, all GO) 
Categorical Registry (Aim 2 
only) 
Aim 3    
Patient Demographics Age Continuous RUTH 
 Race Categorical  RUTH 
Perceived self-
efficacy 
Item 7.6 
 
Likert (0=not at all; 
1=a little; 
2=somewhat; 
3=confident; 4= 
very confident) 
RUTH/Decision 
Efficacy 
Scale(O'Connor 
1995) 
Social Support Item 8.1 
 
Likert (0=none of 
the time; 1=a little; 
2=some of the 
time; 3=most of the 
time; 4=all of the 
time) 
RUTH/Medical 
Outcomes Study 
Social Support 
Survey(Sherbourne 
and Stewart 1991) 
Treating physician 
specialty (GO as the 
most important 
physician in treatment 
decision-making) 
Item 3.3 Categorical RUTH 
 
 
Covariates 
Covariates were similar across all three aims.  These were patient characteristics that had 
previously been associated with timeliness of cancer care (Cooper, Kou, and Reynolds 2008), 
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which included both demographic and tumor/clinical characteristics.  For Aims 1 and Aim 2: 
continuous insurance coverage (primary payer at diagnosis, treatment initiation, and completion), 
rural/urban residence (based on census track/block of where the patient lives), income (not in 
poverty vs in poverty), histologic type, grade, and co-morbidity count (0 through 4+).  Histologic 
type and grade are standard NAACCR data elements.  Given that histology and grade both affect 
prognosis and impact treatment, epithelial histologies (serous, mucinous, endometrioid, clear 
cell) were adjusted for in the analyses (NCCN Clinical Practice Guidelines in Oncology for 
Ovarian Cancer 2014).  The Charlson comorbidity score is commonly used to provide a better 
understanding of the patient’s physical health.  Scoring for the index was calculated for each 
ovarian cancer patient based on their comorbid conditions available at admission for the ovarian 
cancer surgery, on the discharge summary from the diagnosing facility, or from prior inpatient or 
outpatient admissions, as noted in Charlson, et al (1994) (Charlson et al. 1994).  Specific 
comorbidities captured in the index included: myocardial infarction, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary 
disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, liver disease, 
hemiplegia, chronic kidney disease, lymphoma, leukemia, acquired immune deficiency 
syndrome.  For Aim 3, covariates included: patient-reported education, stage of disease, number 
of comorbidities, number of symptoms, income, perceived quality of life.  
 
Statistical Analysis by Aim  
 Data analyses included both descriptive and analytic statistics.  Descriptive statistics (the 
mean, standard deviations, proportions and 95% confidence intervals) characterized the sample 
of women included in the study (Aims 1-3) and/or survey response options (Aim 3).  Summary 
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statistics were examined prior to data analysis (regression models) to determine proportions and 
means of patient demographics and disease characteristics and to ensure appropriate sample 
sizes.  Chi-squared tests and t-tests were used, as appropriate, to determine statistically 
significant differences.  Univariate statistics helped identify the potential impact of missing data 
on the planned analysis.  Data analyses were primarily conducted using STATA software 
(version 13, StataCorp, College Station, Texas) and SAS version 9.3 (SAS Institute, Inc. Cary, 
North Carolina). 
 
Aim 1  
Ordinal logistic regression (or proportional-odds model) (Cameron and Trivedi 2005) 
was used to determine the association between patient-level (i.e. age, race/ethnicity) and 
healthcare systems- level characteristics (i.e. NCI designation) and the timing of GO 
involvement continuously at all phases (preoperatively/consult, intraoperatively, and 
postoperatively), intra/postoperatively, preoperative/consult only, or no GO involvement.  Given 
the natural ordering of the outcome variable, the ordered logit was the most appropriate and 
parsimonious approach for analysis.  However, since an underlying assumption of the ordered 
logit model is that the relationship between each pair of outcome group is the same, the model 
was tested for the proportional odds or parallel regression assumption (Long and Freese 2014).  
An insignificant test statistic (p>0.05) would have provided evidence that the assumption had not 
been violated.  However, given that such was not the case (and the parallel regression 
assumption was violated), consideration was given to the generalized ordered logistic model 
approach, partial proportional odds model, and the multinomial logit model (Long and Freese 
2014; Williams 2006).  To determine the best-specified model, Likelihood Ratio (LR) tests were 
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conducted and model fit statistics like the pseudo R-squared and Akaike information criterion 
(AIC) were examined (Wooldridge 2009).  The functional form of variables such as age and 
comorbidity count were assessed to determine if continuous or categorical forms should be used. 
Multicollinearity (Wooldridge 2009) of explanatory variables were examined based on pairwise 
correlations and variance inflation factor between right-hand side variables.  The Huber-White 
robust standard errors were used to correct standard errors in the final model arising from 
heteroskedasticity in the model (Cameron and Trivedi 2005; Wooldridge 2009). 
 
The basic form of the ordered logit model is: 
 
Ordered logit = ∏[(
1
1 + e−(δ0−XB
)
y=1
x [(
1
1 + e−(δ1−XB
)
N
i=1
− (
1
1 + e−(δ0−XB
)]y=2x [1
− (
1
1 + e−(δ1−XB
)]y=3]] 
 
where  α + ∑ 𝑋𝐵= 𝛽0 + 𝛽1race + 𝛽2𝑎𝑔𝑒 +  𝛽3ℎ𝑒𝑎𝑙𝑡ℎ𝑐𝑎𝑟𝑒_𝑠𝑦𝑠𝑡𝑒𝑚_𝑐ℎ𝑎𝑟𝑎𝑐𝑡𝑒𝑟𝑖𝑠𝑡𝑖𝑐𝑠 +  𝛽4𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝜀 
where healthcare_system_characteristics and covariates represent the vector of healthcare system 
variables and covariates described above. 
 
Aim 2 
The Kaplan-Meier (KM) method (Allison 2010) is a widely used method for estimating 
survivor functions.   KM method was used to plot time to event curves for patients of timing 
variable and to test each independent variable of interest for the proportional hazards assumption.  
Cox proportional hazard regression models was used to estimate the relative risk of death by 
timing of gynecologic oncologist involvement (Allison 2010).  Adjusted hazard ratios (HR) were 
reported.  Models were examined for the most appropriate variable functional forms and 
41 
 
interaction terms.  The logrank test was used to examine consistent differences between survival 
curves, by timing, using a 5% level of significance. The key independent variable of interest was 
the timing of GO involvement continuously at all phases (preoperatively/consult, 
intraoperatively, and postoperatively), intra/postoperatively, preoperatively/consult only, or no 
GO involvement, as previously specified. 
The basic form of the KM estimator is: 
?̂?(𝑡) =  ∏ (1 −
𝑑𝑗
𝑛𝑗
)
𝑗|𝑡𝑗<𝑡
 
where dj is the number dying in month j and nj is the number still alive at the beginning of the 
month. 
 
Aim 3 
Univariate and multivariate linear regression analyses were used to examine the 
association between demographic, clinical, and/or psychosocial factors on decisional perceived 
self-efficacy and cancer-related worrying during treatment decision-making for ovarian cancer.  
Unadjusted and adjusted ordinary least squares regression (OLS) models were examined against 
models assumptions, examining for linearity, normality of residuals, multicollinearity, and 
constant error variance (Wooldridge 2009).  Given that heteroskedasticity was a concern in the 
perceived self-efficacy regression model based on the Breusch-Pagan / Cook-Weisberg Test 
(Wooldridge 2009), consideration was given to the Feasible Generalized Least Squares (FGLS) 
model (or a log-model on the square of the residuals) for the perceived self-efficacy scores 
(Wooldridge 2009).  Ordinary least squares regression was used for the worry scale dependent 
variable with robust standard errors specified.   
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 Aim 3 was largely exploratory in terms of examining perspectives of GO involvement 
and the factor structure of the twelve-item cancer worry scale.  Cronbach’s alpha (Cronbach 
1951) was used to assess the reliability of the scale items.  Principal component analysis method 
was used initially and then exploratory factor analysis through Varimax rotation (orthogonal) and 
Promax (oblique rotation) method (SAS/STAT User's Guide) extracting up to 4 factors for 
further examination.  For analytic purposes, since worry was a proxy for decisional state and 
psychological well-being, we retained a single latent construct (or 1-factor solution) for 
regression models.  Results were reported as marginal (or differential) effects with standard 
errors and proportions with 95% confidence intervals.   
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CHAPTER 4:  PATIENT- AND HEALTHCARE SYSTEMS-LEVEL FACTORS 
ASSOCIATED WITH THE TIMING AND INVOLVEMENT OF GYNECOLOGIC 
ONCOLOGISTS IN PERIOPERATIVE OVARIAN CANCER CARE (AIM 1) 
OVERVIEW 
Objectives: The beneficial effects of gynecologic oncologist involvement in ovarian cancer care 
have been previously examined.  This study’s purpose was to identify patient- and healthcare 
systems- level factors predictive of the extent of gynecologic oncologists’ (GO’s) involvement in 
ovarian cancer care. 
Methods:  We conducted an analysis of state-based (South Carolina and Georgia) cancer 
registry data, supplemented with detailed treatment information manually abstracted from 
medical records of 2,162 ovarian cancer patients.  The final models include 1) a binary logistic 
regression model (of no GO involvement vs. ever involved) and 2) a multinomial logistic 
regression of dependent variables: no GO involvement, preoperative/consult only, 
intraoperatively/post-operatively only, and GO involvement at all phases (e.g. preoperatively, 
intraoperatively, and postoperatively).        
Results:  A GO was involved in the care of 79.7% of patients. Among the women who had a GO 
involved, 7.9% women received GO care preoperatively or as consult only, 67.7% received both 
intraoperative and postoperative GO care, and 24.4% had a GO involved at all perioperative 
phases of their care.  Older women (aged ≥ 70 years) had statistically significantly lower odds 
(OR=0.48, 95% CI, 0.27-0.83) of ever having a GO involved compared to women aged 49 years 
or younger.  There was an interaction effect by race for ever seeing a GO at an NCI-cancer 
center.  White women were more likely to ever see a GO at an NCI-designated cancer center and 
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had greater odds (OR=3.65, 95% CI, 1.46-9.15) of intra/post-operative from a GO, when seen at 
NCI vs non-NCI-designated centers.  
Conclusion:  Differences in GO involvement were observed by patient age, race, and place of 
care. This likely reflects heterogeneity of clinical management, the process of patient care in 
large cancer centers, as well as the complexity of provider and patient-level factors and patient 
preferences in determining the extent of care. 
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INTRODUCTION 
 
Ovarian cancer is among the top five leading causes of cancer deaths for women in the 
U.S. (USCS 2015).  Despite reductions in incidence and mortality rates over the past several 
decades, still each year, 20,000 women are diagnosed and nearly 15,000 die from ovarian cancer 
(USCS 2015).  Prognosis at diagnosis (often at advanced stage) is poor and the 5-year survival 
rate is about 37%-45% (Howlader et al. 2015).   
At present, surgery—with a focus on providing high quality perioperative care (defined 
as preoperative, intraoperative, and postoperative care received (Riddle and Stannard 2014)) 
from a gynecologic oncologist (GO)—plays an important role in treating ovarian cancer.  
Standard recommendations from the National Comprehensive Cancer Network (NCCN) include 
the involvement of GOs in consult (for patient assessment of surgical candidacy and/or 
considerations for neoadjuvant chemotherapy) and primary surgery and follow-up (NCCN 
2014).  Patients presenting with the disease require careful preoperative evaluation, as primary 
surgery for those with advanced stage tumors generally involve a complex operation to 
maximally cytoreduce the tumor (NCCN 2014) followed by several rounds of multi-agent 
chemotherapy (NCCN 2014).  Patients with bulky (i.e. advanced) stage III or IV disease, a high 
comorbidity index, or who are otherwise medically compromised may alternatively be 
candidates to receive either chemotherapy only, no surgery/therapy, or chemotherapy first then 
surgery at a later time (NCCN 2014).  As with all surgeries, patients are exposed to risks of 
complications and morbidity; thus, post-operative follow-up care is necessary (Vonlanthen et al. 
2011).   
Although the beneficial effects of receiving guideline-adherent treatment from a GO on 
survival have been extensively reported (Chan et al. 2007b; Earle et al. 2006; Goff et al. 2007), 
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research suggests that a substantial number of women with ovarian cancer still do not receive 
care from a GO at any point during their care (Vernooij et al. 2007).  Furthermore, less is known 
about what proportion of women at the population-level who are accessing GOs at various times 
in the treatment trajectory (at preoperative/consult only, intraoperatively, postoperatively, or 
continuous involvement at all phases) and the factors associated with this timing and extent 
(hereafter referred to as extent) of GO care received.   
To our knowledge, the literature is sparse on the timing of access to GO specialist care 
and whether patients are being evaluated at each phase and continuously throughout the course 
of care.  From the physicians’ perspective, the distinct phases of perioperative care achieve 
different clinical objectives (Riddle and Stannard 2014); and likewise from the patients’ 
perspective, there are a number of reasons for why a patient may not ever receive GO care or 
may have varying extent of care.  These may include both access to care-related concerns (such 
as proximity to Commission on Cancer-accredited center or National Cancer Institute-designated 
cancer care facility) as well as patient-level preference complexities.  Patients who received GO 
care at preoperative/consult only may be characteristically different from those who received 
intraoperative care (i.e. surgery) from a GO.  The main objective of this analysis was to identify 
patient- (i.e. age, race/ethnicity) and healthcare systems- level characteristics (i.e. NCI 
designation, teaching hospital status, which are more likely to offer better specialist access and 
performance on process measures (Merkow et al. 2014)) in relation to the extent of GO 
involvement in ovarian cancer care.  Understanding these predictive factors may provide insight 
into specific subpopulations for whom access to GO care needs to be improved.   
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METHODS 
The conceptual model for this analysis incorporates elements of the Andersen and Aday’s 
Behavioral Model of Health Service Use (Andersen 1995) to better categorize a person’s clinical 
and socio-demographic factors related to access to care that influence the extent of receiving care 
from a GO.  There are factors that predispose individuals to access or seek care (i.e. age, race, 
socioeconomic status); factors that enable, such as income, insurance, comorbidities, education, 
urban/rural region; and lastly, need factors which include the clinical need based on stage of 
diagnosis, histologic type, and tumor size (Andersen 1995).  
We hypothesize that a woman’s race and age (i.e. African American compared to White 
women and older women compared to younger women) may be significantly associated with 
lower odds of continuous GO involvement in care, based on previous literature showing age and 
racial disparities (Terplan et al. 2012).  We also expect, based on the literature, that NCI hospital 
designation compared to non-NCI-designated hospitals and those facilities with teaching 
affiliation compared to those without will have significantly greater odds of providing patients 
with continuous GO care. 
 
Data Source 
The Ovarian Cancer Treatment, Subspecialist Care, and Outcomes Study (2010-2014) 
was funded by the Centers for Disease Control and Prevention (CDC) and conducted by the 
South Carolina and Georgia Cancer Registries 
(http://www.cdc.gov/cancer/npcr/research/poc_studies/poc_ovarian.htm).  Both registries 
routinely conduct high-quality, population-based cancer surveillance per standards of the United 
States Cancer Statistics (USCS) (USCS 2015), and are both certified by the North American 
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Association of Central Cancer Registries (NAACCR).  These registries review medical records 
to abstract demographics, tumor characteristics and treatment data as part of state-mandated 
cancer surveillance. However, for this study, cancer registry staff  from these respective 
registries collected more detailed treatment data (e.g. timing of GO involvement, 
chemotherapeutic agents received, results of cytoreductive surgery) from various sources 
including hospital, outpatient facility and physician records.  Cases identified between 2004-
2014 were abstracted by specially-trained certified tumor registrars using standard practices 
[NAACCR dictionary 2006)].  A contracting, non-federal organization coordinated data 
collection and de-identified data from both states.  This study was reviewed and approved by the 
CDC IRB through an expedited review process in accordance with standard procedures. 
The study sample included women with a primary diagnosis of epithelial ovarian cancer 
(defined by International Classification of Disease classification code C56).  Benign and low 
malignant potential tumors, primary peritoneal and fallopian tube cancer cases were not included 
in the study population (Goodman and Shvetsov 2009).  Persons diagnosed at autopsy or by 
death certificate only were ineligible. Vital status was determined by linkage with the National 
Death Index.   
 
Key Variable Definitions 
The dependent variable of GO involvement was defined in two ways.  We created mutually 
exclusive categories of: 0= no GO involvement, 1= preoperatively or consult only, 2= 
intraoperative and postoperatively only; 3=at all phases (i.e. preoperatively, intraoperatively, and 
post-operatively).  Outcome categories 1, 2, and 3 collectively represent whether a GO was 
“ever” engaged in care in binary logistic analyses.  For multinomial regression analyses, we 
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examined receipt of intraoperative/post-operative (category 2) and at all phases (category 3) 
compared to the base category (i.e. category 1 or preoperative/consult only).  Categories 
represent both temporally ordered phases of the perioperative patient as well as categorically 
distinct (nominal) groups of women with potentially different access to care and clinical 
indications for treatment.             
The key independent variables included patient-level factors of interest such as age 
(ordinally defined as ≤ 49, 50-59, 60-69, and ≥ 70 yrs) and race/ethnicity (dichotomized as White 
and African American/other races including Asians and Hispanics, combined due to small 
numbers per group and collectively referred to as “non-White”).  Healthcare-level variables of 
interest were dichotomized (yes/no) to reflect whether NCI cancer center designation and/or 
teaching hospital status was granted.  Given that NCI-designated centers are recognized as 
leading U.S. institutions that provide the standard of care and a model of comprehensive, 
coordinated care directly related to cancer diagnosis and treatment (Onega et al. 2009b), this was 
chosen over simple Commission on Cancer designation.     
Covariates included both demographic (i.e. patient income and insurance status), and 
tumor/clinical characteristics (i.e. histologic type, stage, tumor size, and co-morbidity index) that 
have been previously associated with receipt of cancer care (Cooper et al. 2008).  Of the 
epithelial malignancies included, histology per International Classification of Diseases for 
Oncology (ICD-O-3) was categorized as endometriod (ICD-O-3 codes 8380, 8383, 8950), 
serous/papillary serous (8050, 8260, 8460, 8461, 8441, 8450, 8440), clear cell (8310, 8313), 
mucinous (8470, 8471, 8480, 8481), adenocarcinoma, NOS (8140), all other adenocarcinomas 
(8255, 8574, 8323, 8490, 8560, 8240), and all other non-specific histologies (8010-8020, 8041, 
8046, 8074, 8590, 8592, 8246, 8070, 8951, 8980, 9000, 9014, 8810, 8854, 8901, 8933, 9052, 
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9180, 9698, 8000, 8001, 8005, 8120), per prior studies/reports and personal communication with 
an expert ovarian pathologist (Cress et al. 2011; Kosary 2007).  International Federation of 
Gynecologists and Obstetricians (FIGO) stage of disease categories were grouped as stage I, II, 
IIIA/IIIB, IIIC, IV, and unknown, per 1988 requirements (Kandukuri and Rao 2015). Although 
tumor size—the largest dimension or diameter of the primary tumor in millimeters—provides 
prognostic information and allows for a better understanding of expected treatment by stage 
based on the NCCN Clinical Practice Guidelines in Oncology for Ovarian Cancer, given the high 
collinearity with cancer stage, this was not included in the final model.  The Charlson 
comorbidity index can provide a fuller understanding of the patient’s physical health than cancer 
diagnosis alone.  Scoring for the index was calculated for each ovarian cancer patient based on 
their comorbid conditions available at admission for the ovarian cancer surgery, on the discharge 
summary from the diagnosing facility, or from prior inpatient or outpatient admissions, as noted 
in Charlson, et al (1994) (Charlson et al. 1994).  Specific comorbidities captured in the index 
include: myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue 
disease, peptic ulcer disease, diabetes mellitus, liver disease, hemiplegia, chronic kidney disease, 
lymphoma, leukemia, acquired immune deficiency syndrome.       
 
Statistical Analysis   
Data analyses included both descriptive and analytic statistics.  Descriptive statistics 
characterized the sample of women included in the study, including those seen versus not seen 
by a GO, and by perioperative care phase.  If a GO was not involved in the patient’s care, we 
also report on the reasons documented within the medical record.  Cross-tabulations of each 
51 
 
categorical covariate (from Table 3) and the outcome variable were examined for sufficient cell 
sizes.  Frequencies were suppressed when cell sizes did not exceed minimum standards of 
observations (10 per cell size) as described by Long, J.S. et al (Long 1997); in some cases, levels 
within each variable were regrouped for multivariable modeling (e.g. histologies and stage).  
Where appropriate, the t-test, chi-square test, or F-test for joint significance was performed. 
Given the natural ordering of the timing of GO involvement outcome variable, an ordered 
logistic regression (Cameron and Trivedi 2005) was initially considered to assess the association 
between patient- and healthcare systems- level factors and GO involvement continuously at all 
phases (e.g. preoperatively, intraoperatively, postoperatively), at some phases (e.g. 
intraoperatively/post-operatively only), at preoperative/consult only or no GO involvement.  
Since an underlying assumption of the ordered logit model is that the relationship between each 
pair of outcomes is the same (Long 1997; Long and Freese 2014), the model was tested for the 
proportional odds or parallel regression assumption (based on the Brant Test (Brant 1990) and 
the likelihood ratio test of a constrained and unconstrained model (Long and Freese 2014)).  Due 
to the violation of the assumption, other modeling alternatives that do not impose the constraint 
of parallel regression, such as the generalized ordered logit model, partial proportional odds 
model, and multinomial logit model also were considered (Long and Freese 2014).  These 
models are considered appropriate per Long and Freese (Long 1997), who suggest that “simply 
because the values of a variable can be ordered does not imply that the variable should be 
analyzed as ordinal”.   
Given the potential dual interpretation of the dependent variable (i.e. as ordered and 
nominal outcomes), data were fit with the ordered alternatives and nominal regression models 
and were also tested with sequential logit models.  The final models used included 1) a logistic 
52 
 
regression model (of no GO involvement vs. ever involved) and 2) a multinomial logistic 
regression model among those who had ever had a GO involved to examine characteristic 
differences in extent of involvement.  Both models considered patient- and healthcare system- 
characteristics together.  The interaction of race and age as well as the interaction of race and 
NCI-cancer center designation, as suggested by literature (Huang et al. 2014), were examined for 
statistical significance and improvement in model fit as examined by the Akaike Information 
Criterion.     
Multicollinearity between covariates was examined with correlation matrices for high 
correlations (greater than or equal to 0.3) as well as by examining variance inflation factor and 
tolerance values (acceptable tolerance of 0.1 or less, as the general rule of thumb) (Wooldridge 
2009).  Robust standard errors were specified and all data analyses were conducted using 
STATA software version 13.1 (StataCorp, College Station, Texas).  Coefficients were 
transformed to odds ratios (ORs) and 95% confidence intervals (CI) were reported for all 
parameter estimates.  Interactions were reported as predictive margins. 
 
Model Specification and Testing     
While the interaction of race and age was not significant and did not improve model 
specification, inclusion of the interaction of race and NCI-cancer center designation was 
significant and did improve model fit as examined by the Akaike Information Criterion.  Joint 
significance testing suggested rejecting the null hypothesis of no effect by NCI-cancer center 
designation and race (p<0.01).   
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RESULTS 
Table 3 shows the characteristics of women in the Ovarian Cancer Treatment, 
Subspecialist Care, and Outcomes Study.  A total of 2,162 women with epithelial ovarian cancer 
were included from South Carolina and Georgia state cancer registries between 2004-2014.  The 
mean age at primary cancer diagnosis was 61 years; approximately 17-22% of women had a 
recurrence.  Most women were White (75.5%), insured through Medicare (44.8-45.6%) or 
private insurance (38.1-38.4%), and most resided in urban areas (79.4%).  About half had serous 
adenocarcinomas (53.0%), were diagnosed with FIGO stage IIIC (39.0%) or IV (19.1%), grade 
III or IV (i.e. poorly differentiated tumors/unknown) (77.0%), and had no comorbidities (72.2%).  
About 80% of the women in the sample were not seen at an NCI-designated cancer center and 
only about one-third received any care at a teaching hospital facility.  
Of the women in the study, approximately 20% never had a GO involved in their care 
(Table 4).  Among the women who had a GO involved, 7.9% were involved preoperatively or as 
consult only, 67.7% received both intraoperative and postoperative care from the GO, and 24.4% 
had a GO involved at all perioperative phases of their care.  Most women had a GO involved in 
surgery (88.6%) and in chemotherapy (80.4%).  Among the women who did not have a GO 
involvement in care, about 15% reported the reason to be the treating physicians’ preference, 
10% indicated lack of availability, 5% patient’s preference, and about 48% reported unknown 
reasons for no GO involvement. 
A greater proportion of women who did not have a GO involved or had seen a GO for 
preoperatively or consult only were older (age ≥ 70 years) (45.6% vs 26.2% receiving 
intra/postoperative care), African American/other (30.9% vs 21.9%), had Medicare as the payer 
at diagnosis, resided in rural regions (25.6% vs 16.9%), and were of lower socioeconomic status 
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(as indicated by region of patient income 20% or more below poverty level) (48.7% vs 24.4%).  
A greater proportion of patients with no involvement or GO involvement at preoperative/consult 
only had stage IV or unknown stage disease, a diagnosis of adenocarcinomas NOS (26.3% vs. 
7.3%), and greater (≥3) comorbidities (7.3% vs. 4.8%).  (Data shown in Appendix 1.) 
Table 5a shows the results of the logistic regression model of GO “ever” involvement in 
ovarian cancer care among women in the study (based on the dependent variable recategorized to 
binary, as described in the Methods).  Older women (aged ≥ 70 years) had statistically 
significantly lower odds (OR=0.48, 95% CI, 0.27-0.83) of ever having a GO involved compared 
to women aged 49 years or younger.  The odds of ever seeing a GO were significantly greater 
among women above the poverty level (OR=2.01, 95% CI, 1.42-2.86), those treated in a teaching 
hospital facility (OR=1.85, 95% CI, 1.26-2.70), and among women seen in NCI-cancer center 
facilities versus those not seen in a NCI-cancer center (Table 5a).  NCI-cancer center as a 
predictor of ever having seen a GO had differential effects by race (Table 5b).  At NCI-
designated cancer centers, White women were significantly more likely to ever see a GO than 
non-White women.  Among women not seen at a NCI cancer center, there was no statistically 
significant difference by race of “ever” seeing a GO (Table 5b).   
Table 6a shows results from the multinomial logistic regression model comparing the 
extent of GO involvement among women who had seen a GO only during the course of 
perioperative care.  Consistent with results from other models, older women (aged ≥ 70 years) 
had lower odds of receiving intra/post-operative care or continuous care.  When the interaction 
of race- and NCI-designated cancer center was included in the model (Table 6b), White women 
seen at an NCI-designated cancer center were more likely to receive intra/post operative care 
than pre-operative/consult only.  Regardless of race, women seen at non-NCI-designated cancer 
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facilities had about a 30% probability of receiving continuous care from GO at all phases (Table 
6b).         
                 
DISCUSSION 
Our data indicate a GO was involved in the care of about 79.7% of the 2,162 total 
patients.  While this is slightly higher than previous reports, there is much variation in the 
literature of GO involvement (ranging from 39-70.9% (Carney et al. 2002; Chan et al. 2007a; 
Cress et al. 2011; Earle et al. 2006)) and also within our study between GA versus SC.  Among 
those having a GO involved in their care, only about two-thirds (67.7%) received both 
intraoperative and postoperative care from the GO.  Our study suggests that age was a significant 
predictor of whether women had ever seen a GO and the extent to which women received 
perioperative care from a GO.  Consistent with prior studies, older women (aged ≥ 70 years) 
were less likely than younger women to be seen and treated (intra/post-operatively) by a GO 
(Hightower et al. 1994; Tew and Fleming 2015).  Among women without GO involvement, 
reasons for non-involvement were largely (48%) unknown.   
Age-based differences in treating cancer patients have been documented previously 
(Carney et al. 2002; Tew and Fleming 2015; Tew et al. 2014).  Prior studies have shown that 
older women with ovarian cancer have lower odds of receiving surgical and chemotherapeutic 
standards of care and are more likely to endure worse toxicity and survival (O'Malley et al. 2012; 
Rim et al. in press; Terplan, Smith, and Temkin 2009; Terplan et al. 2008; Tew and Fleming 
2015).  Reasons offered for differential treatment and poorer outcomes among the elderly have 
included: potential differences in tumor biology, patient-level complexities with coexisting 
conditions, and physician biases in delivering surgerical and chemotherapeutic care to older 
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patients (Duska et al. 2015; Tew and Fleming 2015).  While access to care and patient input of 
her treatment preferences may be reasons for non-treatment in the elderly, given that >25% of 
ovarian cancer patients are aged ≥ 70 years (with the proportion likely to grow with 
improvements in overall life expectancy), understanding factors affecting treatment patterns in 
this subpopulation and ways of delivering targeted care are needed.   
Improving (early) referrals to and patient education/awareness (particularly among the 
elderly) about better survival outcomes, guideline-adherent treatment, and/or high quality 
surgical care (Chan et al. 2007b; Chan et al. 2008; Earle et al. 2006; Goff et al. 2007; Goff et al. 
2011; Vergote et al. 2011) from GO subspecialty may be one way of addressing concerns and 
barriers to treatment among older patients.  Particularly in the case of surgery, data have 
consistently indicated improved overall survival when patients receive the surgical standard of 
care and optimal cytoreduction (Duska et al. 2015; Engelen et al. 2006; Morgan et al. 2008; Rim 
et al. in press).  Cytoreductive surgeries were conducted with greater likelihood of minimal 
visible residual disease when a gynecologic oncologist performed the surgery (Bristow et al. 
2002; Chang et al. 2013; Elattar et al. 2011).  However, older patients have been known to be 
less frequently treated by an oncologist (and more commonly by general surgeons or 
obstetrician/gynecologists) (Engelen et al. 2006; Hightower et al. 1994) and have differing 
referral patterns to GOs than younger women, which may also contribute to the variation in 
survival observed in the literature.        
Our study findings also suggest women receiving all phases of care from a GO to be 
characteristically different from women receiving pre-operative/consult only vs. intra/post-
operative care from a GO.  Much like the women who indicated not having a GO involved or 
had seen a GO for preoperative consult, nearly a quarter of these women resided in rural regions 
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and were potentially more “complex” patients –i.e. had more advanced disease (i.e. late 
stage/unstaged disease), difficult-to-treat histologic subtypes (i.e. mucinous/clear cell 
histologies) and also had three or more underlying comorbid conditions.  Though we are not able 
to directly conclude this from our data, there are two possible explanations for the receipt of “all 
phases” of care.  First, the patients’ clinical condition may have warranted careful GO 
evaluation, treatment/surgical techniques, and continuous monitoring from a GO, over simply 
providing intraoperative consultation during/for surgery (Aviki et al. 2015).  Alternatively, 
geographic distance and variations in access and use of NCI-cancer centers versus community 
care centers may be responsible for the observed differences.  For example, Bristow and 
colleagues (2014), in a spatial analysis of ovarian cancer patients identified from the California 
Cancer Registry, reported that while White women were more likely to live ≥80km (~50 miles) 
from a high-volume care facility, a larger proportion of White women were traveling ≥32km 
(~20 miles) to receive care, compared to African American women and those of other races 
(Bristow et al. 2014a).  In a different study, Bristow et al (2014) showed that though similar 
proportions of African American women (23%) compared to White women (17.9%) and women 
of other races (p=0.004) were accessing high ovarian cancer case volume hospitals, African 
American and Hispanic women as well as those insured by Medicare and Medicaid had lower 
likelihood of being operated on by a high volume surgeons (i.e. those with ≥10 cases per year), 
suggesting potential differential access to physicians within institutions (Bristow et al. 2014b).  
Other studies examining factors influencing use of NCI cancer centers or “quality” hospitals 
among racial/ethnic minorities and by socioeconomic status also noted some differences by 
specific subpopulations (Dimick et al. 2013; Huang et al. 2014).   
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Race and place of care (NCI-designated cancer center), in our study, had a differential 
effect as a predictor of “ever” seeing a GO and the extent of GO involvement for perioperative 
care.  Overall, women seen at an NCI cancer facility had a high probability of ever seeing a GO, 
specifically for intra/post-operative care, as expected given that comprehensive cancer centers 
and academic hospitals (like NCI-designated facilities) have care processes that yield 
multidisciplinary care teams and allow smoother transitions across different phases of care.  
However, these systems and facilities do not currently exist broadly and for everyone.  Of the 
nearly 22,000 oncology-related specialties in the U.S., 521 (or 2%) are gynecologic oncologists 
with even fewer practicing in direct patient care (2015).  While the NCCN guidelines 
recommend that consult or primary surgeries be performed by a GO, the uneven distribution of 
oncologist and oncology subspecialists previously reported and recently highlighted in the State 
of Cancer Care Report (2015) from the American Society of Clinical Oncology, continue to pose 
a problem for this recommendation (2015; Stewart et al. 2014).  Furthermore, as the State of 
Cancer Care Report suggests, with the increasing demand for oncologists and lack of 
subspecialists in some areas across the U.S., innovative ways of involving clinical expertise 
including potential new roles of specialist and subspecialist care may need to be explored (Aviki 
et al. 2015). 
Telemedicine is a virtual method of interfacing points of the healthcare process and may 
be used for both physician-to-physician video-consulting as well as provider-patient post-
operative follow-up (Stypulkowski, Uppaluri, and Waisbren 2015).  One study led by Shea, et al. 
(2014) reported on the feasibility of a virtual tumor board program to provide community-based, 
non-academic-affiliated clinicans from across North Carolina access to a multidisciplinary tumor 
board consulting system at the University of North Carolina Lineberger Comprehensive Cancer 
59 
 
Center (Shea et al. 2014).  Though it has not yet been thoroughly evaluated, the authors note 
positive feedback among participants regarding the usefulness and value of the program; and 
such programs may be a potentially cost-effective way of expanding access to individuals in 
rural regions and ensuring continuity of care (Di Cerbo et al. 2015; Shea et al. 2014).  However, 
reasonable barriers and challenges (i.e. lack of time, reimbursement incentives, etc) exist in 
expanding to wider-use and reach of community-based clinicians (Shea et al. 2014).    
It remains to be seen how technology can improve clinical practice and impact care 
delivery in this regard; however, telemedicine does hold promise in the current context of 
healthcare reform to provide “cost-effective and clinically effective solution” to uneven 
distributions in access to care and quality of care (Bashshur et al. 2009).  In the meantime, 
prompt referrals (and improvements in referrals) of ovarian cancer patients to comprehensive 
cancer centers, like NCI-designated cancer centers, may continue to be an appropriate option.  
These comprehensive centers have historically received referrals from local/regional service area 
(Su et al. 2010) for a diverse population, with varying clinical complexity (Friese et al. 2010; Su 
et al. 2010) and according to some studies served greater proportions of ovarian, prostate, and 
pancreatic cancer-specific patients (Friese et al. 2010).  Offering these women access to 
comprehensive, specialized cancer care facilities and services (Woo et al. 2012), including 
supportive care services, may be among the best options for improving outcomes and survival 
(Woo et al. 2012).  
The limitations of this study are among those commonly reported with use of registry 
data including  possible variation in carcinoma classification by hospital pathologists (Registries 
2006) and omission of detailed information on patient- and physician- characteristics and 
treatment decisions/rationale.  Furthermore, having data sources only from select states (Georgia 
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and South Carolina) in the U.S. Southeast region, and the sampling frame of each, limits the 
external validity and the generalizability of the results.  Although this region has the second 
highest tertile of ovarian cancer incident rates within the United States, and among the highest 
proportion of African Americans (http://wonder.cdc.gov/cancer.html), regression models 
required aggregating race as non-White (include African Americans and other races) and as such, 
limited our ability to examine differential effect by specific race categories.  Finally, although 
physician specialty and timing of GO involvement was specifically collected for this analysis, 
the retrospective data collection and medical records abstraction process is not without potential 
measurement error.  
This study offers some strengths.  First, this study was based on data collected from a 
population-based cancer registry and benefited from medical records abstraction for more 
detailed information on treatment-related data.  It includes a relatively large proportion of 
ovarian cancer patients, particularly African American patients, from both academic, cancer 
centers, and community-based facilities.  The study provides information specifically on the 
timing of GO involvement which has not been previously examined.   
 
Conclusion 
Women who are seen for preoperative/consult only were characteristically different 
(clinically or geographically) than those who receive intra/post-operative care and care at all 
phases.  Those seen at NCI-designated cancer centers were more likely to ever see a GO for 
intra/post-operative care; however, this varied by race.  Though the differences observed by age, 
race and place of care likely reflect a complex mix of the process of patient care seen in large 
cancer centers (for example, in terms of continuous care), heterogeneity of clinical management, 
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as well as the complexity of provider and patient-level factors considered including tumor 
characteristics and patient preferences in determining the extent of care, still further research 
warrants investigating these differences more closely.   Understanding these factors associated 
with the extent of GO care received can help understand survival disparities from ovarian cancer 
and may provide opportunities to better transition care and enhance survivorship. 
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Table 3.  Descriptive Statistics of Ovarian Cancer Disease in the Cancer Registry Sample  
 
 Total 
Characteristics n    % 
Patients 2162  
By Data Abstraction Site   
   Georgia 1159 53.6 
   South Carolina 1003 46.4 
Mean age at primary cancer diagnosis 
(SD) 61.4 (15.4) 
 
Number of Recurrences 450 17.2 
Age   
   ≤49 458 21.2 
   50-59 471 21.8 
   60-69 570 26.4 
   ≥70 663 30.7 
Race/ethnicity   
   White 1,632 75.5 
   African American/Other 530 24.5 
Insurance coverage   
   Payer at diagnosis    
      No insurance/unknown 194 9.0 
      Private 829 38.4 
      Medicaid 116 5.4 
      Medicare 968 44.8 
      Military/other/unknown 54 2.6 
   Payer at completion   
      No insurance/unknown 125 5.8 
      Private 823 38.1 
      Medicaid 164 7.6 
      Medicare 986 45.6 
      Military/other/unknown 64 3.0 
Undereducated (≥25% of population 
without high school education)  231 12.2 
Residence   
  Urban 1510 79.4 
  Rural 193 10.2 
  Urban-Rural Mix 199 10.5 
Income (≥20% below poverty level) 590 31.0 
Clinical Characteristics   
FIGO Stage   
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   I  433 20.0 
   II  172 8.0 
   IIIA/IIIB 196 9.1 
   IIIC 741 34.3 
   IV 332 15.4 
   Unknown 288 13.3 
Charlson Comorbidity Score   
   None 1,488 74.3 
   One 86 4.3 
   Two 86 4.3 
   Three 100 5.0 
   Four 95 4.7 
   Five or more 148 7.4 
Histology   
Adenocarcinoma   
   Serous / papillary serous 1,088 53.0 
   Endometrioid 236 11.5 
   Clear Cell 78 3.8 
   Mucinous 109 5.3 
   Adenocarcinoma, NOS 222 10.8 
   All Other Adenocarcinoma 87 4.2 
Other carcinoma/histologies 231 11.3 
Grade   
   I (well-differentiated) 179 8.3 
   II (moderately differentiated)  320 14.8 
   III (poorly differentiated) 1,002 46.4 
   IV/ Unknown 661 30.6 
Hospital Characteristics   
NCI Cancer Center   
   Yes 422 19.5 
   No 1722 79.7 
Teaching hospital   
  Yes  704 32.6 
  No 1456 67.4 
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Table 4.  Characteristics of Women Treated by a Gynecologic Oncologist 
Characteristics Total (n)    % 
GO Involvement   
   No 434 20.3 
   Yes 1703 79.7 
Timing of GO Involvement    
   Preoperative/consult only 125 7.9 
   Intraoperative/Postoperative 1,077 67.7 
   All phases 389 24.4 
GO Involved in Surgery   
   No  68 4.0 
   Yes  1,512 88.8 
   No surgery  122 7.2 
Level of GO Involvement in Surgery   
   Yes, present at surgery, but not part of the  
     surgical team (consultant only) 
23 
1.4 
   Yes, present as member of the surgical team 1489 87.4 
   Yes, but don’t know how involved 78 4.6 
GO Involved in Chemotherapy   
   No  309 18.1 
   Yes  1,373 80.6 
   Unknown  21 1.2 
Timing of Chemotherapy in Relation to Surgery   
   Neoadjuvant  300 14.0 
   Post-debulking surgery 1,162 54.4 
   Unknown 675 31.6 
   
Reasons for Why GO were not involved (n=434) 
   Treating physician preference  65 14.9 
   Patient Preference  20 4.6 
   Lack of availability  45 10.4 
   Insurance coverage  2 0.5 
   Patient illness  33 7.6 
   Patient dies  49 11.3 
   Unknown  208 47.9 
   Other  12 2.8 
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Table 5a.  Logistic Regression Model of Gynecologic Oncologist Involvement in Ovarian 
Cancer Care Among Women in the Cancer Registry Sample  
Characteristics Ever Received GO Care 
 Odds Ratio 95%CI P-value 
Age    
   ≤49 Reference   
   50-59 1.14 (0.65-1.99) 0.66 
   60-69 0.65 (0.37-1.14) 0.13 
   ≥70 0.48 (0.27-0.83) 0.01 
Race/ethnicity    
   White 1.08 (0.71-1.65) 0.72 
   African American/Other Reference   
Income     
   Not poverty 2.01 (1.42-2.86) <0.001 
   20%+ below poverty level Reference   
FIGO Stage    
   I Reference   
   II 1.06 (0.51-2.19) 0.88 
   IIIA/IIIB 1.06 (0.56-2.03) 0.86 
   IIIC 1.78 (1.02-3.13) 0.04 
   IV 0.63 (0.37-1.10) 0.11 
Charlson Comorbidity Score    
   None Reference   
   One/Two 1.48 (0.82-2.68) 0.19 
   Three or more 2.25 (1.43-3.53) <0.001 
Histology    
   Serous papillary Reference   
   Endometrioid 2.44 (1.22-4.87) 0.01 
   Clear cell/mucinous/all other  
   adenocarcinoma 2.30 (1.24-4.27) 0.01 
   Adenocarcinoma NOS 0.54 (0.34-0.87) 0.01 
   Other carcinoma 0.44 (0.26-0.74) <0.001 
Teaching hospital    
   Yes 1.85 (1.26-2.70) <0.001 
   No Reference   
NCI Cancer Center    
   Yes  13.12 (6.17-27.92) <0.001 
   No Reference   
Insured continuously 1.35 (0.71-2.56) 0.37 
Constant 0.62 (0.26-1.46)   
Number of Observations: 1683 
Akaike information criterion (AIC): 944.8 
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Table 5b.  Predictive Probability of Ever Receiving GO Care by Race- and NCI-designated 
Cancer Center Interaction 
  Probability 95% CI P-value 
    
White women, non-NCI center 0.79 (0.77-0.81) <0.001 
White women, NCI center 0.99 (0.97-0.99) <0.001 
Non-White women, non-NCI center 0.80 (0.76-0.83) <0.001 
Non-White women, NCI center 0.90 (0.84-0.96) <0.001 
        
Note: Logistic regression model controls for urban/rural and data abstraction site (Georgia and 
South Carolina).  The dependent variable is the binary recode of the GO care variable.  Non-
White women includes African American women and women of “other” races. 
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Table 6a.  Multinomial Logistic Regression Model on Timing of Involvement Among 
Women Who Had Seen a Gynecologic Oncologist   
 
 Intra/Postop All 
Characteristics vs. preoperative/consult only vs. preoperative/consult only 
Age OR 95% CI 
p-
value OR 95% CI 
p-
value 
   ≤49 Reference   Reference   
   50-59 1.18 (0.37-3.78) 0.78 1.08 (0.33-3.49) 0.90 
   60-69 1.43 (0.49-4.16) 0.51 0.99 (0.33-3.02) 0.99 
   ≥70 0.21 (0.08-0.56) <0.001 0.10 (0.04-0.29) <0.001 
Race*NCI Cancer 
Center       
NCI vs non-NCI-
designated       
   White  3.65 (1.46-9.15) 0.006 0.18 (0.06-0.49) <0.001 
   Non-White  0.68 (0.25-1.88) 0.46 0.15 (0.04-0.55) 0.004 
White vs Non-White       
   NCI-designated  4.94 (1.50-16.32) 0.009 2.08 (0.49-8.89) 0.322 
   Non-NCI-designated 0.92 (0.48-1.76) 0.807 1.76 (0.85-3.61) 0.13 
Insured 
Continuously  2.36 (0.90-6.22) 0.08 2.87 (1.01-8.18) 0.05 
       
Model Akaike information criterion (AIC): 1326.70 
OR=odds ratio; CI=confidence interval 
Note: Model controls for site of data collection (South Carolina and Georgia), stage, urban/rural, 
histology, income (measure of socioeconomic status).  
Notes: * indicates an interaction; Non-White includes African American women and women of 
“other” races.   
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Table 6b.  Predictive Probability of Race- and NCI-designated Cancer Center Interaction 
and GO Timing 
 
 
Preoperative/ 
Consult only 
Intra/ 
Postoperative All phases 
 Probability (95% CI) Probability (95% CI) Probability (95% CI) 
White women, non-NCI 
cancer center 0.08 (0.06-0.09) 0.59 (0.57-0.61) 0.33 (0.31-0.36) 
White women, NCI-
cancer center 0.06 (0.03-0.08) 0.87 (0.83-0.90) 0.07 (0.05-0.10) 
Non-White women, non-
NCI cancer center 0.08 (0.06-0.11) 0.65 (0.60-0.70) 0.27 (0.22-0.32) 
Non-White women, NCI 
cancer center 0.13 (0.07-0.19) 0.75 (0.68-0.82) 0.12 (0.06-0.18) 
Note: Non-White includes African American women and women of “other” races.   
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CHAPTER 5:  ASSOCIATIONS OF TIMING AND INVOLVEMENT OF 
GYNECOLOGIC ONCOLOGISTS IN PERIOPERATIVE OVARIAN CANCER CARE 
WITH OVERALL SURVIVAL (AIM 2) 
OVERVIEW  
 
Objectives: This study’s objective was to examine differences in the timing of gynecologic 
oncologist (GO) involvement in care on overall survival time.   
Methods:  We conducted an analysis of state-based (South Carolina and Georgia) cancer 
registry data, supplemented with detailed treatment information abstracted from medical records 
of 2,162 ovarian cancer patients.  Impact of timing of gynecologic oncologists (i.e. 
preoperatively/consult only, intraoperatively, postoperatively, or continuously at all phases), 
patient- and healthcare systems-level factors on outcomes of 3-year all-cause mortality were 
examined with Kaplan-Meir survival curves and proportional hazards models.         
Results:  The median (unadjusted) survival time was approximately ~20.9 months among 
women who had not had a GO involved during their care vs. ~46.5 months among women with 
intraoperative/post-operative GO involvement.  Survival time was shorter among women with 
advanced age, stage, and those with greater comorbidities; White women and those seen at NCI-
designated cancer centers had longer median survival time (Log-rank p<0.001).  After 
adjustment for covariates, women who received GO care intraoperative/post-operatively had 
lower risk of death [HR=0.46 (95% CI: 0.34-0.61), p<0.001].  Additionally, White women had 
significantly better survival outcomes (lower risk of death [hazard ratio=0.63 (95%CI: 0.41-0.96, 
p=0.03)] when seen at NCI-designated cancer center than women of other races.   
70 
 
Conclusion:  Overall 3-year survival probabilities were lower among women who had no GO 
involvement (36%) compared to those who had received intraoperative/post-operative care 
(59%) and GO care at all phases (54%).  Three-year survival probabilities were higher for 
women receiving intraoperative/postoperative GO care at NCI-designated cancer centers vs non-
NCI-designated cancer centers (73% vs. 50%, respectively).  Subgroups of women access GO 
care differently, whether by choice or not.  Given the persistently dismal survival rates among 
ovarian cancer survivors, despite the association between GO involvement and better survival, 
examining ways of improving other outcomes (i.e. quality of life) may be important.     
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INTRODUCTION 
Ovarian cancer is a major public health problem, causing about 15,000 deaths among 
women each year (USCS 2015).  For most women with ovarian cancer, timing and extent of 
treatment can be critical, since the probability of survival is closely linked with the stage at 
diagnosis (92% for localized vs 27% for distant stage diagnoses) and the treatment received.  In 
the absence of known, effective methods for primary prevention and screening, the focus for 
improving survival has been in ensuring women receive guideline-adherent surgical and 
chemotherapeutic standard of care (SOC) (i.e. complete primary debulking 
surgery/cytoreduction) and quality perioperative care from a gynecologic oncologist (GO)  
(NCCN 2014).   
The evidence supporting better guideline-adherent care and outcomes among patients 
seen by a GO has been previously examined (Earle et al. 2006; Eisenkop et al. 1992; Kehoe et al. 
1994; Mayer et al. 1992).  One study by Cress et al showed that patients treated by a GO had 
nearly four times the probability of receiving all recommended surgical staging procedures than 
those who were not (Cress et al. 2011).  Additionally, clinical procedures such as lymph node 
dissection for stage I patients and debulking surgery, were performed more often by GOs than by 
gynecologists or general surgeons (Chan et al. 2007b; Earle et al. 2006; Goff et al. 2006; Stewart 
et al. 2011; Vergote et al. 2011).  More recently, a study of 11,688 ovarian cancer Medicare 
beneficiaries showed that women who had ever seen a GO among their providers had a greater 
likelihood of receiving the surgical and chemotherapeutic standard of care; women receiving the 
surgical and chemotherapeutic standard of care, in turn, had a 14-month median survival 
advantage compared to women who received less than the standard of care (Rim, et al. in press).    
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Although the National Comprehensive Cancer Network (NCCN) and Society of 
Gynecologic Oncology (SGO) recommend the early involvement of subspecialist care in consult 
and surgery, up to now, the analytic focus of these earlier studies have relied on the definition of 
“ever seeing” a GO to evaluate survival outcomes.  To our knowledge, the extent of involvement 
(i.e. timing of GO involvement at various phases of care) has not been examined as a quality 
process measure associated with improved survival.  Specifically, it is unknown whether GO 
involvement preoperatively/consult only, intraoperatively, postoperatively, or continuously at all 
phases (i.e. timing) is associated with improved survival.  While the potential role of GO 
involvement as a consultant during gynecologic surgeries and among cancer patients was 
recently examined by Aviki, et al (2015), (Aviki et al. 2015) survival outcomes were not reported 
in the study.  The primary purpose of this analysis was to examine differences in the timing of 
GO involvement in care on survival time.  We also explored the differential impact of care 
facility [i.e. National Cancer Institute (NCI)-designated cancer center vs non-NCI-designated 
cancer center] on timing of GO involvement and outcomes, by race.  Some studies have found 
NCI cancer center attendance to be associated with better surgical outcomes and reduced odds of 
mortality among non-ovarian cancer patients (Birkmeyer et al. 2005; Onega et al. 2009b) and 
more recently among ovarian cancer patients (Bristow et al. 2015); however, both the use of and 
outcomes from treatment at NCI-cancer centers among ovarian cancer patients have not been 
extensively examined by race.   
Given the beneficial effects of treatment from a GO per NCCN guidelines, we 
hypothesize that receiving care from a GO continuously at all phases (i.e. preoperatively, 
intraoperative, and postoperatively) will be significantly associated with better survival outcomes 
than those who did not.  Additionally, while we hypothesize that NCI cancer center attendance 
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would result in better overall survival based on literature and prior findings, we test the 
hypothesis that patient-level characteristics (i.e. age and race) may moderate the relationship 
between NCI cancer center attendance and survival.  
 
METHODS 
The conceptual model guiding this analysis is borrowed from the widely used 
Donabedian approach for assessing quality of care (Donabedian 1980), which considers the three 
components of structure, process, and outcome.  Structure is defined as the “physical and 
organizational properties of the setting in which care is provided” (Donabedian 1992) such as 
NCI cancer center designation/accreditation.  Process measures include GO involvement as well 
as the timing of GO care (i.e. no involvement; preoperative/consult only; 
intraoperative/postoperative; all phases).  Lastly, outcome is the survival time (diagnosis to 3-
year follow-up) (Andersen 1995).   
 
Data Source and Study Population 
The Ovarian Cancer Treatment, Subspecialist Care, and Outcomes Study (2010-2014) 
was funded by the Centers for Disease Control and Prevention (CDC) and conducted by the 
South Carolina and Georgia Cancer Registries.  Both registries routinely conduct high-quality, 
population-based cancer surveillance per standards of the United States Cancer Statistics (USCS 
2015), and are both certified by the North American Association of Central Cancer Registries 
(NAACCR).  These registries review medical records to abstract demographics, tumor 
characteristics, and treatment data as part of state-mandated cancer surveillance. However, for 
this study, cancer registry staff  from these respective registries collected more detailed treatment 
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data (e.g. timing of GO involvement, chemotherapeutic agents received, results of cytoreductive 
surgery) from various sources including hospital, outpatient facility, and physician records.  
Cases identified between 2004-2014 were abstracted by specially-trained certified tumor 
registrars using standard practices [NAACCR dictionary 2006].  A contracting, non-federal 
organization coordinated the data collection efforts from both states.  This study was reviewed 
and approved by the CDC IRB through an expedited review process in accordance with standard 
procedures. 
The study sample included women with a primary diagnoses of epithelial ovarian cancer 
(defined by International Classification of Diseases classification code C56).  Persons diagnosed 
at autopsy or by death certificate only were ineligible. Vital status was determined by linkage 
with the National Death Index.   
 
Key Variable Definitions 
The main dependent variable was timing (in days) from diagnosis to death or vital status 
at last date of contact or censoring at 3-years.  Death was from any underlying cause.   
The primary independent variable of GO involvement was a mutually exclusive variable 
of: 0= no GO involvement, 1= preoperatively or consult only, 2= intraoperative and 
postoperatively only; 3=at all phases (i.e. preoperatively, intraoperatively, and post-operatively).   
Patient-level covariates included age (treated as continuous in the final model but 
categorically as: ≤49, 50-59, 60-69, and ≥ 70 yrs in descriptive statistics), race (dichotomized as 
White and African American/other races due to the small numbers per group), stage at diagnosis, 
comorbidities (Charlson et al. 1987), and histology.  As defined in the previous analysis, specific 
comorbid conditions recorded from medical files included: myocardial infarction, congestive 
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heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive 
pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, liver 
disease, hemiplegia, chronic kidney disease, lymphoma, leukemia, acquired immune deficiency 
syndrome (Charlson et al. 1987).  Per International Classification of Diseases for Oncology 
(ICD-O-3),  epithelial malignancies included: endometriod (ICD-O-3 codes 8380, 8383, 8950), 
serous/papillary serous (8050, 8260, 8460, 8461, 8441, 8450, 8440), clear cell (8310, 8313), 
mucinous (8470, 8471, 8480, 8481), adenocarcinoma, NOS (8140), all other adenocarcinomas 
(8255, 8574, 8323, 8490, 8560, 8240), and all other histologies (8010-8020, 8041, 8046, 8074, 
8590, 8592, 8246, 8070, 8951, 8980, 9000, 9014, 8810, 8854, 8901, 8933, 9052, 9180, 9698, 
8000, 8001, 8005, 8120) (Cress et al. 2011; Kosary 2007).  Healthcare systems-level variables of 
interest were dichotomized (yes/no) to reflect teaching status or whether NCI cancer center 
designation was granted.   
All National Program of Cancer Registries and Surveillance, Epidemiology and End 
Result registries assign Hispanic ethnicity through a Spanish surname algorithm (NAACCR 
Hispanic Identification Algorithm (NHIA) version 2).  However, some state registries (for 
example, South Carolina) do not opt to report Hispanic ethnicity case counts to USCS for state-
specific analyses (though they are included in aggregated national data); thus, in our analysis we 
do not examine race/ethnicity as mutually-exclusive categories.  Though race is inclusive of 
Hispanic ethnicity, we estimate that of the data available in our analysis, only about 1.8% are of 
Hispanic origin.   
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Statistical Analysis 
The Kaplan-Meier method was used to estimate time-to-event unadjusted curves.  
Comparisons of survival curves were examined using the Log-rank test, “the best known and 
most widely used test for differences in the survivor function.” (Allison, P. 2010; pg. 41)  Cox 
proportional hazard models were used to determine the effect of timing/extent of GO 
involvement on all-cause mortality, adjusting for covariates identified as important from the 
literature.  Multicollinearity between covariates was examined with correlation matrices for high 
correlations (greater than or equal to 0.3) as well as by examining variance inflation factor and 
tolerance values (or 1/variance inflation factor) at acceptable tolerance of 0.1 or less, as the 
general rule of thumb (Wooldridge 2009).  For this analysis, we additionally examined the 
collinearity between receipt of cytoreductive surgery and timing/extent of GO care.  Due to the 
high correlation (pairwise correlation statistic of 0.60) attributed to GO generally performing 
cytoreductive surgery with minimal/no residual tumor, receipt of cytoreductive surgery was not 
included in the model.  The final model did, however, include an indicator for chemotherapy 
treatment receipt, given its association with survival time, modeled as a time-independent fixed 
effect.  Model specifications and the proportional hazards assumption were examined by analysis 
of Schoenfeld residuals (Cleaves, M. et al 2010; pg 206).  Ties were handled using the Efron 
method (Cleves, M. et al 2010; pg 151).  Cox model results are reported as hazard ratios (HR) 
and 95% confidence intervals (CI).  Interactions of age and NCI-designated cancer center as well 
as race and NCI-designated cancer center were examined for inclusion in the final model.  We 
also examined the interaction of NCI-designated cancer center and the timing variable to 
determine whether GO involvement varied by care facility; however, it was not included in the 
final model due to non-statistically significant association.  We conducted post-hoc analyses to 
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examine differences in characteristics among women in the sample.  All analyses were 
performed using STATA version 13 (College Station, TX).   
 
RESULTS 
A total of 2,162 women with ovarian cancer were identified from South Carolina and 
Georgia state cancer registries between 2004-2014.  The mean age at primary cancer diagnosis 
was 61 years; most women were White (75.5%), insured through Medicare (44.8-45.6%) or 
private insurance (38.1-38.4%), and largely resided in urban areas (79.4%).  About half had 
serous adenocarcinomas (50.3%).  Most were diagnosed with FIGO stage IIIC (39.0%) or IV 
(19.1%), grade III or IV disease (i.e. poorly differentiated tumors/unknown) (77.0%), and had no 
comorbidities (72.3%) (Table 7).  The most commonly diagnosed individual comorbidities were 
diabetes (13.2%) and chronic obstructive pulmonary disease (4.6%) (results not shown).  About 
80% of the women in the sample were not seen at an NCI-designated cancer center and only 
about one-third received any care at a teaching hospital facility.  
The median unadjusted survival time among all women in the sample was approximately 
529 days (standard deviation=391), or the equivalent of about 17.6 months.  Among women who 
had not had a GO involved during their care, the median (unadjusted) time from diagnosis to 
death was approximately 628 days (or ~20.9 months), whereas median (unadjusted) time from 
diagnosis to death was 114 days (or ~3.8 months) among women with pre-operative GO 
involvement only; 1,395 days (or ~46.5 months) among women with intraoperative/post-
operative GO involvement only; and 1,194 days (or ~39.8 months) among women with GO 
involvement at all phases.  Survival time was shorter among women of advanced age, stage, and 
those with greater comorbidities.  White women had longer median time from diagnosis to death 
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(1126 days vs. 842 days, Log-rank p<0.001) than women of other races.  By place of care, 
women seen at NCI-designated cancer centers had longer median survival time compared to 
those who were not seen at an NCI cancer center (1828 days vs 897 days, Log-rank p<0.001), 
but there was no statistically significant difference between those seen at teaching facilties vs. 
non-teaching facilities (1113 days vs. 1020 days, Log-rank p=0.461) (Table 8).  
After adjusting for all covariates, a statistically significantly lower risk of mortality was 
observed for women who received GO care intraoperative/post-operatively [HR=0.46 (95% CI: 
0.34-0.61), p<0.001] and at all phases [HR=0.72 (95%CI: 0.57-0.91), p=0.01] compared to those 
whom had not had a GO involved in care (Table 9a).  When limited to only women who received 
cancer-directed surgery, those receiving intraoperative/postoperative care from a GO still 
demonstrated lower risk of mortality [HR=0.68 (95%CI: 0.49-0.96), p=0.03] (data not shown).  
The lower relative risk of death was also observed among women who received care at an NCI-
designated cancer facility irrespective of GO involvement [HR=0.76 (95%CI: 0.61-0.96), 
p=0.02].  Although in unadjusted analysis, there were differences in survival time by race (Log-
rank p<0.001), there were no racial differences after adjustment [HR=1.04 (95%CI: 0.87-1.24), 
p=0.69].  Also after adjustment, poorer outcomes were observed among those with advancing 
age, stage, and greater comorbidities (Table 9a).  When examining the interaction of race and 
NCI-center designation, there was a statistically significant lower risk of overall mortality 
[HR=0.63 (95%CI: 0.41-0.96, p=0.03)] among White women compared to African 
Americans/other race women seen at NCI-designated cancer centers.  (Table 9b).  
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DISCUSSION 
Previously, we identified the patient- and healthcare systems- level factors and their 
associations with the timing/extent of GO involvement in ovarian cancer care (Rim et al. Aim 1).  
In this analysis, we further examined the effect of the timing/extent of GO involvement on all-
cause survival.  Overall, the 3-year survival probabilities were 36% among women who had no 
GO involvement, 59% among women who had received intraoperative/postoperative care and 
54% among those with GO care at all phases.  Similar to other studies, our results suggested that 
better survival outcomes were observed among women receiving intraoperative/postoperative 
care from GO subspecialists (Bristow et al. 2014b; Mercado et al. 2010; Roland et al. 2004), as 
expected given that surgery is a clinical specialty for GOs and is an important determinant of 
outcomes for ovarian cancer patients.   
Three-year survival was also better among women seen at an NCI cancer center.  In 
concordance with other studies that have found NCI cancer center attendance to be associated 
with reduced odds of mortality and better surgical outcomes (Birkmeyer et al. 2005; Onega et al. 
2009b), in our analysis, women receiving intraoperative/postoperative GO care at NCI-
designated cancer centers had 3-year survival probabilities of 73% vs. 50%, NCI- vs. non-NCI-
designated center, respectively.  Similarly, for women receiving GO care at all phases, the 3-year 
survival probabilities were 82% vs. 50% (NCI- vs. non-NCI-designated centers), respectively.  
By race, Caucausian women had longer median survival time in unadjusted analyses; however, 
race was not statistically significantly associated with increased risk of mortality after controlling 
for covariates (no statistically significant differences were noted in sensitivity analyses where 
Hispanics were removed from Caucasian/White race).  Among women not seen at an NCI-
designated cancer center, there was no difference in mortality risk by race; among women seen at 
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an NCI-designated cancer center, however, there was a statistically significant lower risk of 
mortality among Caucausian patients compared to their other race counterparts [HR=0.63, 
p=0.03].   
Survival statistics are one of the most useful measures in evaluating quality of care 
(Mariotto et al. 2014).  From the patient- and healthcare-systems perspective, it is an integral part 
of measuring equity in access to diagnosis, appropriate treatment, healthcare systems 
performance, and achieving desirable/clinical optimal outcome (Hewitt, Simone, and Editors 
1999).  NCI-designated cancer center, given their centralizing of multidisciplinary teams and 
demonstrated excellence in cancer care, have been shown to have lower surgical mortality rates 
than counterparts treated at high-volume hospitals (Birkmeyer et al. 2005) and better overall 
patient survival outcomes (Onega et al. 2009a).  Our study largely concurred with these findings 
with overall survival generally better among women seen at NCI-designated cancer studies; 
moreover, in post-hoc analyses, a greater proportion of women received cytoreductive surgery at 
NCI cancer centers vs non-NCI centers (86.1% vs 72.6%, p<0.001); greater proportion of GOs 
were involved in surgery (86.8% vs. 67.3% at NCI vs. non-NCI center respectively, p<0.001); 
and a greater proportion of GOs were involved in chemotherapy (70.8% vs 63.4%, p=0.004) at 
NCI vs. non-NCI center, respectively.       
In our analysis, survival was moderated differentially by race.  Three-year survival 
probabilities among women seen at NCI-designated cancer centers was 73% vs 49%, White vs. 
African American/other race, respectively compared to 44% vs. 41%, White vs. African 
American/other race at non-NCI-designated centers.  While mortality did not vary by race among 
women seen outside of an NCI-designated cancer center (as we might expect given the high case 
fatality of ovarian cancers), White women seen at NCI cancer centers had lower risk of mortality 
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than African American women, after adjustment of other factors.  To examine potential 
explanations for these differences, we conducted further post-hoc bivariate analyses of 
variables/attributes related to process of care, surgical/chemotherapeutic treatment receipt, and 
number and type of specialty care providers involved in care.  Briefly, some reasons why 
survival may have differed at NCI-cancer centers by race include  1) greater proportion of 
African American women had diagnoses of stage IV cancers, 2) African American women less 
frequently accepted intraperitoneal chemotherapy (which has been associated with improved 
disease-specific survival), 3) lower likelihood of surgical and chemotherapeutic treatment receipt 
among African American women compared to White women, 4) and lower proportion of African 
American women accessing GOs at NCI-cancer centers.  The racial differential in survival by 
NCI- vs non-NCI-designated cancer center attendance also may be driven by differences in 
geographic barriers to access—i.e. given variation on reported use of NCI-cancer centers 
associated with proximity to cancer facilities (particularly for African Americans) (Huang et al. 
2014; Onega et al. 2009a)--financial barriers, referral patterns and/or other 
predictors/impediments of NCI cancer center attendance that were not examined in this study.   
Our results differ from one previously noting no significant mortality differences among 
African Americans vs. Caucasian Medicare patients with lung, breast, colorectal and prostate 
cancers who attended an NCI cancer center for their care (Onega, et al (2010)) (Onega et al. 
2010b); there is at least one potential explanation in that the demographics of the analytic sample 
were different.  Ovarian cancer patients have a different disease trajectory (mostly diagnosed at 
later stages when the prognosis can be poor despite surgical treatment) and multilevel factors 
associated with treatment receipt and treatment preferences (i.e. differential access to clinical 
trials and aggressive chemotherapy by race).  As such, our results likely reflects heterogeneity of 
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clinical management, the process of patient care in large cancer centers, as well as provider and 
patient-level preferences that are not measured in this study.   
Our findings should be considered in light of several limitations. First, though our data 
show an association between race and care delivered from an NCI-designated cancer center, the 
data are retrospective and observational and should be interpreted with caution as patient- and 
provider- preferences, referral patterns, adjuvant chemotherapeutic treatment receipt and other 
factors may play a role in where a patient receives their care and how such influences survival 
outcomes.  Further exploration is warranted to examine other potential reasons (biologic or 
environmental, system/ process or preference) for differences in survival among African 
Americans vs. Caucausians seen at NCI-designated cancer centers.  Similarly, when examining 
the association between women who had seen a GO pre-operatively/consult only and survival, 
findings may need to be interpreted with the understanding that women who had seen a GO for 
pre-operative/consult only, consistent with the previous study (Rim et al. Aim 1), were likely 
clinically different patients than those who received intraoperative/postoperative care and 
continuous care at all phases; they were more frequently were older (aged ≥70 years), had a 
higher proportion of stage IV cancers, diagnoses of adenocarcinomas not otherwise specified, 
and greater (≥3) comorbidities.  (Data shown in Appendix 1 and 3).  These patients had median 
survival time of less than four months (114 days) and consistently poorer survival probabilities in 
multiple adjusted analyses; it is possible that these women may have had lower prior 
probabilities of survival at the outset of diagnosis and thus may not have benefited from GO 
involvement.  Second, despite our best efforts to capture all prognostic indicators, these data 
were not inclusive of optimal cytoreduction and the extent of residual disease as a covariate (in 
survival models) due to high collinearity with the GO variable.  Also, it is likely that the timing 
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of chemotherapy treatment receipt (neoadjuvant) with respect to debulking surgery from a GO 
may have influenced survival time (Kuhn et al. 2001; Mueller et al. 2016; Siesto et al. 2016; 
Vergote et al. 2011), chemotherapy treatment receipt was included as a time-independent fixed 
effect, resulting in potentially biased estimates.  Third, while previous studies (Birkmeyer et al. 
2005; Onega et al. 2009a; Onega et al. 2010b; Onega et al. 2009b; Onega et al. 2014) were 
inclusive of multiple SEER regions (or collectively 15 NCI-designated cancer centers among the 
SEER registries), our analysis was limited to only data from two states (Georgia and South 
Carolina).  As such, the demographic distribution and healthcare access within these states may 
not be generalizable to women in other U.S. regions.  Still, understanding differences by specific 
cancer center site may help to establish “benchmarks” that could assist in improving referral 
processes and/or other oncology services (Onega et al. 2009a).  Furthermore, per data use 
agreement with these state registries, the analysis was also restricted to White and African 
American/other races and did not separately examine Hispanic ethnicity.  While these registries 
do offer a larger proportion of African American ovarian cancer patients than most other states 
(http://wonder.cdc.gov/cancer.html), future studies should attempt to draw upon larger samples 
sizes and explore the role of Hispanic ethnicity in terms of survival.  Lastly, due to the 
limitations of the data, our approach did not require more than one incidence of care from an 
NCI cancer center in order to be considered receiving care from an NCI-designated cancer 
facility.  Also, due to the limitation of the data, our analysis did not examine ovarian cancer-
specific mortality.  
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Conclusion 
This study contributes to the literature on the impact that gynecologic oncologists and 
specialized cancer care facilities, like NCI-designated cancer centers, have on outcomes 
(Birkmeyer et al. 2005; Onega et al. 2009b).  GO involvement intraoperatively/postoperatively 
as well as continuously at all phases, per NCCN recommendation, have an important impact on 
3-year probability of survival, particularly when patients are seen at an NCI-designated cancer 
center.  Our findings provide added evidence in terms of the importance of examining access to 
comprehensive, quality cancer care centers and also underscore the importance of examining 
equitable care delivery among all subpopulations.   
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Table 7.  Descriptive Statistics of the Analytic Sample of Women in the Ovarian Cancer 
Treatment, Subspecialist Care, and Outcomes Study (n=2,137) 
 
 
Total  
GO involved 
(n=1,591) 
GO not 
involved 
(n=434) 
Characteristics n (%)  (%) or Mean (SD) 
Dependent Variable      
Mean Days from Diagnosis to Death 
(standard deviation) 
 
 547 (391) 480 (393) 
Independent Variable     
Timing of GO involvement  n (%)  (%) (%) 
   No involvement 434 (21.4)  ₋₋ ₋₋ 
   Preoperative/consult only 125 (6.2)  ₋₋ ₋₋ 
   Intraoperative/Postoperative 1077 (53.2)  ₋₋ ₋₋ 
   All phases 389 (19.2)  ₋₋ ₋₋ 
Covariates     
Age     
   ≤49 449 (21.0)  20.7 19.1 
   50-59 466 (21.8)  23.3 17.1 
   60-69 566 (26.5)  27.7 23.3 
   ≥70 656 (30.7)  28.3 40.6 
Race     
   White 1614 (75.5)  77.2 70.3 
   African American/Other 523 (24.5)  22.8 29.7 
FIGO Stage     
   I 469 (22.6)  22.8 18.1 
   II 191 (9.2)  9.7 8.0 
   IIIA/IIIB 213 (10.3)  9.5 13.3 
   IIIC 794 (38.3)  43.3 20.8 
   IV 409 (19.7)  14.8 39.9 
Charlson Comorbidity Score     
   None 1544 (72.3)  71.0 75.4 
   One/Two 480 (22.5)  23.4 19.6 
   Three or more 113 (5.3)  5.7 5.1 
Histology     
   Serous papillary 1080 (53.3)  56.3 43.2 
   Endometrioid 233 (11.5)  12.8 5.4 
   Clear cell/mucinous/all other  
   adenocarcinoma 270 (13.3)  15.0 6.6 
   Adenocarcinoma NOS 220 (10.9)  7.8 22.4 
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   Other carcinoma 224 (11.1)  8.2 22.4 
NCI-designated Cancer Center     
   Yes 417 (19.7)  24.7 3.5 
   No 1703 (80.3)  75.4 96.5 
Teaching hospital     
  Yes  698 (32.7)  33.8 26.8 
  No 1438 (67.3)  66.2 73.2 
Note: The analytic sample excluded 25 individuals for whom all gynecologic oncologist (GO) 
variables were unknown.  Abbreviation: SD = standard deviation 
 
 
  
87 
 
Table 8. Kaplan-Meir Median (unadjusted) Time (in days) from Diagnosis to Death by 
Individual Subgroups 
 
 Diagnosis to Death 
Characteristics Median SE p-value 
Independent Variable    
Timing of GO involvement    <0.001 
   No involvement 628 71.5  
   Preoperative/consult only 114 12.6  
   Intraoperative/Postoperative 1,395 66.0  
   All phases 1194 97.8  
Covariates    
Age   <0.001 
   ≤49 1778 92.5  
   50-59 1461 155.6  
   60-69 1037 63.8  
   ≥70 570 44.8  
Race   <0.001 
   White 1126 51.2  
   African American/Other 842 71.4  
FIGO Stage    
   I n/a  <0.001 
   II 1956 158.6  
   IIIA/IIIB 840 42.8  
   IIIC 951 45.9  
   IV 425 54.1  
Charlson Comorbidity Index   <0.001 
   None 1228 73.9  
   One/Two 784 68.2  
   Three or more 467 85.5  
NCI-designated Cancer Center   <0.001 
   Yes 1828 208.4  
   No 897 36.5  
Teaching Facility   0.461 
   Yes 1113 71.1  
   No 1020 59.6  
        
Note: Log-rank Test for testing the equality of the survivor functions across groups. Statistical 
significance considered at p=0.05. 
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Table 9a.  Cox Proportional Hazard Model Regression Results of Time from Diagnosis to 
Death Among Women in the Ovarian Cancer Treatment, Subspecialist Care, and 
Outcomes Study  
 
 Diagnosis to Death 
Characteristics HR 95% CI  p-value 
Timing of GO involvement     
   No involvement 1.00   
   Preoperative/consult only 1.62 (1.21-2.16) <0.001 
   Intraoperative/Postoperative 0.46 (0.34-0.61) <0.001 
   All phases 0.72 (0.57-0.91) 0.01 
Chemotherapy Receipt (yes) 1.00   
   No receipt 3.73 (3.06-4.56) <0.001 
Age (continuous) 1.02 (1.01-1.02) <0.001 
Race    
   White 1.04 (0.87-1.24) 0.69 
   African American/Other 1.00   
FIGO Treatment Stage    
   I/II 1.00   
   IIIA/IIIB 5.00 (3.50-7.13) <0.001 
   IIIC 5.70 (4.22-7.70) <0.001 
   IV 7.69 (5.65-10.47) <0.001 
Charlson Comorbidity Index 
(continuous) 1.12 (1.06-1.18) <0.001 
Histology    
   Serous papillary 0.92 (0.72-1.17) 0.48 
   Adenocarcinoma NOS 1.49 (1.11-1.99) 0.01 
   Other carcinoma 1.36 (1.02-1.80) 0.04 
   Clear cell/mucinous/all other  
   adenocarcinoma 1.00   
NCI-designated Cancer Center     
   Yes 0.76 (0.61-0.96) 0.02 
Insured Continously  0.77 (0.55-1.07) 0.12 
HR=hazard ratio; CI=confidence interval 
Note: Model controls for registry state; includes patients with complete survival at 3-years 
(56%). 
Number of Subjects: 1913 
Number of Failures: 679 
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Table 9b.  Cox Proportional Hazard Model Regression Results of Time from Diagnosis to 
Death Among Women in the Ovarian Cancer Treatment, Subspecialist Care, and 
Outcomes Study – Interaction of Race and Place of Care (NCI-designated Cancer Center) 
 
 
 Diagnosis to Death 
Characteristics HR 95% CI  p-value 
    
Race*NCI Cancer Center 0.55 (0.35-0.88) 0.01 
NCI vs non-NCI-designated     
   White 0.64 (0.48-0.84) 0.002 
   Non-White 1.15 (0.78-1.69) 0.47 
White vs Non-White    
   NCI-designated 0.63 (0.41-0.96) 0.03 
   Non-NCI-designated 1.13 (0.93-1.38) 0.21 
        
 
HR=hazard ratio; CI=confidence interval 
Note: other covariates from Table 9a were also included in the model: timing of GO 
involvement, chemotherapy receipt, age, race, FIGO stage, Charlson comorbidity index, 
histology, NCI-designated cancer center, insurance status (continuously insured), registry site.    
Complete survival at 3-years (56%).  
  
90 
 
 
 
 
 
 
 
 
 
CHAPTER 6: TREATMENT DECISIONAL ROLE AND PSYCHOSOCIAL RESPONSE 
DURING AND AFTER AN OVARIAN CANCER DIAGNOSIS: a CDC-Funded Study on 
Research to Understand Treatment Choices in Ovarian Cancer (AIM 3)  
OVERVIEW 
Objectives: This study’s objective was to explore patient-level concerns during treatment 
decision-making and factors associated with decisional self-efficacy during perioperative care.   
Methods:  We conducted phone-based surveys with 170 ovarian cancer patients (response rate 
66%), recruited from hospitals in Alabama and Georgia and the Alabama Statewide Cancer 
Registry.  Survey questions were adapted from Cancer Care Outcomes Research and 
Surveillance Consortium questionnaire. Women were asked about gynecologic oncology care, 
decisional role, decisional self-efficacy, social support, and cancer/treatment-related concerns 
during decision-making. 
Results:  More than half of the women in the study (58%) reported a “shared” role with the 
clinician in decision-making; 79% indicated a GO as the most important physician in helping 
them make treatment decisions.  Overall, most women had high confidence in their ability to get 
facts about treatment choices, ask questions, and make choices that suited them.  However, after 
adjusting for covariates, African American, older women, and those of lower income status, had 
lower decisional self-efficacy.  African American women also had greater probability of regret 
about their decisional role.  Younger age and lower income brackets were also statistically 
significantly associated with greater worries after their cancer diagnoses, adjusting for perceived 
self-efficacy and social support.   
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Conclusion:  Despite the overall high confidence about making treatment-related decisions, 
there are still subgroups of ovarian cancer patients who may benefit from better patient-physician 
communication and additional decisional/social support services during perioperative care.   
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INTRODUCTION 
An ovarian cancer diagnosis can be a traumatic life experience that significantly impacts 
one’s psychological health.  It is a disease often characterized by a high mortality rate and/or 
high risk of recurrence (du Bois et al. 2003).  As such, women with ovarian cancer are 
particularly vulnerable to psychosocial challenges and potential adverse effects of distress, 
anxiety, and depression during and after a diagnosis (du Bois et al. 2003; Roland et al. 2013).  
Cancer survivors frequently report experiences of psychological distress (Massie 2004) that have 
adversely impacted health behaviors, quality of life, and survival (Chou et al. 2012; Pinquart and 
Duberstein 2010; Satin, Linden, and Phillips 2009).  Survivors’ responses to their cancer 
diagnosis can be both problem-focused (i.e. beliefs or strategies about managing the condition) 
or emotionally-regulated, with responses that involve both positive coping (e.g., believing that 
the cancer experience makes them stronger, helps them to cope with other life challenge) or 
negative coping (e.g., harboring fear/worries) (Hack and Degner 2004).   
Prior research has suggested that a patient’s psychological response to cancer can 
differentially influence disease progression, recovery, and survival outcomes (Burgess, Morris, 
and Pettingale 1988; Lutgendorf and Andersen 2015; Lutgendorf and Costanzo 2003; Lutgendorf 
and Sood 2011; Stavraky et al. 1988).  Based on the biopsychosocial model of disease (Engel 
1977), a combination of psychological, biologic, and social factors are thought to jointly 
influence disease etiology, progression, and health outcomes (Lutgendorf and Costanzo 2003).  
Under this framework, these factors interact along two main pathways—psychosocial processes 
and health behaviors—to affect disease vulnerability, onset, and downstream mechanisms of 
exacerbation, recovery, and survival (Lutgendorf and Andersen 2015; Lutgendorf and Costanzo 
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2003; Lutgendorf and Sood 2011).  Both synergistically affect one’s quality of life (Costanzo et 
al. 2006; Lutgendorf and Andersen 2015). 
Given that long-term survival (defined as greater than 5 years) is a challenge for most 
ovarian cancer patients and that the psychological burden of fear of disease recurrence is high 
(Ozga et al. 2015), other aspects of care like health-related quality of life is an important 
consideration (Herzog et al. 2014).  As such, understanding the psychosocial processes (i.e. 
“factors that affect interpretation of and response to life events and stressors” (Lutgendorf and 
Costanzo 2003)) that women experience in managing the stress of their cancer diagnosis and 
treatment decisions for care, as well as the social support needs they may have during the course 
of care, is an important step in improving ovarian cancer survivorship and health outcomes.  
Furthermore, it may lead to more patient-centered care, a key element of the U.S. Patient 
Protection and Affordable Care Act of 2010 (HR3590).   
Patient-centered care has been defined as “providing care that is respectful of and 
responsive to individual patient preferences, needs, and values, and ensuring that patient values 
guide all clinical decisions” (Institute of Medicine, 2001) (IOM 2001).  Within this patient-
physician partnership, patients are encouraged to take an active role in their care and discuss 
needs (both emotional and practical) – communication and shared decision-making about 
treatment options are expected to benefit patient outcomes (IOM 2001).  However, in the early 
stages of the cancer diagnosis – when the stress may be intense and the clinical relationships 
nascent – patients may be more likely to defer treatment decision-making to the oncology 
specialist, a historically clinical role (Rutten et al. 2005; Thorne, Oliffe, and Stajduhar 2013), and 
may not feel empowered to ask questions and voice their concerns or preferences for care.       
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Although the perioperative period (prior and post-surgical treatment) can provide an ideal 
opportunity for improving patient-physician communication, optimizing a patient’s decisional 
self-efficacy and improving upon survivorship needs (Seibaek et al. 2013), to date, the literature 
has been sparse on how to address these needs and the patient-level preferences and constructs 
that influence emotional well-being at the time of treatment decision-making (Andersen et al. 
2012; Luketina et al. 2012).  While studies have examined general role preferences in decision-
making (Andersen et al. 2012; Stewart et al. 2000) and factors influencing treatment decisions 
among ovarian cancer patients via qualitative interviews (Elit et al. 2010; Elit et al. 2003; Elit et 
al. 2015; Fitch, Deane, and Howell 2003; Jolicoeur et al. 2009), still very little is known about 
whether certain subgroups of women may be susceptible to needing greater assistance in 
decision-making and ways of addressing the concerns these women have during treatment.     
We used the Transactional Model of Stress and Coping framework to better understand 
the psychosocial response during and after a cancer diagnosis and to further examine whether a 
patient’s decisional self-efficacy or social circumstances can alter the survivorship concerns for 
women with ovarian cancer (Glanz et al. 2008).  First, we explored ovarian cancer patient-level 
concerns (i.e. what women worry about such as cost, physical, and psychological needs) during 
treatment decision-making and factors associated with decisional self-efficacy during 
perioperative care.  Second, we examined the impact of decisional confidence and social support 
on the magnitude of worries during treatment.  We aimed to identify the women potentially most 
vulnerable to having decisional/supportive care needs and in doing so, identify whether there are 
opportunities to intervene and improve upon patient needs during perioperative care. 
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METHODS 
The Research to Understand Treatment Choices in Ovarian Cancer (RUTH) study was 
initiated to understand the factors that women and their physicians consider in decision-making 
about ovarian cancer treatment.  The RUTH study was approved by the University of Alabama at 
Birmingham and Centers for Disease Control and Prevention Institutional Review Board 
(protocol # X120914008).     
 
Conceptual Framework 
The diagnosis of cancer, the medical treatment of it, and/or other internal/environmental 
determinants may affect psychological and physical well-being and behavioral outcomes.  To 
more carefully examine the patient-level beliefs/behaviors that influence a women’s emotional 
well-being and decisional state during and after diagnosis, we drew upon key constructs of the 
Transactional Model of Stress and Coping, a framework to better understand the impact of the 
diagnosis process and management through the stressful/traumatic life event (Glanz et al. 2008).  
Figure 5 details RUTH survey items corresponding to each framework construct.   
According to the Transactional Model of Stress and Coping, in the primary appraisal 
phase, a woman initially assesses the potential significance of the threat (i.e. her perceived 
susceptibility and perceived severity of signs/symptoms).  Such RUTH items included questions 
on the number of symptoms, care sought for these symptoms and the patient’s psychological 
response to these symptoms.  Secondary appraisal involves the perceived ability to control/cope 
with the “stressor” (i.e. cancer diagnosis) (Glanz et al. 2008), for example, their decisional self-
efficacy and role in decision-making.  Coping efforts mediate these appraisals, but involve 
complexities of both a problem-management and an emotionally- /meaning-based focus.  This 
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encompasses both the perceived physical and emotional benefits and barriers to treatment.  
According to this model, coping strategies may be affected further by a sense of meaning or 
purpose (i.e. spiritual beliefs and religion) and the presence/type of social support in the 
individuals’ life.  For this analysis, we focused particularly on the effects of secondary appraisal 
(perceived self-efficacy) and social support on cancer-related worries during treatment decision-
making, a proxy for decisional state and well-being.  Within this framework, we hypothesized 
that stronger (more confident) perceived self-efficacy and stronger (more reliable) social support 
was associated with lower cancer-related worries.    
 
Survey Development 
The RUTH survey collected information (during 2013-2014) on demographics, 
symptoms that led to the diagnosis, initial treatment offered and received, medical decision 
making, goals of treatment and prognosis, and other financial/coverage-related information 
among ovarian cancer patients.  The survey instrument was adapted from the questionnaire used 
for the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) 
(http://appliedresearch.cancer.gov/cancors/), which surveyed lung and colorectal cancer patients 
to examine patient-reported outcomes and clinical and psychosocial domains pertaining to 
medical decision-making (Malin et al. 2006).  Questions most-relevant to the intent of the RUTH 
study (described above) were retained from CanCORS.  Questions directly related to ovarian 
cancer were added, as identified from the literature, including questions related to fertility 
sparing surgery or sexual concerns which have been shown to be important domains for women 
with ovarian cancer (Grzankowski and Carney 2011; Mirabeau-Beale et al. 2009; Sun et al. 
2005) and questions about care needs (Darby et al. 2009; Sherwood et al. 2008).  Questions from 
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the decision self-efficacy scale (O'Connor 1995) were also added as important aspects of medical 
decision-making.  
The survey was piloted in two rounds with ovarian cancer patients identified through the 
University of Alabama at Birmingham’s healthcare system, and cancer survivors from an ovarian 
cancer support group in Birmingham, AL.  The final revised survey questions were informed by 
these discussions.   
 
Patient Population and Recruitment 
Patients in the RUTH Study included women within one year of an ovarian cancer 
diagnosis recruited from several different sources.  Recruitment took place through:  1) the 
Alabama Statewide Cancer Registry (ASCR), 2) partnerships with the University of South 
Alabama/Mitchell Cancer Institute in Mobile, AL and Northside Hospital in Atlanta, GA and 3) 
in-reach recruitment efforts through the University of Alabama at Birmingham (UAB) hospitals.   
Eligible patients included women who 1) were aged 21 years or older, 2) had a diagnosis 
of ovarian cancer (stage I-IV or unstaged) within one year, 3) were proficient in the English 
language, and 4) were able and willing to provide their consent to participate in a telephone-
based survey.  Women were specifically excluded if they were currently being treated for 
another primary cancer or were institutionalized.  Reasons for non-eligibility (e.g., disconnected 
phone/could not be reached, non-English speaker, etc.), or declining to participate (e.g., personal 
preference) were documented.    
Only women (n = 170) who met the RUTH study inclusion criteria were recruited and 
interviewed in the study.  Survey recruitment strategies had minor variations by site.  Study 
coordinators at each site reviewed a list of newly diagnosed ovarian cancer patients obtained 
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from each of the sources and assessed eligibility.  When appropriate, physicians were consented 
for permission to contact their patients.  Potential participants were then initially contacted by a 
letter providing detailed information about the study and an invitation to contact a 1-800 phone 
number or email address to learn more about the study.  Within several days (of the letter being 
mailed out), the potential participant was contacted by phone for an eligibility screen, verbal 
consent, and to schedule a date/time for the 60-minute structured, phone-based interview.  
Potential participants were also given the option to decline participation at any time.        
 
Survey Administration  
All surveys were administered via Computerized Assisted Telephone Interview (CATI) 
system by the UAB Survey Research Unit (SRU) of the Center for the Study of Community 
Health (a CDC-funded Prevention Research Center).  All participants received a $50 gift card for 
completing the survey.  Each of the three interviewers received study-specific training to assure 
familiarity with the content (and were additionally trained on proper interviewing techniques, 
unbiased probing, questions/skip patterns and using the CATI system).  As a quality assurance 
measure, interviewers were randomly, electronically monitored, at minimum four times per 
month.  Interviews were recorded through the CATI system and data were maintained in secure 
format.   
As a part of the RUTH Study, a qualitative, sub-study was conducted three months after 
the end of the initial study period.  A convenience sample of ten additional women agreed to 
participate in in-depth interviews to further elaborate on their experiences.    
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Measures 
The RUTH survey included original questions as well as previously-used instruments and 
existing scale items to address treatment decision-making concerns among women with ovarian 
cancer.  For this analysis, we selected variables that corresponded to constructs of our conceptual 
model and examined them for internal consistency and reliability.    
 
Decisional Role 
We assessed the patients’ self-reported decisional role in decision-making during 
treatment as well as their preference for a different decisional role (i.e. decisional regret) in 
making treatment decisions.  Response options for self-reported decisional role were: 1) you (i.e. 
the patient) made the decision with little or no input from your doctors 2) you made the decision 
after considering your doctors’ opinions 3) you and your doctors made the decision together 4) 
your doctors made the decision after considering your opinion 5) your doctors made the decision 
with little or no input from you 6) don’t know what role you had in treatment decisions.  For 
analyses, responses were categorized as “patient control” (response 1 or 2), “shared control” 
(response 3), “physician control” (responses 4 or 5), “unclear patient role” (response 6), as 
previously described (Kehl et al. 2015).  
Decisional regret was assessed from respondents’ indicating “yes” to the following 
question: “Did the role you had in making decisions about cancer treatment differ from what you 
prefer your role to be?”  
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Ovarian Cancer Patient Worries 
This twelve-item worry scale was adapted from the CanCORS Survey to assess 
participants’ concerns about ovarian cancer treatment and the degree to which these concerns 
relate to aspects of finances/cost, daily functioning, and psychological concerns.  Borrowing 
from the CanCORs survey item, participants were asked: “At the time you were making 
decisions about your treatment for [ovarian cancer], how much were you worried about each of 
the following?” Response options included: very worried, somewhat worried, a little worried, 
and not at all worried.  Individuals who refused to response or indicated “don’t know” were 
excluded from the analysis for that variable.  Individual items of the scale are shown in 
Appendix 4.  Responses were summed across the twelve items for composite scores ranging 
from 0 to 36, with higher scores indicating greater worry.  The internal consistency estimate of 
reliability for this scale was adequate (Cronbach’s alpha for worry items=0.87).  The item-total 
correlation ranged from 0.35 to 0.79.    
For analysis, we were interested in worry as a proxy for decisional state and 
psychological well-being; thus, we retained a single latent construct (or 1-factor solution) for 
regression model.  We examined the factor structure of a twelve-item worry scale derived and 
adapted from the CanCORs survey item. Factor loadings for 2-factor, 3-factor, and 4-factor 
solutions are reported in the Appendix 5.  Patient worries about financial cost of treatment 
explained approximately 80% of the variance in the patient worry scale based on exploratory 
factor analysis.  Although cost concerns continued to be a dominant factor in 2-factor and 3-
factor analyses (data shown in Appendix 5), other domains of worry included that of cancer 
treatment/impact on functioning as well as more practical/familial/body image concerns.   
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Perceived Decisional Self-Efficacy 
To gauge patients’ involvement in treatment decision-making, study participants were 
asked to score how confident they felt in making an informed choice based on eleven self-
efficacy items adapted from the Decisional Self-Efficacy Scale (O'Connor 1995).  For 
interpretation of these items, the 5-point responses for each scale item were summed, divided by 
11, and multiplied by 25, such that the scores would range from 0 (not at all confident/extremely 
low self-efficacy) to 100 (very confident/extremely high self-efficacy), per the user’s manual for 
the scale (AM O’Connor, 1995) (O'Connor 1995).  Cronbach’s alpha for perceived self-efficacy 
scale items was 0.92.   
       
Social Support Scale  
Social support was measured with a scale adapted from the Medical Outcomes Study 
Social Support Survey (Sherbourne and Stewart 1991), a 19-item self-administered survey 
covering four major domains: emotional/informational, tangible (or instrumental), positive social 
interaction, and affection (Sherbourne and Stewart 1991).  The scale, intended for combined and 
individual use, has been commonly administered in various populations including cancer patients 
(Malin et al. 2006).  The CanCORs survey further adapted these items to include subscales of 
both institutional (or instrumental/tangible) social support and affective (or emotional) social 
support.(Consortium)  More specifically, institutional social support included having help 1) if 
confined to bed 2) to go to the doctor if needed 3) to prepare meals and 4) to conduct daily 
chores.  Affectionate social support included items of emotional comfort such as having someone 
1) to talk to 2) to give you good advice 3) to give you information to help you understand 4) to 
confide in 5) to share your worries/fears with.  The full list of social support scale items is listed 
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in Appendix 4.  Values for overall and subscales ranged from 0 to 100, with higher score values 
indicating greater social support.  The overall social support scale had sufficient internal 
consistency (Cronbach’s alpha=0.94); the social support subscales for affective social support 
had an alpha of 0.92 and institutional social support had an alpha of 0.89.  
 
Key Variable Definitions 
Covariates included demographic (i.e. age, race), clinical (i.e. number of symptoms, 
number of comorbidities, stage) and self-reported health status.  Race was dichotomized as 
White vs. African American/Other (due to the small counts of other racial groups) and stage was 
grouped as either early (stage I or II) or late (stage III or stage IV); unknown stage (n=52) was 
included in the late stage grouping since women diagnosed at later stages (i.e. stage IIIC or IV) 
are more likely to not be optimally or feasibly have surgical staging procedures.  Self-reported 
health status was determined from one item borrowed from the Short Form 12-item Health 
Survey: “In general, would you say your health is Excellent, Very Good, Good, Fair, or Poor?”  
While “good” was retained as a standalone category, the first two (Excellent and Very Good) and 
last two (Fair and Poor) were combined into single categories, as there were insufficient numbers 
(<10% of respondents) in the “excellent” and “poor” quality of life categories.   
 
Statistical Analysis 
Descriptive statistics were used characterize the study sample in terms of their 
sociodemographic and clinical variables and to summarize survey items across each of the 
domains.  We conducted bivariate analyses of the relationship between each covariate and the 
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outcomes of interest.  Chi-square tests were used for categorical variables and t-tests to assess 
bivariate relationship for continuous variables.   
Linear regression analyses (univariate and multivariable) were used to examine the 
association between demographic, clinical, and/or psychosocial factors on cancer-related worry 
during treatment decision-making for ovarian cancer.  Unadjusted and adjusted ordinary least 
squares regression (OLS) models were examined on two outcomes 1) perceived self-efficacy 
scores and 2) worry scores.  Regression models were examined against OLS model assumptions.  
Briefly, no clear nonlinear pattern was noted in plotting the standardized residuals against each 
of the predictor variables; normality of residuals were examined for valid hypothesis testing.  
However, given that unequal variance (heteroskedasticity) was a concern in the perceived self-
efficacy regression model based on the Breusch-Pagan / Cook-Weisberg Test (Wooldridge 
2009), the final models presented in this paper include a Feasible Generalized Least Squares 
(FGLS) model (or a log-model on the square of the residuals) (Cameron and Trivedi 2005; 
Wooldridge 2009) for the perceived self-efficacy scores and OLS regression for the worry scale 
dependent variable with robust standard errors specified.   
Multicollinearity between covariates was examined using pairwise correlation 
coefficients and the variance inflation factor (vif), which quantifies how much of the variance is 
inflated.  Results from this test showed a mean vif of 1.67 for the perceived self-efficacy linear 
regression model and vif of 2.10 for the worry regression model (i.e. less than the 0.1 cautionary 
threshold for tolerance, equaled to 1/vif) (Wooldridge 2009).     
Recruitment site was examined but not controlled for in final regression models given the 
non-statistically significant association between it and outcome variables. Robust and nonrobust 
standard errors were examined as an informal test of model misspecification.  All tests for 
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statistical significance were assessed at p<0.05.  Analyses were conducted in SAS version 9.3 
(Cary, NC) and STATA version 13.0 (College Station, TX).  Average  marginal (or differential) 
effects from regression modeling were used to estimate the difference in each scale unit (i.e. self-
efficacy or worry) for a difference in one unit of the independent variable, holding all else 
constant (Long and Freese 2014).        
 
Model Specification 
Though the model specification was theory-driven, regression specification error test 
(RESET) was performed to examine potential model specification error, specifically, whether 
higher order terms were omitted or irrelevant variables are included.  No higher order terms were 
included in the final model.   
 
RESULTS 
Characteristics of the Study Participants 
Table 10 shows the characteristics of the 170 women with ovarian cancer who 
participated in the RUTH survey.  The mean age at diagnosis was 61 years of age.  A greater 
proportion of women were White (72%), had more than a high school education (62%), were 
retired (38%), married/living with a partner (51%), and reported less than $25,000 in income 
(34%).  Most women also indicated having access to a primary care doctor (91%); the proportion 
of women having accessed at least one gynecologic oncologist during their care was high (66% 
for diagnosis; 97% for surgery; and 71% for chemotherapy).  Greater than half of the study 
participants reported being “religious” (67%) and about one-third reported good (32%) or very 
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good/excellent health (38%).  About 22% had International Federation of Gynecology and 
Obstetrics (FIGO) Stage I/II disease, 47% FIGO Stage III/IV, and 31% were unknown/unstaged.   
 
Decisional Role  
 About 58% of women in the RUTH Study reported a “shared” role with their provider at 
the time of treatment decision-making.  Among women reporting a shared role, 79% indicated 
gynecologic oncologists vs. other physician specialties as being the “most important physician in 
helping [them] to decide on treatment.”  Most women indicated either being in control over their 
decisions or sharing the decision with the physician; still 17% indicated having an unclear role in 
the decision process (Table 11a).  Overall, most women (88%) did not have regrets about their 
role in the decision; however after controlling for age, stage, and comorbidities, African 
American women had a 19 percentage point greater probability of regret about their decisional 
role (i.e., preferring a different role than the one they had) compared to White women (p=0.01) 
(Table 11b).   
 
Social Support 
 More than 70% of the women participating in the RUTH study indicated having someone 
available “all or most” of the time to help with transportation to the doctors’ office, meal 
preparation, informational or emotional support (a listening ear, good advice in a crisis, or 
available to confide in).  The mean social support score was 83.0 for affective support (i.e. 
individuals to talk to, provide help in understanding a situation, confide in, or share with) and 
79.8 for institutional (i.e. help with daily chores, physical functioning, and tangible activities) 
support. 
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Perceived Self-Efficacy 
 Upon their cancer diagnosis, women generally had high confidence (> 70 decisional 
perceived self-efficacy score) in their ability to get the facts about their treatment choices, ask 
questions, and figure out choices that best suited them (Table 12).  Still some women, such as 
African American women (β=-7.55, p<0.01) and older age women (β=-0.31, p<0.01), had an 
expected decisional self-efficacy score that was lower than their respective White and younger 
aged counterparts.  While stage, perceived (self-reported) quality of life, and perceived (self-
reported) importance of a gynecologic oncologist as the most important treating physician were 
not significantly associated with self-efficacy, higher income levels (β=10.60, p<0.01) and 
overall social support did have a significant association with greater confidence/self-efficacy for 
treatment decision-making (β=0.17, p=0.045).   
 Specifically in terms of social support, more affectionate social support (i.e. individuals 
to talk to, provide help in understanding a situation, confide in, or share with) was positively 
associated with a unit increase (β=0.44, p<0.001) in decisional self-efficacy and being confident 
about treatment decisions, adjusting for other covariates.  Needing institutional social support 
(i.e. help with daily chores, physical functioning, and tangible activities) was associated with 
lower decisional self-efficacy at the time of treatment decision-making (β=-0.11, p<0.05) (Table 
13).           
 
Effect of Perceived Self-Efficacy and Social Support on Patient Worries During Treatment  
 In multivariable linear regression models, the association of perceived self-efficacy and 
both affectionate and institutional social support on worry were not statistically significantly 
different from zero after adjustment for other covariates (Table 13).  Age (a one-unit increase) 
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and higher income brackets (those making > $75,000 compared to lower income) however, was 
statistically significantly associated with decreased worries after adjustment for perceived self-
efficacy and social support.   
 In additional analyses adjusting for covariates (Appendix 6), we examined the association 
of perceived self-efficacy and social support on specific item-level worries.  Being confident to 
express concerns was statistically significantly associated with approximately 25% point lower 
probability of worries specifically about cost.  Having reliable support (i.e. support most or some 
of the time) for help with daily chores was significantly associated with a 17 to 21 percentage 
point lower probability of worries about cost, transportation, and body image, after adjustment 
for other covariates.  African American women had a 16% point greater probability (p=0.05) of 
being worried about transportation, though after adjustment for self-reported health status and 
social support, this differential effect was not statistically significant.  (Appendix 6).   
 
DISCUSSION  
 This cross-sectional study of 170 ovarian cancer survivors recruited into the RUTH Study 
examined the individual and social influences on cancer-related worries during the course of 
care.  Our study adds to the relatively sparse literature on ovarian cancer patient experiences 
(How et al. 2015) and provides better insight into how a woman perceives her diagnosis and her 
ability to make decisions about and cope with treatment of the disease.  Knowledge of these 
considerations can aid in addressing the psychosocial care and support needs of cancer patients, 
which is a crucial component of delivering high-quality care during and after treatment and is a 
focus of federal initiatives per the Institute of Medicine’s 2006 report From Cancer Patient to 
Cancer Survivor: Lost in Transition, the 2008 call to action on Cancer Care for the Whole 
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Patient: Meeting Psychosocial Health Needs, and the Affordable Care Act (IOM 2006; IOM 
2008).  Awareness of these psychosocial support needs can also aid in developing interventions 
to improve quality of life and emotional well-being throughout ovarian cancer survivorship. 
 Our descriptive analyses showed that women in our study generally displayed a relatively 
high degree of confidence in their ability to make informed decisions about treatment.  Still, 
there were subgroups of women with greater decisional needs (i.e. older women, African 
American women, and women of lower income/socioeconomic status had poorer perceived 
decisional self-efficacy).  Furthermore, there were important cancer treatment-related and non-
cancer treatment-related concerns that they faced, including worry about side effect, cost, sexual 
concerns, family-related care or productivity loss.  Specifically, younger aged, lower income 
women had poorer psychological well-being at the time of treatment decision-making (i.e. 
greater cancer worry).  Social support among these women also varied with about a quarter or 
more indicating unreliable support for chores, daily activities, emotional and financial advice.  
The type of social support (affectionate or institutional) appeared to have differing effects on the 
degree of decisional confidence, either enhancing or suppressing self-efficacy.        
 While extending life and “curing cancer” are high priorities for women with ovarian 
cancer, the treatment decision-making studies and qualitative narratives of women with the 
disease have also suggested the importance of quality of life (Fitch 2003; Fitch et al. 2003; Fitch 
et al. 1999; Frey et al. 2014; Havrilesky et al. 2014).  For example, previous studies with 
advanced stage patients have suggested progression-free survival to be the most important factor 
women considered in preferences for chemotherapy (Havrilesky et al. 2014).  However, 79% 
women in the same study participating in a discrete choice experiment indicated a willingness to 
accept some reduction (approximately 5-7 months) in survival time for improvements in 
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treatment-related side effects (Havrilesky et al. 2014).  Similarly, in a more recent focus group 
study (Frey et al, 2014), only 2 of the 22 women (9%) indicated that they would “tolerate side 
effects that negatively impact[ed] quality of life” (Frey et al. 2014); hence, the majority of 
women desired better quality of life over toxic side effects.  Their preference for “an 
individualized approach to care focusing on quality of life measures” and their narratives of 
personal experience suggests that conversations about severity of side effects and the benefits of 
therapy should be coupled together during physician discussions with the patient (Frey et al. 
2014).            
 Discussions about treatment decisions are complex and occur at multiple layers (patient, 
caregiver/family/friends, provider, etc.).  The literature is limited and inconsistent in terms of the 
role cancer patients prefer in making treatment decisions about their care (Luketina et al. 2012).  
Though some earlier studies have suggested that patients dealing with serious, life-threatening 
illnesses were unable to gather information and engage fully in treatment decisions due to the 
trauma of the diagnosis (Sanders and Skevington 2003; Ziebland, Evans, and McPherson 2006), 
the women in our study were overall generally confident in terms their perceived self-efficacy of 
treatment choices: to “get the facts about treatment choices available,…the benefits of each 
choice,…the risks and side effects of each choice” and “figure out the choice that best suited 
[them].”  In our study, this effect was more prominently observed among those with affectionate 
social support.  Our results showed that those with affectionate social support had a statistically 
significant higher probability of being confident about treatment decisions.  As others have 
examined (DiMatteo 2004; Forsythe et al. 2014; Magai et al. 2007), having social support can 
create an environment or provide practical assistance for a patient that facilitates their “active 
involvement” in receiving or following-up with their care (Forsythe et al. 2014).  In particular, 
110 
 
emotional support (such as having someone to talk to, provide help in understanding a situation, 
or confide in) can improve a patient’s sense of control and actual participation in treatment 
decision (Forsythe et al. 2014).      
 In our study, a high proportion (approximately 59-60%) of women indicated “sharing” 
the decisions about their treatment with their doctor or with their family.  Though these findings 
were similar to another study among ovarian cancer survivors (Stewart et al. 2000), it is expected 
that not all patients desire the same extent of voicing a role in their care.  The vast discordance 
between the preferred vs actual role in decision-making across cancer types, based on a 
systematic review of 19 studies (2010), suggests a need to examine, understand, and articulate 
treatment goals and decisions more clearly between physician-patient individually and by cancer 
types (Tariman et al. 2010).  While a greater proportion of gynecologic cancer patients appeared 
to prefer a “passive role” (47%, leaving decisions to the doctor) over a more “active role” (21%, 
autonomous) or “shared role” (32%, agreement with the physician) based on the single 
gynecologic cancer study included in the systematic review, as the authors note, these 
preferential roles could change throughout the course of treatment and thus, decisional role 
preference should require regular assessment and clinician sensitivity to these issues for better 
treatment decision-making (Tariman et al. 2010).  Even still, as our study suggests, the ability 
and confidence of voicing concerns during treatment may be important and closely associated 
with specific reduced worries (and greater well-being) during and post treatment.  
 
 Our RUTH survey data were also enriched with a qualitative, follow-up sub-analysis of 
semi-structured interviews with ten participants.  The major themes that emerged from these 
women’s personal narratives of their ovarian cancer diagnosis and survivorship experience 
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mirrors some of the major domains of our study.  The most significant worries during and after 
treatment were related to treatment and how side-effects impact family/work/other activities as 
well as social support and informational needs about other aspects of care (including financial 
aspects) post-diagnosis.  About one-third of participants in the RUTH study indicated unmet 
emotional needs (having someone to share private worries and fears with) and 
financial/informational advice about treatment and appointments.  Overall, about a quarter of the 
women in the RUTH study indicated needing (desiring) such a support group, but about 69% of 
those women did not receive it.   
 One participant experience in our study indicated needing resources “for knowing how to 
deal with [the] cancer” and the survivorship issues (i.e. maintaining health and well-being in the 
months after treatment) during and after treatment.  Similarly, another participant affirmed the 
need to speak with other women who had been diagnosed with the same type of cancer to talk 
about “daily activities…how much exercise [to] get during chemo[therapy]…,” etc.  Like the 
women in our study, a prior study of hematological cancer survivors reported that emotional 
health such as “dealing with feeling worried” and relational needs like “finding someone to talk 
to who understands and has been through a similar experience” were important concerns; these 
issues were among the top 5 ‘high/very high’ unmet needs for patients in that study (Hall et al. 
2015a).  Feelings of worry were higher specifically among survivors reporting difficulty meeting 
day-to-day expenses resulting from their cancer and treatment (Hall et al. 2015a).   
 The under-recognition and under-utilization of psychosocial support services among 
cancer patients have continued to be documented in the literature (Forsythe et al. 2013; Hall et al. 
2015a; Han et al. 2015).  An analysis of the 2010 National Health Interview Survey data 
suggested that more than half (55%) of cancer survivors in the U.S. (approximately 6.9 million) 
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did not receive psychosocial counseling (Forsythe et al. 2013).  The most common barrier, 
among the reasons for non-use of professional counseling and support groups, was from a lack of 
knowledge about the availability of such services (Forsythe et al. 2013).  The study also noted 
that provider discussions were positively associated with use of psychosocial counseling and 
support groups (22% use vs 8% non-use, p<0.001) (Forsythe et al. 2013).  Although, in our study 
and qualitative interviews, we did not assess whether the women were aware of these provisions 
and/or whether a provider engaged them in discussions about these services, there was a clear 
indication of an unmet need.        
 In addition to the major stressor of a cancer diagnosis (Lutgendorf et al. 2013), women in 
our study experienced other “non-cancer life stressors” (e.g. financial concerns, job loss, etc.), 
which one study has shown, has a greater impact on the quality of life burden and mental health 
of the cancer patient than the severity of the stressor itself (Lutgendorf et al. 2013).  In this time-
series analysis of 123 epithelial ovarian cancer patients, those with a greater number of non-
cancer stressors at baseline (pre-operatively) had poorer quality of life at one-year post diagnosis, 
after adjusting for cancer stage, age, anxiety/depressive mood, and chemotherapy status 
(Lutgendorf et al. 2013).  Such long-term effects on quality of life have also been noted for other 
cancer patients, including melanoma, breast, and prostate cancer (with quality of life decrements 
at >3-4 months post-diagnosis) (Lehto et al. 2008; Lutgendorf et al. 2013).   
 The presence of social support groups have been shown to mitigate the effects of such 
“stressors” as they have been associated with better psychological response (i.e. depression and 
distress) that affect biological response (Costanzo et al. 2005) and subsequent health outcomes.  
Psychosocial-immune research with ovarian cancer patients have implicated the advantages of 
social support (both emotional and tangible) and psychological factors (such as positive/active 
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coping strategies) on innate immune response (Costanzo et al. 2005; Lutgendorf et al. 2012), by 
offering informational and human networks for coping, giving/receiving empathy, and 
resources/advice for symptom/disease management (Roland et al. 2013).  These social support 
networks are particularly important for women with ovarian cancer, as they may be prone to 
experiencing high gender-specific psychosocial burden (i.e. problems with self-image and 
sexuality (Roland et al. 2013)) and social isolation associated with having a relatively rare cancer 
diagnosis with fewer long-term survivors (Ferrell et al. 2003a; Ferrell et al. 2003b; Ferrell et al. 
2003c).  Psychologic burden is also exacerbated with concerns like fear of death/disease 
recurrence, which are prevalent for ovarian cancer survivors (Ozga et al. 2015); however, we did 
not specifically assess this domain in our study given the recency of diagnosis among the 
participants.      
 There are limitations of this study that need to be acknowledged.  First, the RUTH Study 
represents a proportion of ovarian cancer survivors recruited largely from AL and GA cancer 
facilities, including an in-reach recruitment effort through the UAB hospitals.  As such, results 
from this study cannot be generalized to the broader population of ovarian cancer patients.  The 
data presented are descriptive and intended to be hypothesis-generating.  Furthermore, a larger 
proportion of patients, than previously observed in the literature (Carney et al. 2002; Chan et al. 
2007b; Cress et al. 2011; Earle et al. 2006), had been seen by a gynecologic oncologist, at any 
point during their care.  Given the limitations of the study design and that recruitment efforts 
may attribute to this, we were unable to examine how patients not seen by a GO may differ from 
those seen by a GO.  Second, as with most surveys and participant recruitment strategies, there is 
a potential for selection bias.  For example, participants who agreed to participate in the RUTH 
study may be systematically different from those who chose not to participate; non-respondents 
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may have had differing responses to survey items.  We are unable to assess the degree to which 
these responses differ.  Furthermore, our data may be subject to recall bias, as there is a lag time 
(up to one year) in which we rely on patient’s to recall treatment-related decisions.  Despite these 
limitations, lessons learned and insights garnered from individual survivors within the study 
provide important information potentially missed opportunities to connect survivors to 
appropriate interventions; the psychosocial concerns and supportive care needs among ovarian 
cancer patients that surfaced within the surveys can be further examined (with the goal of 
alleviation) in a population-based manner, using methodologically rigorous research designs.     
 
Conclusion 
 Under the biopsychosocial model, behavioral stress-reduction interventions and 
improving social support (along the disease trajectory) may be viable disease management 
strategies for enhancing the effectiveness of cancer treatment (Lutgendorf and Costanzo 2003).  
Monitoring stress burden at the time of diagnosis and continuing to re-evaluate the 
quantity/quality of acute and chronic “stressors” and social connectedness throughout the 
trajectory of disease and treatment, may have important implications for long-term quality of life 
and for addressing cancer survivorship.  Such monitoring may also provide opportunities for 
cognitive or behavioral interventions – i.e. coping strategies that can be taught – to improve the 
emotional well-being and survivorship for these patients.  Given the economic impact of 
psychosocial concerns on cancer survivorship, amounting to an estimated $4431 more annually 
compared to cancer patients without these issues according to one study (Han et al. 2015), 
addressing these concerns effectively in clinical practice could additionally aid in reducing the 
cost of survivorship while delivering patient-centered care.  
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Table 10.  Characteristics of Women in the RUTH Sample (n=170) 
Characteristics Total n % 
Age   
   ≤54  44 25.9 
   55-59 20 11.8 
   60-64 34 20.0 
   ≥65 72 42.4 
Race   
   White 123 72.4 
   African American/Other 47 27.7 
Education   
   Less than high school  15 8.8 
   High school graduate 50 29.4 
   Some college 63 37.1 
   College graduate 42 24.7 
Employment Status   
   Employed for wages or self-employed 42 24.7 
   Retired 64 37.6 
   Disabled 35 20.6 
   Temporarily unable to work 14 8.2 
   Other* 15 8.8 
Marital Status   
   Married/living together 87 51.5 
   Widowed/divorced/separated 68 40.2 
   Never married 14 8.3 
Income   
   Less than $25,000 53 34.0 
   $25 to $49,999 39 25.0 
   $50 to $74,999 25 16.0 
   More than $75,000 39 25.0 
Primary Care Doctor   
   Yes 154 91.1 
   No 15 8.9 
Religious   
   Very 113 66.5 
   Moderately 48 28.2 
   Non-/slightly 9 5.3 
Self-reported health status   
   Excellent  12 7.1 
   Very good 42 25.0 
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   Good 63 37.5 
   Fair 36 21.4 
   Poor 15 8.9 
FIGO Stage    
   I/II 38 22.5 
   III/IV 79 46.8 
   Unknown  52 30.8 
      
Note: Other employment includes homemaker and otherwise not specified. 
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Table 11a.  Unadjusted Frequencies of Decisional Role by Race  
 Overall  White 
African American/ 
Other p-value* 
RUTH Sample (n=170) n (%)  n (%) n (%)  
Decisional Role     0.72 
   Patient Control  35 (20.8)  25 (20.5) 10 (21.7)  
   Shared Control 98 (58.3)  71 (58.2)  27 (58.7)  
   Physician Control 7 (4.2)  4 (3.3) 3 (6.5)  
   Unclear Patient Role 28 (16.7)  22 (18.0) 6 (13.0)  
      
Preferred to have a different role than the role you had  0.002 
   Yes 19 (11.8)  8 (6.7) 11 (26.2)  
   No 142 (88.2)  111 (93.3) 31 (73.8)  
            
 
 
Table 11b.  Decisional Regret by Race, Adjusting for Age, Stage, and Comorbidities 
Preferred to have a different role 
than the role you had (Decisional 
Regret) 
 Margins (SE) 
Race  
   White Reference 
   African 
American 0.19 (0.07)# 
  
Note: # African American women compared to White women had a statistically significant 19% 
point increase of decisional regret (preferring a different role than the one they had) after 
controlling for age, stage, and comorbidities.  
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Table 12.   Unadjusted Mean and Adjusted Marginal (or Differential) Effects from 
Multivariable Linear Regression of RUTH Participants’ Perceived Self-Efficacy  
 Decisional Perceived Self-Efficacy† 
 
Unadjusted 
Mean (SE)  p-value*  Marginal Effect SE§ 
Age —   -0.31** 0.10 
Number of Symptoms    0.82* 0.39 
Number of Comorbidities    1.10 1.38 
Social Support‡      
   Institutional  —   -0.11* 0.05 
   Affectionate —   0.44*** 0.08 
Race  0.02    
   White 77.79 (1.6)   Reference  
   African American/Other 70.74 (2.8)   -7.55** 2.36 
Perceived Quality of Life  0.89    
   Excellent/Very Good 76.24 (2.6)   Reference  
   Good 75.07 (2.2)   0.47 2.45 
   Fair/Poor 76.69 (2.6)   2.95 2.89 
FIGO Stage  0.78    
   Early 75.00 (3.5)   Reference  
   Late 75.95 (1.5)   0.95 2.87 
Education  0.50    
   < High school graduate 71.82 (5.3)   Reference  
   High School graduate 77.86 (2.1)   -1.53 3.56 
   > High School  75.44 (1.9)   1.84 3.03 
Income  0.08    
   Less than $25,000 70.68 (3.0)   Reference  
   $25 to $49,999 77.16 (2.3)   6.93 3.55 
   $50 to $74,999 78.73 (3.1)   10.60** 3.84 
   More than $75,000 79.72 (2.9)   11.19** 4.03 
Treating Physician Specialty  0.18    
   Gynecologic Oncologist 76.78 (1.5)   1.10 3.04 
   Other 72.06 (3.3)     Reference   
    r2 = 0.3565  
    N=150  
†Perceived Self-efficacy mean scale items range from 0 to 100. 
‡Social support scale was further examined by subscales for institutional social support and 
affectionate social support, per CanCORs (values range from 0 to 100). 
* indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001.  p-value for unadjusted means 
were based on Wald F-tests from unadjusted linear regression models 
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Table 13.  Unadjusted Mean and Average Marginal (or Differential) Effects from 
Multivariable Linear Regression of Patient Worries During Cancer Treatment Decision-
Making  
 
 Overall Worry Score¥ 
  
Unadjusted 
Mean (SE) p-value  
Marginal 
Effect SE§ 
      
Age —   -0.20** 0.06 
Number of Symptoms —   0.036 0.30 
Number of Comorbidities —   -0.99 0.60 
Perceived self-efficacy†  —   0.0013 0.05 
Social Support      
   Institutional  —   0.036 0.05 
   Affectionate —   -0.036 0.06 
Race  0.79    
   White 15.47 (0.8)   Reference  
   African American/Other 15.89 (1.6)   -0.43 1.84 
Perceived Quality of Life  0.04    
   Excellent/Very Good 14.42 (1.2)   Reference  
   Good 14.31 (1.1)   -0.58 1.73 
   Fair/Poor 18.22 (1.4)   3.06 1.83 
FIGO Stage  0.32    
   Early 16.88 (1.5)   Reference  
   Late 15.22 (0.8)   -2.18 1.84 
Education  0.54    
   < High school graduate 18.08 (2.5)   Reference  
   High School graduate 15.10 (1.2)   -2.05 2.39 
   > High School  15.47 (0.9)   -0.074 2.44 
Income  0.45    
   Less than $25,000 17.48 (1.5)   Reference  
   $25 to $49,999 15.85 (1.3)   -3.11 1.85 
   $50 to $74,999 15.00 (1.9)   -3.06 2.73 
   More than $75,000 14.45 (1.3)   -6.41** 2.47 
Treating Physician Specialty  0.94    
   Gynecologic Oncologist 15.61 (0.8)   -1.75 1.82 
   Other 15.48 (1.8)   Reference  
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Marital Status  0.12    
   Married/living together 14.7 (1.0)   Reference  
   Widowed/divorced/separated 15.8 (1.2)   -0.82 1.88 
   Never married 20.1 (1.6)   0.089 2.25 
Religious  0.03    
   Non-/slightly 20.0 (2.0)   Reference  
   Moderately 17.8 (1.5)   -2.56 2.87 
   Very 14.3 (0.8)     -5.24 2.63 
Note: ¥Worry values range from 0 (least) to 36 (greatest).  
†Perceived Self-efficacy mean scale items range from 0 to 100. 
‡Social support scale was further examined by subscales for institutional social support and 
affectionate social support, per CanCORs (values range from 0 to 100). 
* indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001.  p-value for unadjusted means 
were based on Wald F-tests from unadjusted linear regression models 
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CHAPTER 7:  SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY,  
PRACTICE, AND RESEARCH 
Summary of Findings and Implications for Policy, Practice, and Research 
Timely and comprehensive access to quality care remains a priority in the treatment of 
ovarian cancer.  This dissertation examined 1) the overall and differential access of GO care by 
patient- (i.e. age, race/ethnicity) and healthcare systems-level characteristics (i.e. NCI-designated 
cancer center) 2) the relationship between GO timing/extent and its effect on survival outcomes 
by patient- and healthcare systems-level characteristics and 3) the patient-level perspectives and 
attributes that affect treatment decision-making for care.  Briefly, as others have documented, we 
found that younger women, those with higher income, and women seen at an NCI-designated 
cancer center were more likely to ever see a GO (Carney et al. 2002; Chan et al. 2007b; 
Hightower et al. 1994; Mercado et al. 2010).  Also, we found that accessing GO at all phases of 
care and particularly within NCI-designated cancer centers was associated with best survival.  
Our study was among the few to report on the differential impact of care at NCI-designated 
cancer centers on survival (Birkmeyer et al. 2005; Onega et al. 2009b) specifically among 
ovarian cancer patients (Bristow et al. 2015).  We found that while GO involvement and care at 
NCI-cancer care centers did improve median survival overall, differences were apparent by 
patients’ race and where they accessed care (i.e. NCI-designated cancer center vs. non NCI-
designated cancer center).  These differences in care may contribute to the observed differences 
in ovarian cancer survival.  Among patients largely seen by a GO, patients’ perception of the GO 
being the most important physician in their care had no effect on their treatment decisional self-
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efficacy.  However, other psychosocial domains (like affectionate social support) did impact 
patients’ level of confidence about treatment decisions.  Our findings highlight the importance of 
both GO subspecialty in delivering quality ovarian cancer care and the healthcare system 
characteristics (i.e. where patient care is received), such as NCI-designated cancer center, as 
relevant to survival.  At the patient-level, this research emphasizes important considerations in 
decision-making that may help improve the delivery of patient-centered ovarian cancer care.    
In Chapter 4, we found that nearly 80% of patients in the Ovarian Cancer Treatment, 
Subspecialist Care, and Outcomes Study sample of women with ovarian cancer had accessed a 
GO at some point during their care.  Among the women who had a GO involved, most (68%) 
had received both intraoperative/post-operative care from the GO.  Only about a quarter had a 
GO involved at all perioperative phases of their care.  Age was a significant predictor of whether 
women had ever seen a GO and the extent to which women received perioperative care from a 
GO.  Consistent with prior studies, older women (aged ≥ 70 years) were less likely than younger 
women to be seen and treated (intra/post-operatively) by a GO (Hightower et al. 1994; Tew and 
Fleming 2015).  Women were more likely to ever see a GO if they had higher income, were 
treated in a teaching hospital facility, or were seen in NCI-cancer centers.  At NCI-designated 
cancer centers, White women were significantly more likely to ever see a GO than non-White 
women.  Despite concerns for a lack of subspecialists across the U.S. (ASCO 2015), the 
proportion of women with a GO involved in their care was higher in our study than other 
published studies, (which ranged from as low as 21% to 71% in earlier studies from earlier years 
(Carney et al. 2002; Chan et al. 2007a; Cress et al. 2011; Earle et al. 2006; Nguyen et al. 1993)).  
Although it is difficult to speculate why women in our registry sample had a high proportion of 
accessing GO care, some potential reasons for this may be due to the mounting evidence and call 
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for action over the years, towards a more centralized approach to gynecologic oncology care 
(Bristow et al. 2007; Woo et al. 2012).  As such, though only a handful of practicing GOs may 
be within the state (for example, less than 20 each in South Carolina and Georgia, based on a list 
of practicing GOs in 2009 obtained from the Foundation for Women’s Cancer website 
[http://www.foundationforwomenscancer.org/find-a-gynecologic-oncologist]), our results may 
depict the willingness of women (within different “social gradiants” (Robertson and Burge 
2011)) to travel to see a subspecialists for their care over time (particularly in geographically 
smaller states like South Carolina where the distance to travel to a major city like Charleston, 
Columbia, and Greenville may be less of a barrier).  Additionally, these findings may also reflect 
the results of the outreach and awareness efforts in the last decade (since 2005) of major 
organizations like the American College of Obstetricians and Gynecologists, the Society of 
Gynecologic Oncologists, the National Comprehensive Cancer Network as well as the CDC and 
the National Institutes of Health in suggesting women with ovarian cancer obtain treatment from 
a GO and/or be referred to a GO for further evaluation when encountering suspected cases of 
ovarian cancer (ACOG 2011; NCCN 2014; Rim et al. 2011).  A natural extension of this study 
would follow-up with an analysis of temporal trends in GO use by healthcare systems-level 
characteristics and further examine the reasons for state-level differences in access to GOs.  
Policy analysis may be used to examine the impact of recommendation changes on actual 
population-level uptake and adoption of referrals.        
In Chapter 5, we examined the associations of timing and involvement of gynecologic 
oncologists with overall survival.  Not surprisingly, the median survival time was longer (by 
approximately an additional 25.6 months) among women who had had a GO involvement 
intraoperatively/postoperatively.  Subsequently, we explored variations in timing and 
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involvement of GO and survival by race and healthcare facility where the care was received (i.e. 
NCI-designated cancer center vs. non-NCI-designated cancer center).  We confirmed the 
favorable outcome of women seen at an NCI-designated cancer center, as others have shown 
(Friese et al. 2010; Onega et al. 2010b; Onega et al. 2009b).  In our study, women receiving 
intraoperative/postoperative GO care at NCI-designated cancer centers had 3-year survival 
probabilities of 73% vs. 50%, NCI- vs. non-NCI-designated center, respectively.  However, after 
adjustment of covariates, we reported that White women had significantly better survival 
outcomes (lower risk of death) when seen at NCI-designated cancer center than non-White 
women.  Undoubtedly, accessing a GO is dependent upon geographic availability; thus, with the 
concentration of GOs in specialized centers (or affiliations to specialized centers), it is expected 
that women seen at an NCI-designated cancer centers have a high probability of ever seeing a 
GO, as did in our study.  Given that GOs have been shown to more often adhere to standard of 
care, which has been directly linked to improved survival (Rim et al. in press), it is also not 
surprising that survival would be better at NCI-designated cancer centers where there are greater 
proportions of GOs present (in theory) and processes that yield multidisciplinary care teams and 
smoother transitions across different types/phases of care.  We can only speculate on the 
potential reasons for the racial differential in survival by NCI- vs non-NCI-designated cancer 
center attendance that we observed in our study, however, some hypotheses based on prior 
studies suggest variation on reported use of NCI-cancer centers to be a result of a mix of 
geographic (proximity) and cultural (race/ethnicity-related) influences (Huang et al. 2014; Onega 
et al. 2009a).  Our findings do warrant a more careful examination of the flow and process of 
care within NCI-designated cancer centers and/or large, specialized cancer facilities to better 
 125 
 
understand disparate treatment within facilities and how attendance and specific attributes of 
treatment impacts patient care and survival.   
In Chapter 6, we explored patient-level perspectives of GO involvement and concerns 
during perioperative treatment that might affect decision-making/decisional efficacy among 
women with ovarian cancer diagnoses.  While specific health systems and provider attributes can 
and does contribute to the timeliness and extent of care a patient receives, patients also may have 
their own psychosocial or preference-based reasons for treatment receipt (Duska et al. 2015; 
Harder et al. 2013; Puts et al. 2015; Tew and Fleming 2015), including lack of good patient-
provider relationship and effective communication about treatment plans.  This analysis of 
RUTH data provided better insight into how a patient perceives her ovarian cancer diagnosis and 
her ability (self-efficacy) to communicate with her provider and make decisions about and cope 
with treatment of the disease.  Overall, our descriptive analysis highlighted that women in our 
study mostly believed in the benefits of surgery and chemotherapy in prolonging life and even 
curing the cancer.  Though a high proportion of women received surgical and chemotherapeutic 
care from a GO, when examining the actual vs. perceived GO specialty, there was an apparent 
disconnect in women knowing that they saw/received care from a GO.  The majority of women 
(79%) indicated a GO as the most important physician in helping them make treatment decisions, 
yet the treating physician specialty had no significant effect on a patient’s decisional self-
efficacy and their worries.   
Women also generally displayed a high degree of confidence in their ability to get facts 
about treatment choices, ask questions, express concerns about treatment choices, and ultimately 
make choices that suited them.  After adjusting for covariates, however, we identified African 
American women, older women, and those of lower income status as having lower decisional 
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self-efficacy and thus, potential decisional support needs during care.  African American women  
also had greater probability of regret about their decisional role, in our analysis.  While the 
reasons for this were undeterminable from our study, as others have suggested (Mead et al. 
2013), there may be some association between the decisional regret that ethnic minorities more 
commonly experience (compared to their White counterparts) and the level of impact that the 
decision-making unit (the spouse/family member/companion) has on treatment decisions among 
racial/ethnic subgroups.   
Lastly, there were important concerns about side effects, cost, and sexual/body image that 
women in our study faced.  Similarly, there were unmet communication and support needs that 
these women also experienced, as in the case of other studies (Forsythe et al. 2013; Hall et al. 
2015a; Han et al. 2015), despite known associations between effective patient-provider 
communication and social support and better psychological outcomes (Burgess et al. 1988; 
Lutgendorf and Andersen 2015; Lutgendorf and Costanzo 2003; Lutgendorf et al. 2012; 
Lutgendorf and Sood 2011; Mead et al. 2013).  As such, we highlighted these specific areas (i.e. 
in decisional support, psychological/social support needs, and patient-provider communication) 
from our findings, as potentially appropriate focal points for future investigations and 
interventions aimed towards delivering a patient-centered approach to ovarian cancer care.    
Cancer survival reflects complicated processes in care and has been suggested to be a 
measure indicative of access to care and quality of care (Butler et al. 2013; Forbes et al. 2013).  
However, significant gaps and disparities in treatment and survival still persist by demographic 
subgroups that cannot be uniformly explained by adequate access to health care; thus, it is 
important to continue to explore patient-level attributes that may explain reasons for differences 
and variations in survival (Butler et al. 2013; Consortium).  Furthermore, in light of the only 
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marginal increases in overall 5-year relative survival in the past two decades (Kohler et al. 2015), 
and persistently dismal survival rates particularly at 3 to 5-years post diagnosis, continuing to 
identify ways of improving survival as well as other patient-relevant outcomes (i.e. quality of 
life) are important.   
This dissertation research makes several important contributions to the literature in terms 
of potential avenues for improving the quality of ovarian cancer care.  Its contribution is in 
understanding when, where and which patients are accessing GOs and the timing and extent of 
GO involvement on survival outcomes; it additionally provides insight into the differential 
impact that healthcare systems-level characteristics may have on overall survival among racial 
subgroups.  Second, this research explores important patient-level psychosocial and behavioral 
domains that play into treatment-relevant decision-making that may improve communication and 
patient-physician decision-making as well as delivery of better patient-focused ovarian cancer 
care.  Given the renewed national focus on patient-centered outcomes as a measure of quality 
care, an understanding of treatment preference is a critical component of care delivery.  This 
research may provide an essential groundwork for future studies that build upon developing 
inventions and educational materials both for the patient and clinicians and inform strategies for 
improving the quality of ovarian cancer care.   
“The Institute of Medicine (IOM) has defined quality as the degree to which health 
services for individuals and populations increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge” (IOM 1990).  It further specifies that “good 
quality [can entail] providing patients with appropriate services in a technically competent 
manner, with good communication, shared decision-making, and cultural sensitivity” (IOM 
1990).  To further extend the contributions of this research, more evidence is needed to build the 
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science-base for what constitutes high quality care consistent with patient preferences in ovarian 
cancer care.  Given that ovarian cancer is a deadly disease, without effective early detection 
methods, timeliness to quality treatment is (and continues to be) important.  Future research 
efforts should focus on developing better (more refined) quality metrics for ovarian cancer care.  
These may involve a closer examination of the referral process among providers/healthcare 
systems that ovarian cancer patients interface (e.g. primary care, obstetricians-gynecologist, 
emergency room hospitalists, etc.) and detailed examination of the critical (threshold) points for 
the timeliness of referrals and/or care delivery that would impact either the ovarian cancer 
patient’s quality of life or survival outcomes.  While breast cancer studies have associated the 
lack of timely care with racial disparities in breast cancer mortality and the evolution of research 
has led to the “benchmarking” of quality standards (of 60 days from diagnosis to treatment) 
(Richardson et al. 2010), for ovarian cancer, there are no similar quality metrics.  Currently, no 
consistently measured and/or enforced quality metrics exist for timely referrals for surgical and 
chemotherapeutic care to a gynecologic oncologist.  Filling these gaps in research on process 
measures that are critical for ovarian cancer patients receiving timely care may be an important 
launchpoint for narrowing the racial disparities in survival from ovarian cancer.  Having 
considered the recent randomized controlled trial results (from the 14-year United Kingdom 
Collaborative Trial of Ovarian Cancer Screening (Jacobs et al. 2015)), ensuring timely treatment 
still appears to among the most effective strategy for addressing ovarian in patients in this 
country.      
Several limitations exist within the analyses of this dissertation.  First, there are 
limitations on generalizability of the data and findings present within all three aims/analyses.  
Our data were regional, collected from three states (Georgia, South Carolina, Alabama) within 
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the southeast region of the United States, representing different rates of ovarian cancer incidence 
(USCS 2015), distributions of GO subspecialists (Stewart et al. 2014; Stewart et al. 2011) and 
access to healthcare (Austin et al. 2013).  Given data-reporting agreements with states like South 
Carolina, which opted out of reporting state-specific data for Hispanic ethnicity 
(http://www.cdc.gov/cancer/npcr/uscs/technical_notes/interpreting /race.htm), we did not 
examine mutually exclusive race/ethnicity categories within our analyses of Aims 1 and 2.  
Generalizability is further limited in Aim 3 due to a) patient recruitment efforts inherent within 
the study design and b) the susceptibility to selection bias in survey recruitment and 
administration efforts.  Furthermore, for Aims 1 and 2, some factors that have been previously 
shown to impact timeliness to care or outcome from treatment (i.e. high volume facilities/high 
volume physicians, distance to care facilities, etc. (Bristow et al. 2014a; Bristow et al. 2014b)) 
were not captured in the dataset, and as such were not able to included in multivariable 
regression analyses.  Additionally, despite our best efforts to capture all prognostic indicators, 
these data were not able to assess optimal cytoreduction (tumors sized <1cm in diameter or 
thickness (NCCN 2014)) and thus, the extent of residual disease as a covariate were omitted 
from survival models.  These factors, along with other unobservable factors like differences in 
patient choice (uniquely individual decision-making factors), genetic predisposition, general 
health (mental and physical), and health behaviors may have biased our estimates.  Despite the 
potential implications that this may have on our findings and the greater risk of mortality 
observed for specific subgroups, our conclusions were largely supported by the literature and the 
results were in accordance with other prior studies (Bristow et al. 2014b; Bristow et al. 2013; 
Bristow et al. 2002; Bristow et al. 2009; Earle et al. 2006; Mercado et al. 2010; O'Malley et al. 
2012; Onega et al. 2009a, 2010a; Onega et al. 2010b; Onega et al. 2009b).  
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Another notable limitation of our analyses is that our definition of treatment receipt from 
an NCI-designated cancer facility only assumed that the patient repeatedly and continuously 
sought their care primarily at this facility.  Based on our definition, a single incident could have 
qualified as accessing an NCI-designated cancer center, which may not be indicative of the 
quality care that NCI-designated cancer centers have been noted to provide 
(http://www.cancer.gov/research/nci-role/cancer-centers) (Onega et al. 2009b).  Furthermore, 
mortality (in Aim 2) was defined as death from all-causes and was not ovarian cancer-specific.  
Though we note this as a limitation, given the high case fatality rate of ovarian cancers (or stated 
differently, the proportion of individuals who die from the cancer (Rothman 2008); for example, 
in any given year, 11.3 women per 100,000 are diagnosed and 7.4 per 100,000 die from the 
disease), it is anticipated that all-cause mortality was a reasonable approximation of ovarian 
cancer-specific mortality.  Lastly, these studies (Aims 1-3) were observational and thus the data 
have limitations on statements about causality.  Particularly for Aim 3, participants were 
retrospectively assessed on treatment decision-making and as such, data are likely reflective of 
some recall bias given the lag time between patient diagnosis and completion of the survey. 
 
Future Research 
 As previously discussed, our findings highlight opportunities for future research.  While 
clinical medicine continues to search for novel chemotherapeutic agents and delivery approaches 
(Herzog et al. 2014), the major questions for future public health research in ovarian cancer care 
arguably are: 1) How does public health continue to improve ovarian cancer survivorship? and 2) 
What are innovative ways of simultaneously improving ovarian cancer survival and the 
survivorship experience?   
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To postulate areas for future research and improvements in clinical practice in light of our 
findings and the ovarian cancer literature, we draw upon some of the ten essential components to 
public health services (http://www.cdc.gov/nphpsp/essentialServices.html).  First, there is a need 
to “inform, educate, and empower” the public.  Second, we—in public health—have to “assure 
competent public health care workforce”, continue to monitor disease burden, and “evaluate 
effectiveness, accessibility, and quality of personal and population-based health services” 
(http://www.cdc.gov/nphpsp/essentialServices.html).   
Among the women in our registry sample who did not have a GO involvement in their 
care, nearly 50% had “unknown” reasons for non-involvement.  According to our data (Aims 1 
and 2), these women were more frequently of older age, African American/other race, lower 
socioeconomic status, or resided in rural regions.  With these findings, there are a number of 
opportunities for public health outreach and future research efforts.  For example, patient lack of 
knowledge and awareness of the GO subspecialty among these subgroups may contribute to low 
GO utilization previously reported in the literature (Austin et al. 2013; Earle et al. 2006; Goff et 
al. 2006; Nguyen et al. 1993; Rim et al. in press).  As such, for cancer patients susceptible to 
greater educational need, using multi-pronged, community-based, informational outreach 
strategies (per The Guide to Community and Preventive Services, 
http://www.thecommunityguide.org/), may be an effective approach for increasing cancer-
specific knowledge and awareness among targeted populations (Hall et al. 2015b; Sabatino et al. 
2012).   
Patient navigation is also a proven method of improving patient awareness and the 
patient’s experience with the clinical system (Freeman, Muth, and Kerner 1995; Hoffman et al. 
2012; Ramsey, Burke, and Clarke 2003; Weber et al. 2012).  In Chapter 6 (Aim 3), we reported 
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that women voiced a need for having a “someone to talk to who understands and has been 
through a similar experience” (qualitative, follow-up sub-analysis of RUTH participant).  Cancer 
patient navigators and navigator programs, since the 1990s (Wells et al. 2008), have been used to 
provide cancer patients with direct (one-to-one) counseling and guidance through healthcare 
systems.  The goal of patient navigation is in improving access to treatment services and 
ensuring receipt of timely, quality cancer care (Freeman et al. 1995; Ramsey et al. 2009).  In the 
first use of the navigator model, patient navigators were used to facilitate diagnostic and 
treatment follow-up among low-income, medically underserved African American women in 
Harlem, New York with abnormal screening mammograms or with a malignancy (Freeman et al. 
1995).  Others have since shown that even within generally affluent populations, navigator use 
reduced the average diagnostic time for breast cancer (approximately 30 days for “navigated” 
women vs. 39 days for “non-navigated” women) (Hoffman et al. 2012).  Navigation effects (i.e. 
of lower odds of diagnostic delays) were similarly observed among uninsured and privately 
insured women (Hoffman et al. 2012).  The use of patient navigation has shown to improve the 
quality of breast cancer care, per the National Initiative for Cancer Care Quality (Weber et al. 
2012).  As such, patient navigation and peer support efforts are not only promising for potential 
application among ovarian cancer patients in clinical practice, but it is also a much needed area 
of future research (Krok-Schoen, Oliveri, and Paskett 2016).  According to a recent synthesis of 
the literature on patient navigation use among women/gynecologic cancer patients (Krok-Schoen 
et al. 2016), the authors found that only a “few studies have explored [patient navigation] in 
gynecologic cancers” and no studies, to date, had examined the ovarian cancer patient 
population.  Such an intervention among ovarian cancer patients at all phases of care (pre-, intra-, 
and post- diagnosis through survivorship) could potentially reap maximum benefits in terms of 
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addressing unmet communication and support needs, educating women, increasing utilization to 
guideline-adherent care, and ensuring a patient-centered, shared decision-making approach to 
healthcare delivery (Krok-Schoen et al. 2016).  The implication of such policy/practice changes 
(e.g. requirements of all specialized cancer facilities to offer patient navigation services to 
gynecologic/ovarian cancer patients), however, needs to be further assessed as it relates to 
patient outcomes and patient satisfaction. 
These issues are particularly salient in the face of health reform, as more women interface 
with the healthcare system and will likely continue to encounter barriers like “geographic 
isolation [from residing in provider shortage areas], limited health literacy or self-efficacy, 
language barriers” and continue to have unmet psychological and supportive care needs 
(http://www.cdc.gov/cancer/nbccedp/new_directions.htm) (Plescia, Richardson, and Joseph 
2012).  On-going research efforts will need to monitor and examine access to comprehensive, 
quality cancer care centers and continue to promote and ensure the equitable care delivery among 
all subpopulations.  While this has historically been a challenge for the “fragmented” American 
healthcare system (Bashshur et al. 2009; Oberlander 2010), movements toward electronic 
medical records, bi-directional reporting systems, and telemedicine (between subspecialists and 
other clinical providers) open doors for new opportunities.   
There are opportunities to research why care and outcomes might vary among specific 
subgroups; for example, why some women are still not seen by a GO, despite noted benefits and 
recommendations to seek treatment from a GO (Chan et al. 2008; Cress et al. 2011; Giede et al. 
2005; Vernooij et al. 2007) and among those who are seen by a GO, why care might vary by 
cancer care facility.  Conducting focus groups, qualitative interviews, or using a mix-method 
approach has been shown to be a useful method of examining patient barriers and facilitators for 
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adoption of behaviors (Babbie 2011; Wisdom and Creswell 2013; Zhang and Creswell 2013), but 
the innovative uses of a rapid learning healthcare systems model might be another potential 
avenue to explore (Abernethy et al. 2010).  Use of electronic medical records, large population-
based databases, enhanced surveillance systems, or large prospective trials of ovarian cancer 
patients that can assess both systems-level and behavioral/preference-sensitive factors could help 
to disentangle the observed variations in subspecialist use, treatment variation and disparities in 
survival and provide opportunities to optimize care delivery (Chen et al. 2014).  Telemedicine, 
for example, holds promise to allievate the “uneven distribution of quality of care, uneven 
adherence to evidence-based medicine, … [and] prevailing inequities in acces to care that reflect 
geographic, socioeconomic, and cultural disparities” (Bashshur et al. 2009).  Economic analyses 
are needed to continue to assess the impact of innovative, patient-care delivery systems (e.g. 
Cancer Patient-Centered Medical Homes (Hoff, Weller, and DePuccio 2012; Hudson et al. 2012; 
Jackson and Powers 2013)) and novel survivorship care plans (Hollis and Stricker 2014; Palmer 
et al. 2015; Stricker and O'Brien 2014; Taplin et al. 2015) or care enhancement systems like 
“enhanced recovery programs” (Barber and Van Le 2015) on healthcare costs and systems-level 
productivity gained from reducing disparities in care. 
 
Conclusion 
Over the past few decades, there has been a decline in the overall age-adjusted incidence 
and mortality rates for ovarian cancer (USCS 2015).  While these rates are promising, as it 
suggests that the overall risk of being diagnosed with cancer is decreasing (Weir et al. 2015a; 
Weir et al. 2015b), they do not always accurately reflect the burden of ovarian cancer and the 
impact that growing demographic changes may have on the healthcare system and the cancer 
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control community.  In the U.S. each year, ovarian cancer accounts for approximately 21,000 
new cases and 14,000 deaths each year (USCS 2015).  As a greater proportion of older adults 
advance into ages where cancer becomes more common (Weir et al. 2015a), the accurate 
assessment of future ovarian cancer trends is important in order to plan for clinical care needs 
and allocate resources effectively.    
Ovarian cancer survivorship is a complex process that requires a multidisciplinary, 
coordinated care approach.  As such, high quality ovarian cancer care requires an “effective 
clinical system” that is characterized by “consistency, patient-centeredness, team-based care, 
registry-based information systems, and [adaptability to] continuous[ly] improve in treatments 
and delivery” (Frieden 2015).  While national Patient-Centered Medical Home expansion efforts 
and telemedicine efforts are taking steps in that direction (Bashshur et al. 2009; Hoff et al. 2012; 
Jackson and Powers 2013; Larson and Reid 2010), on-going evaluation efforts are necessary to 
determine if there are measurable improvements in quality, reductions in cost, and enhanced 
coordination of patient-centered, patient-satisfactory care.   
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Protection of Human Subjects 
This dissertation qualified as human subjects research as defined by federal regulations 
(45 CFR46.102(f)).  It involved both primary data collection and secondary data analysis of an 
existing dataset.  All secondary datasets released to the researcher (S. Rim/CDC investigator) 
contained only de-identified information and even so, strict data security measures were taken 
(stored in encrypted form on the hard drive using computer encryption software) to keep all data 
strictly confidential. 
All protocols for this study were approved by the UAB Human Subjects Institutional 
Review Board (IRB).  For the women involved in the study, no significant risks (social, legal, 
health-related or other risks) were incurred upon the study participants.  Furthermore, the study 
did not intervene with standard/usual care provided to the patient.  IRB approval was obtained 
from the University of North Carolina at Chapel Hill (S. Rim/UNC doctoral candidate).   
All datasets (primary or secondary) was guarded in physical location of data files and 
with electronic encryption and anti-malware software. Confidentiality is assured in reporting of 
all results.  Dissemination contains only de-identified information of participants.   
Inclusion of Women and Minorities 
The resesearch exclusively focused on women (i.e. ovarian cancer patients) and included 
female minority populations.   
Inclusion of Children 
Children were not included in this project.  Only adult women, having a diagnosis of 
ovarian cancer (generally over age 40 years), were included in the analyses. 
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APPENDIX 1.  DISTRIBUTION OF PATIENT-LEVEL AND HEALTHCARE-LEVEL 
CHARACTERISTICS BY GYNECOLOGIC ONCOLOGIST INVOLVEMENT IN 
OVARIAN CANCER CARE 
 
Characteristics 
No involvement/ 
Pre/consult only 
(n=559) 
Intra/Post-
operative 
(n=1,077) 
All involvement 
(n=389) 
 % % % 
Age    
   ≤49 17.0 20.3 25.4 
   50-59 15.2 23.8 26.7 
   60-69 22.2 29.7 24.9 
   ≥70 45.6 26.2 22.9 
Race/ethnicity    
   White 69.1 78.1 78.7 
   African American/Other 30.9 21.9 21.3 
Insurance coverage    
Payer at diagnosis     
   No insurance/unknown 11.6 7.8 10.3 
   Private 26.1 40.1 51.2 
   Public 62.3 52.1 38.6 
Payer at completion    
   No insurance/unknown 10.0 3.5 8.5 
   Private 25.9 39.7 50.6 
   Public 64.0 56.7 40.9 
Residence    
   Urban 74.4 83.1 76.1 
   Rural 25.6 16.9 23.9 
Income (≥20% below poverty 
level) 48.7 24.4 28.2 
Clinical Characteristics    
FIGO Stage    
   I/II 20.4 34.3 33.4 
   IIIA/IIIB 12.2 7.4 13.6 
   IIIC 20.4 46.8 36.8 
   IV 37.9 11.1 15.2 
   Unknown 9.1 0.5 1.0 
Charlson Comorbidity Index    
   None  70.1 71.9 74.6 
   One to two 22.5 22.5 22.9 
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   Three to more 7.3 5.7 2.6 
Histology    
   Endometrioid 4.9 13.7 13.2 
   Serous papillary 39.6 59.0 58.4 
   Clear cell/mucinous/all other  
   adenocarcinoma 5.9 15.6 17.0 
   Adenocarcinoma NOS 26.3 4.4 6.8 
   Other carcinomas 23.3 7.3 4.6 
Hospital Characteristics    
Teaching hospital    
   Yes  29.6 30.5 41.4 
   No 70.4 69.5 58.6 
NCI-designated Cancer Center    
   Yes  8.3 29.3 11.6 
   No 91.7 70.7 88.4 
        
Note: Public insurance includes Medicaid/Medicare/Military/Other of which Medicare was most 
predominant. 
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APPENDIX 2a.  SURVIVAL PROBABILITIES OF WOMEN IN THE OVARIAN 
CANCER, TREATMENT, SUBSPECIALIST CARE, AND OUTCOMES STUDY BY 
GYNECOLOGIC ONCOLOGIST INVOLVEMENT IN PERIOPERATIVE CARE 
 
 
Time 
(days) 
No GO 
involvement 
Preoperative/ 
Consult Only 
Intra/ 
Postoperative 
Continuously 
All Phases 
365 0.60 0.23 0.88 0.85 
548 0.53 0.17 0.80 0.76 
730 0.46 0.13 0.73 0.67 
913 0.41 0.09 0.66 0.59 
1095 0.36 0.09 0.59 0.55 
 
 
APPENDIX 2b.  SURVIVAL PROBABILITIES OF WOMEN IN THE OVARIAN 
CANCER, TREATMENT, SUBSPECIALIST CARE, AND OUTCOMES STUDY BY 
GYNECOLOGIC ONCOLOGIST INVOLVEMENT IN PERIOPERATIVE CARE AND 
BY CARE AT NCI vs. NON-NCI-DESIGNATED CANCER CENTERS 
 
 
 
Gynecologic Involvement in Perioperative Care by Care at NCI vs Non-NCI-
designated Cancer Centers 
 
 
No GO 
involvement 
Preoperative/ 
Consult Only 
Intra/ 
Postoperative 
Continuously All 
Phases 
Time 
(days) 
Non-
NCI 
NCI-
center 
Non-
NCI 
NCI-
center 
Non-
NCI 
NCI-
center 
Non-
NCI 
NCI-
center 
365 0.61 0.53 0.23 0.20 0.87 0.91 0.83 0.98 
548 0.54 0.40 0.20 0.12 0.75 0.87 0.74 0.91 
730 0.46 0.33 0.15 0.08 0.67 0.82 0.65 0.82 
913 0.41 0.33 0.09 0.08 0.58 0.77 0.55 0.82 
1095 0.36 0.33 0.09 0.08 0.50 0.73 0.50 0.82 
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APPENDIX 3.  DESCRIPTIVE STATISTICS OF THE ANALYTIC SAMPLE OF 
WOMEN IN THE OVARIAN CANCER, TREATMENT, SUBSPECIALIST CARE, AND 
OUTCOMES STUDY BY GYNECOLOGIC ONCOLOGIST INVOLVEMENT 
 
GO not 
involved 
(n=434) 
GO 
involved 
(n=1591) 
GO 
preop 
(n=125) 
GO 
intra/ 
post op 
(n=1077) 
GO all 
phases 
(n=389) 
Characteristics % 
(%) or 
Mean 
(SD)  % % % 
Dependent Variable       
Mean Days from Diagnosis to 
Death (standard deviation) 480 (393) 547 (391)    
Independent Variable      
Timing of GO involvement       
   No involvement ₋₋ ₋₋ ₋₋ ₋₋ ₋₋ 
   Preoperative/consult only ₋₋ ₋₋ ₋₋ ₋₋ ₋₋ 
   Intraoperative/Postoperative ₋₋ ₋₋ ₋₋ ₋₋ ₋₋ 
   All phases ₋₋ ₋₋ ₋₋ ₋₋ ₋₋ 
Covariates      
Age      
   ≤49 19.1 20.7 9.6 20.3 25.5 
   50-59 17.1 23.3 8.8 23.8 26.7 
   60-69 23.3 27.7 18.4 29.7 24.9 
   ≥70 40.6 28.3 63.2 26.2 22.9 
Race      
   White 70.3 77.2 64.8 78.1 78.7 
   African American/Other 29.7 22.8 35.2 21.9 21.3 
FIGO Stage      
   I 18.1 22.8 3.7 24.0 24.9 
   II 8.0 9.7 5.5 10.5 8.8 
   IIIA/IIIB 13.3 9.5 13.8 7.5 13.8 
   IIIC 20.8 43.3 28.4 47.0 37.1 
   IV 39.9 14.8 48.6 11.1 15.3 
Charlson Comorbidity Score      
   None 75.4 71.0 52.0 71.9 74.6 
   One/Two 19.6 23.4 32.8 22.5 22.9 
   Three or more 5.1 5.7 15.2 5.7 2.6 
Histology      
   Serous papillary 43.2 56.3 27.3 59.0 58.4 
   Endometrioid 5.4 12.8 3.3 13.7 13.2 
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   Clear cell/mucinous/all other  
   adenocarcinoma 6.6 15.0 3.3 15.7 17.0 
   Adenocarcinoma NOS 22.4 7.8 39.7 4.4 6.8 
   Other carcinoma 22.4 8.2 26.5 7.3 4.6 
NCI-designated Cancer 
Center      
   Yes 3.5 24.7 25.4 29.3 11.6 
   No 96.5 75.4 74.6 70.7 88.4 
Teaching hospital      
   Yes  26.8 33.8 39.2 30.5 41.4 
   No 73.2 66.2 60.8 69.6 58.6 
 
 
 
 
 
 
 
 
 
 
 
142 
 
APPENDIX 4.  FREQUENCY OF RUTH SURVEY ITEM-LEVEL RESPONSE FOR 
SOCIAL SUPPORT AND DECISIONAL PERCEIVED SELF-EFFICACY 
 
RUTH Sample (n=170) Frequency n (%) 
 Reliable Unreliable 
In the past 4 weeks, how often did you have… All or Most Some to None 
Social Support   
a. help you if you were confined to bed 127 (75.6) 41 (24.4) 
b. take you to the doctor if you needed it 148 (88.1) 20 (11.9) 
c. prepare your meals if you were unable to do it 
yourself 126 (75.0) 42 (25.0) 
d. help with daily chores if you were sick (or when 
you are sick) 124 (73.4) 45 (26.6) 
e. you can count on to listen to you when you need to 
talk  146 (86.4) 23 (13.6) 
f. give you good advice in a crisis 139 (82.7) 29 (17.3) 
g. give you information to help you understand a 
situation  133 (79.2) 35 (20.8) 
h. confide in or talk to about yourself or your 
problems  138 (81.7) 31 (18.3) 
i. share your most private worries and fears with  124 (73.4) 45 (26.6) 
   
j. help you deal with your health insurance 111 (66.1) 57 (33.9) 
k. help you figure out how much treatment is going 
to cost you 90 (54.2) 76 (45.8) 
l. make sure you are at your  medical appointments 
when you are supposed to be 140 (82.8) 29 (17.2) 
m. help you prepare for doctor visits so you always 
know what to ask the doctor 118 (69.8) 51 (30.2) 
n. help you understand doctors' orders 131 (77.5) 38 (22.5) 
o. help you identify resources to pay for medical and 
other expenses if you cannot afford them 93 (55.7) 74 (44.3) 
   
 Very/ Confident 
Less than 
Confident 
Perceived self-efficacy  (confident vs. less than 
confident)   
a. Get the facts about treatment choices available  139 (82.5) 30 (17.8) 
b. Get the facts about the benefits of each choice 130 (78.3) 36 (21.7) 
c. Get the facts about the risks and side effects of 
each choice 
120 (71.9) 
47 (28.1) 
d. Understand the information enough to be able to 
make a choice 
144 (85.7) 
24 (14.3) 
e. Ask questions without feeling dumb 147 (87.5) 21 (12.5) 
f. Express my concern about each choice 142 (84.0) 27 (16.0) 
g. Ask for advice 144 (85.2) 25 (14.8) 
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h. Figure out the choice that best suited me 139 (82.7) 29 (17.3) 
i. Handle unwanted pressure from others in making 
my choice 
123 (75.0) 
41 (25.0) 
j. Let the clinic team know what was best for me 138 (82.1) 30 (17.9) 
k. Delay my decision if I felt I needed more time 130 (78.3) 36 (21.7) 
      
 
Note: Social support was dichotomized as “reliable” vs. “unreliable” social support by 
combining response options for having social support “all of the time” and ”most of the time” vs. 
combining response options for having social support “some of the time,” “a little of the time,” 
or ”none of the time” due to small numbers across the 5-point response scale.   Instrumental 
social support was represented by items a-d.  Affectionate social support was represented by 
items d-i.  Perceived self-efficacy was dichotomized as “confident” vs. “less than confident” by 
combining responses for “very confident” and “confident” vs. combining responses for 
“somewhat confident,” “a little confident,” or “not at all confident.”     
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APPENDIX 5. 1- to 4- FACTOR ANALYSIS OF RUTH WORRY SCALE ITEMS 
 
RUTH Worry Items:  Factor  2-Factor  3-Factor 4-Factor  
How much were you worried 
about…. 
Item-total 
correlation 
Factor 
1 
Factor 
1 
Factor 
2 
Factor 
1 
Factor 
2 
Factor 
3  
Factor 
1 
Factor 
2 
Factor 
3  
Factor 
4  
The side-effects from treatment 0.57 0.51 -0.05 0.62 -0.07 -0.01 0.71 -0.07 0.70 -0.07 0.06 
The cost of treatment 0.72 0.75 0.74 0.10 0.73 0.01 0.11 0.73 0.11 0.01 0.00 
Taking time away from your family 0.61 0.50 0.02 0.54 -0.04 0.68 -0.02 -0.07 0.00 0.68 0.05 
Taking time away from work or other 
daily activities 
0.71 0.68 0.20 0.57 0.15 0.52 0.15 0.13 0.16 0.45 0.14 
Transportation to treatment 0.55 0.47 0.34 0.19 0.32 0.15 0.08 0.32 0.07 0.07 0.12 
Going through early menopause  0.49 0.43 0.03 0.45 -0.02 0.46 0.08 -0.03 0.01 0.04 0.58 
Developing other cancers later 0.65 0.65 0.27 0.46 0.25 -0.04 0.56 0.26 0.55 -0.11 0.08 
Changes in body image  0.59 0.51 0.14 0.43 0.10 0.42 0.10 0.09 0.02 -0.02 0.60 
Using  up savings or retirement funds 
to pay for cancer care  
0.72 0.71 0.89 -0.09 0.89 -0.06 -0.04 0.89 -0.04 -0.03 -0.04 
Being set financially back  0.79 0.82 0.85 0.06 0.84 0.11 -0.03 0.84 -0.03 0.09 0.03 
Having to postpone or avoid 
medical  care for other family 
members 
0.35 0.40 0.19 0.26 0.15 0.42 -0.09 0.14 -0.07 0.50 -0.06 
Not knowing what to expect  0.7 0.70 0.07 0.72 0.04 0.09 0.72 0.04 0.75 0.17 -0.10 
            
Correlation between Factors:     0.58   Range: 0.55 - 0.60 Range: 0.49 - 0.56   
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APPENDIX 6.  MULTIVARIABLE LOGISTIC REGRESSION OF PATIENT ITEM-LEVEL WORRIES DURING 
CANCER TREATMENT DECISION-MAKING REPORTING AVERAGE MARGINAL (OR DIFFERENTIAL) EFFECTS 
 Worries about… 
 Cost of treatment  Transportation  Changes in body image 
  
Model 1, 
Marginal 
Effect (SE) 
Model 2, 
Marginal 
Effect (SE)  
Model 1, 
Marginal 
Effect (SE) 
Model 2, 
Marginal 
Effect (SE)  
Model 1, 
Marginal Effect 
(SE) 
Model 2, 
Marginal 
Effect (SE) 
Age 
-0.0059 
(0.0044) 
-0.0063 
(0.0042)  
0.0027 
(0.0026) 
0.0019 
(0.0033)  
-0.0041 
(0.0021)# 
-0.0050 
(0.0038) 
Race         
   White Reference Reference  Reference Reference  Reference Reference 
   African American/Other -0.0042 (0.15) -0.053 (0.081)  0.16 (0.077)# 0.10 (0.080)  0.085 (0.051) 0.039 (0.081) 
Number of 
Comorbidities -0.057 (0.053) -0.052 (0.032)  
-0.041 
(0.019)* -0.031 (0.028)  -0.056 (0.060) -0.050 (0.034) 
FIGO Stage         
   Early (I/II) Reference Reference  Reference Reference  Reference Reference 
   Late  (III/IV) -0.027 (0.094) -0.022 (0.093)  -0.20 (0.10)* -0.18 (0.092)*  -0.092 (0.064) -0.053 (0.10) 
Self-reported health 
status         
   Excellent / very Good Reference Reference  Reference Reference  Reference Reference 
   Good 0.069 (0.086) 0.035 (0.095)  0.14 (0.044)* 0.12 (0.078)  0.055 (0.068) 0.038 (0.083) 
   Fair / Poor 0.18 (0.080)* 0.15 (0.11)  0.34 (0.081)* 0.31 (0.11)*  0.15 (0.067)* 0.13 (0.11) 
Social Support          
Reliable help with daily 
choice vs. Unreliable help  -0.17 (0.079)*   -0.21 (0.092)*   -0.21 (0.089)* 
Perceived self-efficacy 
(less than confident: 
Reference)         
Express my concern about 
each choice   -0.25 (0.082)*   -0.16 (0.096)   -0.20 (0.11) 
                  
Note:  # p-value = 0.05; * p-value < 0.05; Model 1 and Model 2 differ in the covariates included in the model. 
 146 
 
APPENDIX 7.  SELECTED RUTH SURVEY ITEMS (Aim 3) 
 
 
 
 
2.5 What prompted you to seek medical care for these symptoms? Was it because …  [may 
choose more than one] 
 
 YES NO 
YOU HAD MILD SYMPTOMS THAT WERE BOTHERING YOU 
FOR SOME TIME 
  
SYMPTOMS WERE VERY BOTHERSOME    
YOU JUST MENTIONED SYMPTOMS TO YOUR PRIMARY CARE 
DOCTOR 
  
YOU HAVE FAMILY HISTORY OF OVARIAN CANCER    
YOU HAVE A FRIEND WHO HAD OVARIAN CANCER    
YOU DISCUSSED YOUR SYMPTOMS WITH FAMILY 
MEMBERS/FRIENDS AND THEY ENCOURAGED YOU TO SEE A 
DOCTOR 
  
YOU LOOKED UP SOME INFORMATION ON THE INTERNET ABOUT 
YOUR SYMPTOMS AND REALIZED THEY COULD BE SIGNS OF 
OVARIAN CANCER 
  
OTHER?________________________________________   
NONE OF THESE   
REFUSED    
 
 
4.2  Along the same lines, at the time you were making decisions about your treatment for FILL 
CANCER, how much were you worried about each of the following? Please tell me if you 
were not at all worried, a little worried, somewhat worried or very worried about what I will 
mention. These answers are in Box 2 of your Answer Sheet.   
 
 
How much were you worried about…. 
Very 
worried 
Somewhat 
worried 
A little 
worried 
Not at all 
worried 
DON’T 
KNOW 
The side-effects from treatment       
The cost of treatment      
Taking time away from your family      
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4.3  Please tell me if you strongly agree, agree, neither agree nor disagree, disagree or 
strongly disagree with each statement.   
 
Strongly 
Agree Agree 
Neither 
Agree/ 
Disagree Disgree 
Strongly 
Disagree 
  
When bad things happen, we are not 
supposed to know why, we are just 
supposed to accept them 
          
If bad things happen, it is because 
they were meant to be 
     
People die when it is their time to die 
and nothing can change that 
     
Everything that happens is a part of 
God’s plan 
     
You have complete trust in God      
 
5.6 What is your understanding of the services that gynecologic oncologists provide? Tell me 
how much you agree or disagree with these statements about gynecologic oncologists.  
Taking time away from work or other daily 
activities 
     
Transportation to treatment      
  Going through early  menopause       
  Developing other cancers later      
  Changes in body image       
Using  up savings or retirement funds to 
pay for cancer care  
     
Being set financially back because of 
medical expenses  
     
Having to postpone or avoid medical  care 
for other family members 
     
Not knowing what to expect       
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Do you strongly agree, agree, neither agree nor 
disagree, disagree or strongly disagree that…. 
Strongly 
Agree 
Agree 
Neither 
Agree/ 
Disagree 
Disgree 
Strongly 
Disagree 
There are no clear benefits from receiving care 
from them, it is just another surgeon 
     
I am not sure why I should see one of 
them  
     
Gynecologic oncologists follow-up women with 
ovarian cancer from diagnosis through end of 
life 
     
Gynecologic oncologists are surgeons dedicated 
to cancer surgery 
     
Gynecologic oncologists provide all 
treatments, i.e., perform surgery, prescribe 
chemotherapy and any other appropriate 
treatment  
     
Gynecologic oncologists specialize in the 
treatment of  gynecologic cancers  
     
Some women have clearly benefitted from 
receiving treatment from these specialists  
     
 
5.7   The next items ask what you thought about the possible results and side effects of 
SURGERY.  If you have not thought about or discussed the issue, just answer that you 
do not know.  Please tell me if you thought what I mention was very likely, somewhat 
likely, a little likely, not at all likely. 
 
How likely did you think it was that… 
Very 
likely 
Some  
what 
likely 
A little 
likely 
Not at all 
likely 
Don’t 
know 
Surgery would help you live longer?      
Surgery would cure ovarian cancer?      
Surgery would help you with problems you were 
having because of ovarian cancer? 
     
Surgery would have side-effects or complications?      
 
 
 
5.9   The next items ask what you thought about the possible results and side effects of 
CHEMOTHERAPY.  If you have not thought about or discussed the issue, just answer 
that you do not know.  Please tell me if you thought what I mention was very likely, 
somewhat likely, a little likely, not at all likely.  
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How likely did you think it was that… 
Very 
likely 
Some  
what 
likely 
A little 
likely 
Not at all 
likely 
Don’t 
know 
Chemotherapy would help you live longer?      
Chemotherapy would cure ovarian cancer?      
Chemotherapy would help you with problems you 
were having because of ovarian cancer? 
     
Chemotherapy would have side-effects or 
complications? 
     
 
 
 
7.6 Next are some things involved in making an informed choice. Please, for each item that I 
am going to read, tell me how confident you felt in doing these things.  
 
Did you feel you were not at all confident, a 
little confident, somewhat confident, confident 
or very confident that you could: 
Not at all 
confident 
A little 
confident 
Some 
what 
confident 
Confident 
Very 
confident 
Get the facts about the treatment choices available 
to me  
     
Get the facts about the benefits of each choice      
Get the facts about the risks and side effects of 
each choice  
     
Understand the information enough to be able to 
make a choice  
     
Ask questions without feeling dumb       
Express my concern about each choice      
Ask for advice      
Figure out the choice that best suited me       
Handle unwanted pressure from others in making 
my choice  
     
Let the clinic team know what was best for me       
Delay my decision if I felt I needed more time       
[DECISION SELF-EFFICACY SCALE, AM O’CONNOR 1995] 
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8.1  People sometimes look to others for companionship, assistance, or other types of 
support. I am going to ask you how often was each of the kinds of support I am going to 
read available to you if you needed it. Responses to this questions are in Box 6 of your 
answer sheet and are all the time, most of the time, some of the time, a little of the time, 
and none of the times  ….  
 
In the past 4 weeks, how often did you have … 
 
All 
the 
time 
Most of 
the time 
Some 
of the 
time 
A little 
of the 
time  
None of 
the time 
Someone to help you if you were confined to bed      
Someone to take you to the doctor if you needed it.      
Someone to prepare your meals if you were unable to do it 
yourself. 
     
Someone to help with daily chores if you were sick (or 
when you are sick) 
     
Someone you can count on to listen to you when you need 
to talk. 
     
Someone to give you good advice in a crisis.      
Someone to give you information to help you understand a 
situation. 
     
Someone to confide in or talk to about yourself or your 
problems. 
     
Someone to share your most private worries and fears with.      
Someone to help you deal with your health insurance       
Someone to help you figure out how much treatment is 
going to cost you  
     
Someone to make sure you are at your medical 
appointments when you are supposed to be 
     
Someone to help you prepare for doctor visits so you 
always know what to ask the doctor 
     
Someone to help you understand doctors’ orders      
Someone to help you identify resources to pay for medical 
and other expenses if you cannot afford them 
     
 
  
 151 
 
REFERENCES 
ACOG. 2011. "The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial 
Ovarian Cancer." The American College of Obstetrcians and Gynecologists. [accessed on 
October 30, 2014]. Available at http://www.acog.org/Resources-And-Publications/Committee-
Opinions/Committee-on-Gynecologic-Practice/The-Role-of-the-Obstetrician-Gynecologist-in-
the-Early-Detection-of-Epithelial-Ovarian-Cancer. 
 
ASCO. 2015. “The State of Cancer Care in America, 2015: a report by the American Society of 
Clinical Oncology.” Journal of Oncology Practice 11(2): 79-113. 
 
Abernethy, A. P., L. M. Etheredge, P. A. Ganz, P. Wallace, R. R. German, C. Neti, P. B. Bach, 
and S. B. Murphy. 2010. “Rapid-learning system for cancer care.” Journal of Clinical Oncology 
28(27): 4268-74. 
 
Allison, P. D. 2010. Survival Analysis Using SAS®: A Practical Guide, Second Edition. Cary, 
NC: SAS Institute. 
 
Andersen, M. R., E. Sweet, K. A. Lowe, L. J. Standish, C. W. Drescher, and B. A. Goff. 2012. 
“Involvement in decision-making about treatment and ovarian cancer survivor quality of life.” 
Gynecologic Oncology 124(3): 465-70. 
 
Andersen, R. M. 1995. “Revisiting the behavioral model and access to medical care: does it 
matter?” Journal of Health and Social Behavior 36(1): 1-10. 
 
Austin, S., M. Martin, Y. Kim, E. Funkhouser, E. Partridge, and M. Pisu. 2013. “Disparities in 
use of gynecologic oncologists for women with ovarian cancer in the United States.” Health 
Services Research 48(3): 1135-53. 
 
Aviki, E. M., J. A. Rauh-Hain, R. M. Clark, T. R. Hall, L. R. Berkowitz, D. M. Boruta, W. B. 
Growdon, J. O. Schorge, and A. Goodman. 2015. “Gynecologic Oncologist as surgical 
consultant: Intraoperative consultations during general gynecologic surgery as an important 
focus of gynecologic oncology training.” Gynecologic Oncology 137(1): 93-7. 
 
Babbie, E. 2011. The Basics of Social Research. Fifth Edition. Belmont, CA: Wadsworth 
Cengage Learning. 
 
Barber, E. L. and L. Van Le. 2015. “Enhanced Recovery Pathways in Gynecology and  
Gynecologic Oncology.” Obstetrical and Gynecological Survey 70(12): 780-92. 
 
Barnato, A. E., M. B. Herndon, D. L. Anthony, P. M. Gallagher, J. S. Skinner, J. P. Bynum, and  
E. S. Fisher. 2007. “Are regional variations in end-of-life care intensity explained by patient 
preferences?: A Study of the US Medicare Population.” Medical Care 45(5): 386-93. 
 
 152 
 
Barnholtz-Sloan, J. S., M. A. Tainsky, J. Abrams, R. K. Severson, F. Qureshi, S. M. Jacques, N. 
Levin, and A. G. Schwartz. 2002. “Ethnic differences in survival among women with ovarian 
carcinoma.” Cancer 94(6): 1886-93. 
 
Bashshur, R. L., G. W. Shannon, E. A. Krupinski, J. Grigsby, J. C. Kvedar, R. S. Weinstein, J. H. 
Sanders, K. S. Rheuban, T. S. Nesbitt, D. C. Alverson, R. C. Merrell, J. D. Linkous, A. S. 
Ferguson, R. J. Waters, M. E. Stachura, D. G. Ellis, N. M. Antoniotti, B. Johnston, C. R. Doarn, 
P. Yellowlees, S. Normandin, and J. Tracy. 2009. “National telemedicine initiatives: essential to 
healthcare reform.” Telemedicine Journal and e-Health 15(6): 600-10. 
 
Bilimoria, K. Y., D. J. Bentrem, A. K. Stewart, M. S. Talamonti, D. P. Winchester, T. R. Russell, 
and C. Y. Ko. 2008. “Lymph node evaluation as a colon cancer quality measure: a national 
hospital report card.” Journal of the National Cancer Institute 100(18): 1310-7. 
 
Birkmeyer, N. J., P. P. Goodney, T. A. Stukel, B. E. Hillner, and J. D. Birkmeyer. 2005. “Do 
cancer centers designated by the National Cancer Institute have better surgical outcomes?” 
Cancer 103(3): 435-41. 
 
Brant, R. 1990. “Assessing proportionality in the proportional odds model for ordinal logistic 
regression.” Biometrics 46: 1171-78. 
 
Bristow, R. E., J. Chang, A. Ziogas, H. Anton-Culver, and V. M. Vieira. 2014a. “Spatial analysis 
of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race 
and socioeconomic status.” Gynecologic Oncology 134(1): 60-7. 
 
Bristow, R. E., J. Chang, A. Ziogas, B. Campos, L. R. Chavez, and H. Anton-Culver. 2015. 
“Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment 
and survival.” Journal of the American College of Surgeons 220(5): 940-50. 
 
Bristow, R. E., J. Chang, A. Ziogas, L. M. Randall, and H. Anton-Culver. 2014b. “High-volume 
ovarian cancer care: survival impact and disparities in access for advanced-stage disease.” 
Gynecologic Oncology 132(2): 403-10. 
 
Bristow, R. E., B. E. Palis, D. S. Chi, and W. A. Cliby. 2010. “The National Cancer Database 
report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on 
overall survival and surgical treatment paradigm.” Gynecologic Oncology 118(3): 262-7. 
 
Bristow, R. E., M. A. Powell, N. Al-Hammadi, L. Chen, J. P. Miller, P. Y. Roland, D. G. Mutch, 
and W. A. Cliby. 2013. “Disparities in ovarian cancer care quality and survival according to race 
and socioeconomic status.” Journal of the National Cancer Institute 105(11): 823-32. 
 
Bristow, R. E., A. Santillan, T. P. Diaz-Montes, G. J. Gardner, R. L. Giuntoli, 2nd, B. C. 
Meisner, K. D. Frick, and D. K. Armstrong. 2007. “Centralization of care for patients with 
advanced-stage ovarian cancer: a cost-effectiveness analysis.” Cancer 109(8): 1513-22. 
 
 153 
 
Bristow, R. E., R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz. 2002. 
“Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the 
platinum era: a meta-analysis.” Journal of Clinical Oncology 20(5): 1248-59. 
 
Bristow, R. E., M. L. Zahurak, T. P. Diaz-Montes, R. L. Giuntoli, and D. K. Armstrong. 2009. 
“Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and 
related short-term outcomes.” Gynecologic Oncology 115(3): 334-8. 
 
Bristow, R. E., M. L. Zahurak, and O. A. Ibeanu. 2011. “Racial disparities in ovarian cancer 
surgical care: a population-based analysis.” Gynecologic Oncology 121(2): 364-8. 
 
Brundage, M., D. Feldman Stewart, and C. Tishelman. 2010. “How do interventions designed to 
improve provider-patient communication work? Illustrative applications of a framework for 
communication.” Acta Oncologica 49(2): 136-43. 
 
Burgess, C., T. Morris, and K. W. Pettingale. 1988. “Psychological response to cancer diagnosis-
-II. Evidence for coping styles (coping styles and cancer diagnosis).” Journal of Psychosomatic 
Research 32(3): 263-72. 
 
Butler, J., C. Foot, M. Bomb, S. Hiom, M. Coleman, H. Bryant, P. Vedsted, J. Hanson, M. 
Richards, and I. W. Group. 2013. “The International Cancer Benchmarking Partnership: an 
international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, 
Sweden and the United Kingdom.” Health Policy 112(1-2): 148-55. 
 
Cameron, A. C. and P. K. Trivedi. 2005. Microeconometrics Methods and Application. New 
York, NY: Cambridge University Press. 
 
Carney, M. E., J. M. Lancaster, C. Ford, A. Tsodikov, and C. L. Wiggins. 2002. “A population-
based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and 
who is not?” Gynecologic Oncology 84(1): 36-42. 
 
Champion, V. L. and C. S. Skinner. 2003. “Differences in perceptions of risk, benefits, and 
barriers by stage of mammography adoption.” J Womens Health (Larchmt) 12(3): 277-86. 
 
Chan, J., D. Kapp, J. Shin, A. Husain, N. Teng, J. Berek, K. Osann, G. Leiserowitz, R. Cress, 
and C. O'Malley. 2007a. “Influence of the gynecologic oncologist on the survival of ovarian 
cancer patients.” Obstetrics and Gynecology 109(6): 1342-50. 
 
Chan, J. K., D. S. Kapp, J. Y. Shin, A. Husain, N. N. Teng, J. S. Berek, K. Osann, G. S. 
Leiserowitz, R. D. Cress, and C. O'Malley. 2007b. “Influence of the gynecologic oncologist on 
the survival of ovarian cancer patients.” Obstetrics and Gynecology 109(6): 1342-50. 
 
Chan, J. K., D. S. Kapp, J. Y. Shin, K. Osann, G. S. Leiserowitz, R. D. Cress, and C. O'Malley. 
2008. “Factors associated with the suboptimal treatment of women less than 55 years of age with 
early-stage ovarian cancer.” Gynecologic Oncology 108(1): 95-9. 
 
 154 
 
Chan, L., L. G. Hart, and D. C. Goodman. 2006. “Geographic access to health care for rural 
Medicare beneficiaries.” Journal of Rural Health 22(2): 140-6. 
 
Chang, S. J., M. Hodeib, J. Chang, and R. E. Bristow. 2013. “Survival impact of complete 
cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.” 
Gynecologic Oncology 130(3): 493-8. 
 
Charlson, M., T. P. Szatrowski, J. Peterson, and J. Gold. 1994. “Validation of a combined 
comorbidity index.” Journal of Clinical Epidemiology 47(11): 1245-51. 
 
Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. “A new method of 
classifying prognostic comorbidity in longitudinal studies: development and validation.” Journal 
of Chronic Diseases 40(5): 373-83. 
 
Chen, V. W., C. R. Eheman, C. J. Johnson, M. N. Hernandez, D. Rousseau, T. S. Styles, D. W. 
West, M. Hsieh, A. M. Hakenewerth, M. O. Celaya, R. K. Rycroft, J. M. Wike, M. Pearson, J. 
Brockhouse, L. G. Mulvihill, and K. B. Zhang. 2014. “Enhancing cancer registry data for 
comparative effectiveness research (CER) project: overview and methodology.” Journal Registry 
Management 41(3): 103-12. 
 
Chou, A. F., S. L. Stewart, R. C. Wild, and J. R. Bloom. 2012. “Social support and survival in 
young women with breast carcinoma.” Psycho-Oncology 21(2): 125-33. 
 
Cliby, W. A., M. A. Powell, N. Al-Hammadi, L. Chen, J. Philip Miller, P. Y. Roland, D. G. 
Mutch, and R. E. Bristow. 2015. “Ovarian cancer in the United States: contemporary patterns of 
care associated with improved survival.” Gynecologic Oncology 136(1): 11-7. 
 
Collins, Y., K. Holcomb, E. Chapman-Davis, D. Khabele, and J. H. Farley. 2014. “Gynecologic 
cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic 
Oncology.” Gynecologic Oncology 133(2): 353-61. 
 
CanCORS, National Cancer Institute Cancer Care Outcomes Research & Surveillance 
Consortium. [accessed on December 12, 2015]. Available at 
https://www.cancors.org/public/servlets/open/home/home.cmd. 
 
Cooper, G. S., T. D. Kou, and H. L. Reynolds, Jr. 2008. “Receipt of guideline-recommended 
follow-up in older colorectal cancer survivors : a population-based analysis.” Cancer 113(8): 
2029-37. 
 
Costanzo, E. S., S. K. Lutgendorf, N. E. Rothrock, and B. Anderson. 2006. “Coping and quality 
of life among women extensively treated for gynecologic cancer.” Psycho-Oncology 15(2): 132-
42. 
 
Costanzo, E. S., S. K. Lutgendorf, A. K. Sood, B. Anderson, J. Sorosky, and D. M. Lubaroff. 
2005. “Psychosocial factors and interleukin-6 among women with advanced ovarian cancer.” 
Cancer 104(2): 305-13. 
 155 
 
Cress, R. D., K. Bauer, C. D. O'Malley, A. R. Kahn, M. J. Schymura, J. M. Wike, S. L. Stewart, 
and G. S. Leiserowitz. 2011. “Surgical staging of early stage epithelial ovarian cancer: results 
from the CDC-NPCR ovarian patterns of care study.” Gynecologic Oncology 121(1): 94-9. 
 
Cress, R. D., C. D. O'Malley, G. S. Leiserowitz, and S. L. Campleman. 2003. “Patterns of 
chemotherapy use for women with ovarian cancer: a population-based study.” Journal of 
Clinical Oncology 21(8): 1530-5. 
 
Cronbach, L. 1951. “Coefficient alpha and the internal structure of tests.” Psychometrika 16: 
297-334. 
 
Darby, K., C. Davis, W. Likes, and J. Bell. 2009. “Exploring the financial impact of breast 
cancer for African American medically underserved women: a qualitative study.” J Health Care 
Poor Underserved 20(3): 721-8. 
 
Di Cerbo, A., J. C. Morales-Medina, B. Palmieri, and T. Iannitti. 2015. “Narrative review of 
telemedicine consultation in medical practice.” Patient Prefer Adherence 9: 65-75. 
 
DiMatteo, M. R. 2004. “Social support and patient adherence to medical treatment: a meta-
analysis.” Health Psychology 23(2): 207-18. 
 
Dimick, J., J. Ruhter, M. V. Sarrazin, and J. D. Birkmeyer. 2013. “Black patients more likely 
than whites to undergo surgery at low-quality hospitals in segregated regions.” Health Affairs 
32(6): 1046-53. 
 
DiSaia, P. J. and W. T. Creasman. 2007. “Clinical Gynecologic Oncology.” Philadelphia: 
Elsevier. 
 
Donabedian, A. 1980. "Basic Approaches to Assessment: Structure, Process, Outcome." The 
Definition of Quality and Approaches to Its Assessment, Health Administration Press, Ann 
Arbor, MI. 
 
Donabedian, A. 1992. “The role of outcomes in quality assessment and assurance.” QRB: 
Quality Review Bulletin: 356-60. 
 
du Bois, A., H. J. Luck, W. Meier, H. P. Adams, V. Mobus, S. Costa, T. Bauknecht, B. Richter, 
M. Warm, W. Schroder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, J. 
Pfisterer, and G. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study. 2003. 
“A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line 
treatment of ovarian cancer.” Journal of the National Cancer Institute 95(17): 1320-9. 
 
du Bois, A., M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist, M. Bookman, D. Bowtell, 
M. Brady, A. Casado, A. Cervantes, E. Eisenhauer, M. Friedlaender, K. Fujiwara, S. Grenman, J. 
P. Guastalla, P. Harper, T. Hogberg, S. Kaye, H. Kitchener, G. Kristensen, R. Mannel, W. Meier, 
B. Miller, J. P. Neijt, A. Oza, R. Ozols, M. Parmar, S. Pecorelli, J. Pfisterer, A. Poveda, D. 
Provencher, E. Pujade-Lauraine, M. Randall, J. Rochon, G. Rustin, S. Sagae, F. Stehman, G. 
 156 
 
Stuart, E. Trimble, P. Vasey, I. Vergote, R. Verheijen, U. Wagner, Gynecologic Cancer 
Intergroup. 2005. “2004 consensus statements on the management of ovarian cancer: final 
document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus 
Conference (GCIG OCCC 2004).” Annals of Oncology 16 Suppl 8: viii7-viii12. 
 
du Bois, A., J. Rochon, J. Pfisterer, and W. J. Hoskins. 2009. “Variations in institutional 
infrastructure, physician specialization and experience, and outcome in ovarian cancer: a 
systematic review.” Gynecologic Oncology 112(2): 422-36. 
 
Du, X. L., C. C. Sun, M. R. Milam, D. C. Bodurka, and S. Fang. 2008. “Ethnic differences in 
socioeconomic status, diagnosis, treatment, and survival among older women with epithelial 
ovarian cancer.” International Journal of Gynecological Cancer 18(4): 660-9. 
 
Duska, L. R., W. P. Tew, and K. N. Moore. 2015. “Epithelial ovarian cancer in older women: 
defining the best management approach.” Am Soc Clin Oncol Educ Book 35: e311-21. 
 
Earle, C. C., D. Schrag, B. A. Neville, K. R. Yabroff, M. Topor, A. Fahey, E. L. Trimble, D. C. 
Bodurka, R. E. Bristow, M. Carney, and J. L. Warren. 2006. “Effect of surgeon specialty on 
processes of care and outcomes for ovarian cancer patients.” Journal of the National Cancer 
Institute 98(3): 172-80. 
 
Eisenkop, S. M., N. M. Spirtos, T. W. Montag, R. H. Nalick, and H. J. Wang. 1992. “The impact 
of subspecialty training on the management of advanced ovarian cancer.” Gynecologic Oncology 
47(2): 203-9. 
 
Elattar, A., A. Bryant, B. A. Winter-Roach, M. Hatem, and R. Naik. 2011. “Optimal primary 
surgical treatment for advanced epithelial ovarian cancer.” Cochrane Database Syst Rev(8): 
CD007565. 
 
Elit, L., C. Charles, S. Dimitry, S. Tedford-Gold, A. Gafni, I. Gold, and T. Whelan. 2010. “It's a 
choice to move forward: women's perceptions about treatment decision making in recurrent 
ovarian cancer.” Psycho-Oncology 19(3): 318-25. 
 
Elit, L., C. Charles, I. Gold, A. Gafni, S. Farrell, S. Tedford, D. Dal Bello, and T. Whelan. 2003. 
“Women's perceptions about treatment decision making for ovarian cancer.” Gynecologic 
Oncology 88(2): 89-95. 
 
Elit, L. M., C. Charles, A. Gafni, J. Ranford, S. Tedford-Gold, and I. Gold. 2015. “How 
oncologists communicate information to women with recurrent ovarian cancer in the context of 
treatment decision making in the medical encounter.” Health Expect 18(5): 1066-80. 
 
Engel, G. F. 1977. “The need for a new medical model: A challenge for biomedicine.” Science 
196. 
 
 157 
 
Engelen, M. J., H. E. Kos, P. H. Willemse, J. G. Aalders, E. G. de Vries, M. Schaapveld, R. 
Otter, and A. G. van der Zee. 2006. “Surgery by consultant gynecologic oncologists improves 
survival in patients with ovarian carcinoma.” Cancer 106(3): 589-98. 
 
Erwin, R. L. 2010. “Therapy for advanced stage cancer: What do patients want and expect? A 
patient advocate's perspective.” Oncologist 15 Suppl 1: 11-2. 
 
Fairfield, K., F. L. Lucas, C. Earle, L. Small, E. Trimble, and J. Warren. 2010. “Regional 
variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer 
in the Medicare population.” Cancer 116(20): 4840-8. 
 
Fennell, M. L., I. P. Das, S. Clauser, N. Petrelli, and A. Salner. 2010. “The organization of 
multidisciplinary care teams: modeling internal and external influences on cancer care quality.” 
Journal of the National Cancer Institute. Monographs 2010(40): 72-80. 
 
Ferrell, B., S. L. Smith, C. A. Cullinane, and C. Melancon. 2003a. “Psychological well being and 
quality of life in ovarian cancer survivors.” Cancer 98(5): 1061-71. 
 
Ferrell, B. R., S. L. Smith, K. S. Ervin, J. Itano, and C. Melancon. 2003b. “A qualitative analysis 
of social concerns of women with ovarian cancer.” Psycho-Oncology 12(7): 647-63. 
 
Ferrell, B. R., S. L. Smith, G. Juarez, and C. Melancon. 2003c. “Meaning of illness and 
spirituality in ovarian cancer survivors.” Oncology Nursing Forum 30(2): 249-57. 
 
Fitch, M. I. 2003. “Psychosocial management of patients with recurrent ovarian cancer: treating 
the whole patient to improve quality of life.” Seminars in Oncology Nursing 19(3 Suppl 1): 40-
53. 
 
Fitch, M. I., K. Deane, and D. Howell. 2003. “Living with ovarian cancer: women's perspectives 
on treatment and treatment decision-making.” Canadian Oncology Nursing Journal 13(1): 8-20. 
 
Fitch, M. I., R. E. Gray, D. DePetrillo, E. Franssen, and D. Howell. 1999. “Canadian women's 
perspectives on ovarian cancer.” Cancer Prevention and Control 3(1): 52-60. 
 
Forbes, L. J., A. E. Simon, F. Warburton, D. Boniface, K. E. Brain, A. Dessaix, C. Donnelly, K. 
Haynes, L. Hvidberg, M. Lagerlund, G. Lockwood, C. Tishelman, P. Vedsted, M. N. Vigmostad, 
A. J. Ramirez, J. Wardle, and G. International Cancer Benchmarking Partnership Module 2 
Working. 2013. “Differences in cancer awareness and beliefs between Australia, Canada, 
Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): 
do they contribute to differences in cancer survival?” British Journal of Cancer 108(2): 292-300. 
 
Forsythe, L. P., C. M. Alfano, E. E. Kent, K. E. Weaver, K. Bellizzi, N. Arora, N. Aziz, G. Keel, 
and J. H. Rowland. 2014. “Social support, self-efficacy for decision-making, and follow-up care 
use in long-term cancer survivors.” Psycho-Oncology. 
 
 158 
 
Forsythe, L. P., E. E. Kent, K. E. Weaver, N. Buchanan, N. A. Hawkins, J. L. Rodriguez, A. B. 
Ryerson, and J. H. Rowland. 2013. “Receipt of psychosocial care among cancer survivors in the 
United States.” Journal of Clinical Oncology 31(16): 1961-9. 
 
Freeman, H. P., B. J. Muth, and J. F. Kerner. 1995. “Expanding access to cancer screening and 
clinical follow-up among the medically underserved.” Cancer Practice 3(1): 19-30. 
 
Frey, M. K., S. R. Philips, J. Jeffries, A. J. Herzberg, G. L. Harding-Peets, J. K. Gordon, L. 
Bajada, A. E. Ellis, and S. V. Blank. 2014. “A qualitative study of ovarian cancer survivors' 
perceptions of endpoints and goals of care.” Gynecologic Oncology 135(2): 261-5. 
 
Frieden, T. R. 2015. “SHATTUCK LECTURE: The Future of Public Health.” New England 
Journal of Medicine 373(18): 1748-54. 
 
Friese, C. R., C. C. Earle, J. H. Silber, and L. H. Aiken. 2010. “Hospital characteristics, clinical 
severity, and outcomes for surgical oncology patients.” Surgery 147(5): 602-9. 
 
Giede, K. C., K. Kieser, J. Dodge, and B. Rosen. 2005. “Who should operate on patients with 
ovarian cancer? An evidence-based review.” Gynecologic Oncology 99(2): 447-61. 
 
Glanz, K., B. K. Rimer, and V. E. Viswanath. 2008. Health Behavior and Health Education: 
Theory, Research, and Practice. San Francisco: Jossey-Bass, Inc. 
 
Goff, B. A., B. J. Matthews, E. H. Larson, C. H. Andrilla, M. Wynn, D. M. Lishner, and L. M. 
Baldwin. 2007. “Predictors of comprehensive surgical treatment in patients with ovarian cancer.” 
Cancer 109(10): 2031-42. 
 
Goff, B. A., B. J. Matthews, M. Wynn, H. G. Muntz, D. M. Lishner, and L. M. Baldwin. 2006. 
“Ovarian cancer: patterns of surgical care across the United States.” Gynecologic Oncology 
103(2): 383-90. 
 
Goff, B. A., J. W. Miller, B. Matthews, K. F. Trivers, C. H. Andrilla, D. M. Lishner, and L. M. 
Baldwin. 2011. “Involvement of gynecologic oncologists in the treatment of patients with a 
suspicious ovarian mass.” Obstetrics and Gynecology 118(4): 854-62. 
 
Gomella, L. G., J. Lin, J. Hoffman-Censits, P. Dugan, F. Guiles, C. D. Lallas, J. Singh, P. 
McCue, T. Showalter, R. K. Valicenti, A. Dicker, and E. J. Trabulsi. 2010. “Enhancing prostate 
cancer care through the multidisciplinary clinic approach: a 15-year experience.” Journal of 
Oncology Practice 6(6): e5-e10. 
 
Goodman, M. T. and Y. B. Shvetsov. 2009. “Incidence of ovarian, peritoneal, and fallopian tube 
carcinomas in the United States, 1995-2004.” Cancer Epidemiology, Biomarkers and Prevention 
18(1): 132-9. 
 
Grzankowski, K. S. and M. Carney. 2011. “Quality of life in ovarian cancer.” Cancer Control 
18(1): 52-8. 
 159 
 
Hack, T. F. and L. F. Degner. 2004. “Coping responses following breast cancer diagnosis predict 
psychological adjustment three years later.” Psycho-Oncology 13(4): 235-47. 
 
Hall, A. E., R. W. Sanson-Fisher, M. C. Lynagh, F. Tzelepis, and C. D'Este. 2015a. “What do 
haematological cancer survivors want help with? A cross-sectional investigation of unmet 
supportive care needs.” BMC Research Notes 8: 221. 
 
Hall, I. J., A. Johnson-Turbes, Z. Berkowitz, and Y. Zavahir. 2015b. “The African American 
Women and Mass Media (AAMM) campaign in Georgia: quantifying community response to a 
CDC pilot campaign.” Cancer Causes and Control 26(5): 787-94. 
 
Han, X., C. C. Lin, C. Li, J. S. de Moor, J. L. Rodriguez, E. E. Kent, and L. P. Forsythe. 2015. 
“Association between serious psychological distress and health care use and expenditures by 
cancer history.” Cancer 121(4): 614-22. 
 
Hankinson, S. E. and K. N. Danforth. 2006. Ovarian Cancer. New York, NY: Oxford University 
Press. 
 
Harder, H., R. Ballinger, C. Langridge, A. Ring, and L. J. Fallowfield. 2013. “Adjuvant 
chemotherapy in elderly women with breast cancer: patients' perspectives on information giving 
and decision making.” Psycho-Oncology 22(12): 2729-35. 
 
Harlan, L. C., L. X. Clegg, and E. L. Trimble. 2003. “Trends in surgery and chemotherapy for 
women diagnosed with ovarian cancer in the United States.” Journal of Clinical Oncology 
21(18): 3488-94. 
 
Havrilesky, L. J., A. Alvarez Secord, J. A. Ehrisman, A. Berchuck, F. A. Valea, P. S. Lee, S. L. 
Gaillard, G. P. Samsa, D. Cella, K. P. Weinfurt, A. P. Abernethy, and S. D. Reed. 2014. “Patient 
preferences in advanced or recurrent ovarian cancer.” Cancer 120(23): 3651-9. 
 
Havrilesky, L. J. G., J.M.;  Moorman, P.G.; Coeytaux, R.R.; Peragallo Urrutia R.; Lowery, W.J. 
2013. “Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report 
#101. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-
10066-I).” Rockville, MD. 
 
Hennessy, B. T., R. L. Coleman, and M. Markman. 2009. “Ovarian cancer.” Lancet 374(9698): 
1371-82. 
 
Herzog, T. J., D. K. Armstrong, M. F. Brady, R. L. Coleman, M. H. Einstein, B. J. Monk, R. S. 
Mannel, J. T. Thigpen, S. A. Umpierre, J. A. Villella, and R. D. Alvarez. 2014. “Ovarian cancer 
clinical trial endpoints: Society of Gynecologic Oncology White Paper.” Gynecologic Oncology 
132(1): 8-17. 
 
Hewitt, M., J. V. Simone, and Editors. 1999. “Ensuring Quality Cancer Care.” Washington, 
D.C.: National Cancer Policy Board; Institute of Medicine and National Research Council. 
 
 160 
 
Hightower, R. D., H. N. Nguyen, H. E. Averette, W. Hoskins, T. Harrison, and A. Steren. 1994. 
“National survey of ovarian carcinoma. IV: Patterns of care and related survival for older 
patients.” Cancer 73(2): 377-83. 
 
Hochbaum, G. M. 1958. “Public participation in medical screening programs: A 
sociopsychological study.”. Washington, D.C.: U.S. Government Printing Office. 
 
Hoff, T., W. Weller, and M. DePuccio. 2012. “The patient-centered medical home: a review of 
recent research.” Medical Care Research and Review 69(6): 619-44. 
 
Hoffman, H. J., N. L. LaVerda, H. A. Young, P. H. Levine, L. M. Alexander, R. Brem, L. 
Caicedo, J. Eng-Wong, W. Frederick, W. Funderburk, E. Huerta, S. Swain, and S. R. Patierno. 
2012. “Patient navigation significantly reduces delays in breast cancer diagnosis in the District of 
Columbia.” Cancer Epidemiology, Biomarkers and Prevention 21(10): 1655-63. 
 
Hollis, G. and C. T. Stricker. 2014. “Opportunities for multidisciplinary collaboration when 
caring for women with breast cancer.” Journal of Obstetric, Gynecologic, and Neonatal Nursing 
43(3): 359-60. 
 
How, J. A., J. Abitbol, S. Lau, W. H. Gotlieb, and H. A. Abenhaim. 2015. “The impact of 
qualitative research on gynaecologic oncology guidelines.” Journal of Obstetrics and 
Gynaecology Canada. Journal d'Obstétrique et Gynécologie du Canada 37(2): 138-44. 
 
Howell, E., N. Egorova, M. Hayes, J. Wisnivesky, R. Franco, and N. Bickell. 2013. “Racial 
disparities in the treatment of advanced epithelial ovarian cancer.” Obstetrics and Gynecology 
122(5): 1025-32. 
 
Howlader, N., A. M. Noone, M. Krapcho, J. Garshell, N. Neyman, S. F. Altekruse, C. L. Kosary, 
M. Yu, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, D. R. Lewis, H. S. Chen, E. J. Feuer, and K. 
A. e. Cronin. 2015. "SEER Cancer Statistics Review, 1975-2012" [accessed on January 5, 2016]. 
Available at http://seer.cancer.gov/csr/1975_2012/, based on November 2013 SEER data 
submission, posted to the SEER web site, April 2015. 
 
Huang, L. C., Y. Ma, J. V. Ngo, and K. F. Rhoads. 2014. “What factors influence minority use of 
National Cancer Institute-designated cancer centers?” Cancer 120(3): 399-407. 
 
Hudson, S. V., S. M. Miller, J. Hemler, A. McClinton, K. C. Oeffinger, A. Tallia, and B. F. 
Crabtree. 2012. “Cancer Survivors and the Patient-Centered Medical Home.” Translational 
Behavioral Medicine 2(3): 322-31. 
 
Hui, D., A. Elsayem, M. De la Cruz, A. Berger, D. S. Zhukovsky, S. Palla, A. Evans, N. Fadul, J. 
L. Palmer, and E. Bruera. 2010. “Availability and integration of palliative care at US cancer 
centers.” JAMA 303(11): 1054-61. 
 
 161 
 
Hunter, R. W., N. D. Alexander, and W. P. Soutter. 1992. “Meta-analysis of surgery in advanced 
ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of 
prognosis?” American Journal of Obstetrics and Gynecology 166(2): 504-11. 
 
IOM. 2001. Crossing the Quality Chasm: A New Health System for the 21st Century.  
Washington, D.C: National Academies Press. 
 
IOM. 2006. From Cancer Patient to Cancer Survivor - Lost in Transition: An American Society 
of Clinical Oncology and Institute of Medicine Symposium.  Washington, D.C: National 
Academies Press. 
 
IOM. 2008. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs.  
Washington, D.C: National Academies Press. 
 
IOM. 2016.  Ovarian Cancers Evolving Paradigms in Research and Care.  Washington, D.C: 
National Academies Press. 
 
Jackson, G. L. and B. J. Powers. 2013. “The patient-centered medical home: a systematic 
review.” Annals of Internal Medicine 153(3): 169-78. 
 
Jacobs, I. J., U. Menon, A. Ryan, A. Gentry-Maharaj, M. Burnell, J. K. Kalsi, N. N. Amso, S. 
Apostolidou, E. Benjamin, D. Cruickshank, D. N. Crump, S. K. Davies, A. Dawnay, S. Dobbs, 
G. Fletcher, J. Ford, K. Godfrey, R. Gunu, M. Habib, R. Hallett, J. Herod, H. Jenkins, C. 
Karpinskyj, S. Leeson, S. J. Lewis, W. R. Liston, A. Lopes, T. Mould, J. Murdoch, D. Oram, D. 
J. Rabideau, K. Reynolds, I. Scott, M. W. Seif, A. Sharma, N. Singh, J. Taylor, F. Warburton, M. 
Widschwendter, K. Williamson, R. Woolas, L. Fallowfield, A. J. McGuire, S. Campbell, M. 
Parmar, and S. J. Skates. 2015. “Ovarian cancer screening and mortality in the UK Collaborative 
Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.” Lancet. 
Jelovac, D. and D. K. Armstrong. 2011. “Recent progress in the diagnosis and treatment of 
ovarian cancer.” CA: A Cancer Journal for Clinicians 61(3): 183-203. 
 
Jolicoeur, L. J., A. M. O'Connor, L. Hopkins, and I. D. Graham. 2009. “Women's decision-
making needs related to treatment for recurrent ovarian cancer: a pilot study.” Canadian 
Oncology Nursing Journal 19(3): 117-21. 
 
Jordan, S., C. Steer, A. DeFazio, M. Quinn, A. Obermair, M. Friedlander, J. Francis, S. O'Brien, 
G. Goss, D. Wyld, G. Australian Ovarian Cancer Study, P. Webb, and G. Ovarian Cancer 
Patterns of Care Study. 2013. “Patterns of chemotherapy treatment for women with invasive 
epithelial ovarian cancer--a population-based study.” Gynecologic Oncology 129(2): 310-7. 
 
Kandukuri, S. R. and J. Rao. 2015. “FIGO 2013 staging system for ovarian cancer: what is new 
in comparison to the 1988 staging system?” Current Opinion in Obstetrics and Gynecology 
27(1): 48-52. 
 
 162 
 
Kehl, K. L., M. B. Landrum, N. K. Arora, P. A. Ganz, M. van Ryn, J. W. Mack, and N. L. 
Keating. 2015. “Association of Actual and Preferred Decision Roles With Patient-Reported 
Quality of Care: Shared Decision Making in Cancer Care.” JAMA Oncol 1(1): 50-8. 
 
Kehoe, S., J. Powell, S. Wilson, and C. Woodman. 1994. “The influence of the operating 
surgeon's specialisation on patient survival in ovarian carcinoma.” British Journal of Cancer 
70(5): 1014-7. 
 
Kohler, B. A., R. L. Sherman, N. Howlader, A. Jemal, A. B. Ryerson, K. A. Henry, F. P. Boscoe, 
K. A. Cronin, A. Lake, A. M. Noone, S. J. Henley, C. R. Eheman, R. N. Anderson, and L. 
Penberthy. 2015. “Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring 
Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.” Journal of the 
National Cancer Institute 107(6): djv048. 
 
Kosary, C. L. 2007. "Cancer of the Ovary." In Ries, L.A.G, J.L. Young, G.E. Keel, M.P. Eisner, 
Y.D. Lin, M-J. Horner (editors). SEER Survival Monograph: Cancer Survival Among Adults: 
U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics.  National Cancer Institute, 
SEER Program, NIH Pub. No. 07-6215, Bethesda, MD. [accessed on July 16, 2015]. Available at 
http://seer.cancer.gov/archive/publications/survival/seer_survival_mono_lowres.pdf. 
 
Krok-Schoen, J. L., J. M. Oliveri, and E. D. Paskett. 2016. “Cancer Care Delivery and Women's 
Health: The Role of Patient Navigation.” Frontiers in Oncology 6: 2. 
 
Kuhn, W., S. Rutke, K. Spathe, B. Schmalfeldt, G. Florack, B. von Hundelshausen, D. Pachyn, 
K. Ulm, and H. Graeff. 2001. “Neoadjuvant chemotherapy followed by tumor debulking 
prolongs survival for patients with poor prognosis in International Federation of Gynecology and 
Obstetrics Stage IIIC ovarian carcinoma.” Cancer 92(10): 2585-91. 
 
Larson, E. B. and R. Reid. 2010. “The patient-centered medical home movement: why now?” 
JAMA 303(16): 1644-5. 
 
Le, T., A. Adolph, G. V. Krepart, R. Lotocki, and M. S. Heywood. 2002. “The benefits of 
comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.” 
Gynecologic Oncology 85(2): 351-5. 
 
Lehto, U. S., M. Ojanen, A. Vakeva, A. Aromaa, and P. Kellokumpu-Lehtinen. 2008. 
“Noncancer life stresses in newly diagnosed cancer.” Supportive Care in Cancer 16(11): 1231-
41. 
 
Leroy, L., E. Bayliss, M. Domino, B. F. Miller, G. Rust, J. Gerteis, T. Miller, and A. M. R. 
Network. 2014. “The Agency for Healthcare Research and Quality Multiple Chronic Conditions 
Research Network: overview of research contributions and future priorities.” Medical Care 52 
Suppl 3: S15-22. 
 
Liu, F. W., L. M. Randall, K. S. Tewari, and R. E. Bristow. 2014. “Racial disparities and patterns 
of ovarian cancer surgical care in California.” Gynecologic Oncology 132(1): 221-6. 
 163 
 
Long, J. S. 1997. Regression Models for Categorical and Limited Dependent Variables. 
Thousand Oaks: Sage Publications. 
 
Long, J. S. and J. Freese. 2014. Regression Models for Categorical Dependent Variables Using 
Stata, Third Edition.  College Station: Stata Press. 
 
Lopez, E. D., A. J. Khoury, A. B. Dailey, A. G. Hall, and L. R. Chisholm. 2009. “Screening 
mammography: a cross-sectional study to compare characteristics of women aged 40 and older 
from the deep South who are current, overdue, and never screeners.” Women's Health Issues 
19(6): 434-45. 
 
Lowery, W. J., A. W. Lowery, J. C. Barnett, M. Lopez-Acevedo, P. S. Lee, A. A. Secord, and L. 
Havrilesky. 2013. “Cost-effectiveness of early palliative care intervention in recurrent platinum-
resistant ovarian cancer.” Gynecologic Oncology 130(3): 426-30. 
 
Luketina, H., C. Fotopoulou, R. R. Luketina, A. Pilger, and J. Sehouli. 2012. “Treatment 
decision-making processes in the systemic treatment of ovarian cancer: review of the scientific 
evidence.” Anticancer Research 32(9): 4085-90. 
 
Lutgendorf, S. K. and B. L. Andersen. 2015. “Biobehavioral approaches to cancer progression 
and survival: Mechanisms and interventions.” American Psychologist 70(2): 186-97. 
 
Lutgendorf, S. K. and E. S. Costanzo. 2003. “Psychoneuroimmunology and health psychology: 
an integrative model.” Brain, Behavior, and Immunity 17(4): 225-32. 
 
Lutgendorf, S. K., K. De Geest, D. Bender, A. Ahmed, M. J. Goodheart, L. Dahmoush, M. B. 
Zimmerman, F. J. Penedo, J. A. Lucci, 3rd, P. Ganjei-Azar, P. H. Thaker, L. Mendez, D. M.  
Lubaroff, G. M. Slavich, S. W. Cole, and A. K. Sood. 2012. “Social influences on clinical 
outcomes of patients with ovarian cancer.” Journal of Clinical Oncology 30(23): 2885-90. 
 
Lutgendorf, S. K., G. M. Slavich, K. Degeest, M. Goodheart, D. Bender, P. H. Thaker, F. 
Penedo, B. Zimmerman, J. Lucci, 3rd, L. Mendez, K. Collins, and A. K. Sood. 2013. “Non-
cancer life stressors contribute to impaired quality of life in ovarian cancer patients.” 
Gynecologic Oncology 131(3): 667-73. 
 
Lutgendorf, S. K. and A. K. Sood. 2011. “Biobehavioral factors and cancer progression: 
physiological pathways and mechanisms.” Psychosomatic Medicine 73(9): 724-30. 
 
Magai, C., N. Consedine, A. I. Neugut, and D. L. Hershman. 2007. “Common psychosocial 
factors underlying breast cancer screening and breast cancer treatment adherence: a conceptual 
review and synthesis.” J Womens Health (Larchmt) 16(1): 11-23. 
 
Malin, J. L., C. Ko, J. Z. Ayanian, D. Harrington, D. R. Nerenz, K. L. Kahn, J. Ganther-Urmie, 
P. J. Catalano, A. M. Zaslavsky, R. B. Wallace, E. Guadagnoli, N. K. Arora, M. D. Roudier, and 
P. A. Ganz. 2006. “Understanding cancer patients' experience and outcomes: development and 
 164 
 
pilot study of the Cancer Care Outcomes Research and Surveillance patient survey.” Supportive 
Care in Cancer 14(8): 837-48. 
 
Mandelblatt, J. S., V. B. Sheppard, A. Hurria, G. Kimmick, C. Isaacs, K. L. Taylor, A. B. 
Kornblith, A. M. Noone, G. Luta, M. Tallarico, W. T. Barry, L. Hunegs, R. Zon, M. Naughton, 
E. Winer, C. Hudis, S. B. Edge, H. J. Cohen, H. Muss, and B. Cancer Leukemia Group. 2010. 
“Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference 
and interactions with physicians.” Journal of Clinical Oncology 28(19): 3146-53. 
 
Mariotto, A. B., A. M. Noone, N. Howlader, H. Cho, G. E. Keel, J. Garshell, S. Woloshin, and L. 
M. Schwartz. 2014. “Cancer survival: an overview of measures, uses, and interpretation.” 
Journal of the National Cancer Institute. Monographs 2014(49): 145-86. 
 
Mariotto, A. B., K. R. Yabroff, Y. Shao, E. J. Feuer, and M. L. Brown. 2011. “Projections of the 
cost of cancer care in the United States: 2010-2020.” Journal of the National Cancer Institute 
103(2): 117-28. 
 
Massie, M. J. 2004. “Prevalence of depression in patients with cancer.” Journal of the National 
Cancer Institute. Monographs(32): 57-71. 
 
Mayer, A. R., S. K. Chambers, E. Graves, C. Holm, P. C. Tseng, B. E. Nelson, and P. E. 
Schwartz. 1992. “Ovarian cancer staging: does it require a gynecologic oncologist?” 
Gynecologic Oncology 47(2): 223-7. 
 
Mead, E. L., A. Z. Doorenbos, S. H. Javid, E. A. Haozous, L. A. Alvord, D. R. Flum, and A. M. 
Morris. 2013. “Shared decision-making for cancer care among racial and ethnic minorities: a 
systematic review.” American Journal of Public Health 103(12): e15-29. 
 
Menon, U., V. Champion, P. O. Monahan, J. Daggy, S. Hui, and C. S. Skinner. 2007. “Health 
belief model variables as predictors of progression in stage of mammography adoption.” 
American Journal of Health Promotion 21(4): 255-61. 
 
Mercado, C., D. Zingmond, B. Y. Karlan, E. Sekaris, J. Gross, M. Maggard-Gibbons, J. S. 
Tomlinson, and C. Y. Ko. 2010. “Quality of care in advanced ovarian cancer: the importance of 
provider specialty.” Gynecologic Oncology 117(1): 18-22. 
 
Merkow, R. P., J. W. Chung, J. L. Paruch, D. J. Bentrem, and K. Y. Bilimoria. 2014. 
“Relationship between cancer center accreditation and performance on publicly reported quality 
measures.” Annals of Surgery 259(6): 1091-7. 
 
Meropol, N. J., B. L. Egleston, J. S. Buzaglo, A. B. Benson, 3rd, D. J. Cegala, M. A. Diefenbach, 
L. Fleisher, S. M. Miller, D. P. Sulmasy, K. P. Weinfurt, and C. S. R. Group. 2008. “Cancer 
patient preferences for quality and length of life.” Cancer 113(12): 3459-66. 
 
Merrill, R. M., A. E. Anderson, and J. G. Merrill. 2010. “Racial/ethnic differences in the use of 
surgery for ovarian cancer in the United States.” Advances in Medical Sciences 55(1): 93-8. 
 165 
 
Minig, L., P. Padilla-Iserte, and C. Zorrero. 2015. “The Relevance of Gynecologic Oncologists 
to Provide High-Quality of Care to Women with Gynecological Cancer.” Frontiers in Oncology 
5: 308. 
 
Mirabeau-Beale, K. L., A. B. Kornblith, R. T. Penson, H. Lee, A. Goodman, S. M. Campos, L. 
Duska, L. Pereira, J. Bryan, and U. A. Matulonis. 2009. “Comparison of the quality of life of 
early and advanced stage ovarian cancer survivors.” Gynecologic Oncology 114(2): 353-9. 
 
Morgan, R. J., Jr., R. D. Alvarez, D. K. Armstrong, B. Boston, L. M. Chen, L. Copeland, J. 
Fowler, D. K. Gaffney, D. Gershenson, B. E. Greer, P. W. Grigsby, L. J. Havrilesky, C. 
Johnston, J. M. Lancaster, S. Lele, U. Matulonis, D. O'Malley, R. F. Ozols, S. W. Remmenga, P. 
Sabbatini, J. Schink, N. Teng, and N. National Comprehensive Cancer. 2008. “Ovarian cancer. 
Clinical practice guidelines in oncology.” Journal of the National Comprehensive Cancer 
Network 6(8): 766-94. 
 
Mueller, J. J., Q. C. Zhou, A. Iasonos, R. E. O'Cearbhaill, F. A. Alvi, A. El Haraki, A. G. 
Eriksson, G. J. Gardner, Y. Sonoda, D. A. Levine, C. Aghajanian, D. S. Chi, N. R. Abu-Rustum, 
and O. Zivanovic. 2016. “Neoadjuvant chemotherapy and primary debulking surgery utilization 
for advanced-stage ovarian cancer at a comprehensive cancer center.” Gynecologic Oncology 
140(3): 436-42. 
 
National Comprehensive Cancer Network (NCCN) 2014. "NCCN Guidelines Version 3.2014 
Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer" [accessed on 
September 30, 2014]. Available at 
http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. 
 
Nguyen, H. N., H. E. Averette, W. Hoskins, M. Penalver, B. U. Sevin, and A. Steren. 1993. 
“National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' 
survival.” Cancer 72(12): 3663-70. 
 
North American Association of Central Cancer Registries (NAACCR). 2006. "Chapter X. Data 
Dictionary" [accessed on December 11, 2014]. Available at 
http://www.naaccr.org/Applications/ContentReader/Default.aspx?c=10. 
 
O'Connor, A. M. 1995. “Validation of a decisional conflict scale.” Medical Decision Making 
15(1): 25-30. 
 
O'Malley, C. D., S. J. Shema, R. D. Cress, K. Bauer, A. R. Kahn, M. J. Schymura, J. M. Wike, 
and S. L. Stewart. 2012. “The implications of age and comorbidity on survival following 
epithelial ovarian cancer: summary and results from a Centers for Disease Control and 
Prevention study.” J Womens Health (Larchmt) 21(9): 887-94. 
 
Oberlander, J. 2010. “Long time coming: why health reform finally passed.” Health Affairs 
29(6): 1112-6. 
 
 166 
 
Onega, T., E. J. Duell, X. Shi, E. Demidenko, and D. Goodman. 2009a. “Determinants of NCI 
Cancer Center attendance in Medicare patients with lung, breast, colorectal, or prostate cancer.” 
Journal of General Internal Medicine 24(2): 205-10. 
 
Onega, T., E. J. Duell, X. Shi, E. Demidenko, and D. Goodman. 2010a. “Influence of place of 
residence in access to specialized cancer care for African Americans.” Journal of Rural Health 
26(1): 12-9. 
 
Onega, T., E. J. Duell, X. Shi, E. Demidenko, and D. C. Goodman. 2010b. “Race versus place of 
service in mortality among medicare beneficiaries with cancer.” Cancer 116(11): 2698-706. 
 
Onega, T., E. J. Duell, X. Shi, E. Demidenko, D. Gottlieb, and D. C. Goodman. 2009b. 
“Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate 
cancer patients.” Medical Care Research and Review 66(5): 542-60. 
 
Onega, T., E. J. Duell, X. Shi, D. Wang, E. Demidenko, and D. Goodman. 2008. “Geographic 
access to cancer care in the U.S.” Cancer 112(4): 909-18. 
 
Onega, T., J. Weiss, K. Kerlikowske, K. Wernli, D. S. Buist, L. M. Henderson, M. Goodrich, J. 
Alford-Teaster, B. Virnig, A. N. Tosteson, W. DeMartini, and R. Hubbard. 2014. “The influence 
of race/ethnicity and place of service on breast reconstruction for Medicare beneficiaries with 
mastectomy.” Springerplus 3: 416. 
 
Ozga, M., C. Aghajanian, S. Myers-Virtue, G. McDonnell, S. Jhanwar, S. Hichenberg, and I. 
Sulimanoff. 2015. “A systematic review of ovarian cancer and fear of recurrence.” Palliat 
Support Care: 1-10. 
 
Palmer, S. C., C. T. Stricker, S. L. Panzer, S. A. Arvey, K. S. Baker, J. Casillas, P. A. Ganz, M. 
S. McCabe, L. Nekhlyudov, L. Overholser, A. H. Partridge, B. Risendal, D. L. Rosenstein, K. L. 
Syrjala, and L. A. Jacobs. 2015. “Outcomes and satisfaction after delivery of a breast cancer 
survivorship care plan: results of a multicenter trial.” Journal of Oncology Practice 11(2): e222-
9. 
 
Peikes, D., A. Zutshi, J. L. Genevro, K. Smith, M. Parchman, and D. Meyers. “Early Evidence 
on the Patient-Centered Medical Home. Final Report ”. Rockville, MD: Prepared by 
Mathematica Policy Research. 
 
Pfisterer, J. and J. A. Ledermann. 2006. “Management of platinum-sensitive recurrent ovarian 
cancer.” Seminars in Oncology 33(2 Suppl 6): S12-6. 
 
Pinquart, M. and P. R. Duberstein. 2010. “Depression and cancer mortality: a meta-analysis.” 
Psychological Medicine 40(11): 1797-810. 
 
Plescia, M., L. C. Richardson, and D. Joseph. 2012. “New roles for public health in cancer 
screening.” CA: A Cancer Journal for Clinicians 62(4): 217-9. 
 
 167 
 
Price, J. H., S. M. Desmond, M. Wallace, D. Smith, and P. W. Stewart. 1988. “Black Americans' 
perceptions of cancer. A study utilizing the Health Belief Model.” Journal of the National 
Medical Association 80(12): 1297-304. 
 
Puts, M. T., B. Tapscott, M. Fitch, D. Howell, J. Monette, D. Wan-Chow-Wah, M. 
Krzyzanowska, N. B. Leighl, E. Springall, and S. M. Alibhai. 2015. “A systematic review of 
factors influencing older adults' decision to accept or decline cancer treatment.” Cancer 
Treatment Reviews 41(2): 197-215. 
 
Ramsey, S., E. Whitley, V. W. Mears, J. M. McKoy, R. M. Everhart, R. J. Caswell, K. Fiscella, 
T. C. Hurd, T. Battaglia, J. Mandelblatt, and G. Patient Navigation Research Program. 2009. 
“Evaluating the cost-effectiveness of cancer patient navigation programs: conceptual and 
practical issues.” Cancer 115(23): 5394-403. 
 
Ramsey, S. D., W. Burke, and L. Clarke. 2003. “An economic viewpoint on alternative strategies 
for identifying persons with hereditary nonpolyposis colorectal cancer.” Genetics in Medicine 
5(5): 353-63. 
 
Richardson, L. C., J. Royalty, W. Howe, W. Helsel, W. Kammerer, and V. B. Benard. 2010. 
“Timeliness of breast cancer diagnosis and initiation of treatment in the National Breast and 
Cervical Cancer Early Detection Program, 1996-2005.” American Journal of Public Health 
100(9): 1769-76. 
 
Riddle, D. and D. Stannard. 2014. “Evidence in perioperative care.” Nursing Clinics of North 
America 49(4): 485-92. 
 
Rim, S. H., S. Hirsch, C. C. Thomas, W. R. Brewster, D. Cooney, T. D. Thompson, and S. L. 
Stewart. in press. “Gynecologic Oncologists Involvement on Ovarian Cancer Standard of Care 
Receipt and Survival ” World J Obstet Gynecol.  In press. 
 
Rim, S. H., L. Polonec, S. L. Stewart, and C. A. Gelb. 2011. “A national initiative for women 
and healthcare providers: CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer 
campaign.” J Womens Health (Larchmt) 20(11): 1579-85. 
 
Robertson, R. and P. Burge. 2011. “The impact of patient choice of provider on equity: analysis 
of a patient survey.” Journal of Health Services Research and Policy 16 Suppl 1: 22-8. 
 
Roland, K. B., J. L. Rodriguez, J. R. Patterson, and K. F. Trivers. 2013. “A literature review of 
the social and psychological needs of ovarian cancer survivors.” Psycho-Oncology 22(11): 2408-
18. 
 
Roland, P. Y., F. J. Kelly, C. Y. Kulwicki, P. Blitzer, M. Curcio, and J. W. Orr, Jr. 2004. “The 
benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment.” 
Gynecologic Oncology 93(1): 125-30. 
 
 168 
 
Rosenstock, I. G. M. and J. P. Kirscht. 1984. “The Health Belief Model and Personal Health 
Behavior.” Health Education Monographs, 2, 470-473. 
 
Rothman, K. J. G., S.; Lash, T.L. 2008. Modern Epidemiology Philadelphia, PA: Lippincott 
Williams & Wilkins. 
 
Rutten, L. J., N. K. Arora, A. D. Bakos, N. Aziz, and J. Rowland. 2005. “Information needs and 
sources of information among cancer patients: a systematic review of research (1980-2003).” 
Patient Education and Counseling 57(3): 250-61. 
 
Ryerson, A. B., C. Eheman, J. Burton, N. McCall, D. Blackman, S. Subramanian, and L. C. 
Richardson. 2007. “Symptoms, diagnoses, and time to key diagnostic procedures among older 
U.S. women with ovarian cancer.” Obstetrics and Gynecology 109(5): 1053-61. 
 
Sabatino, S. A., B. Lawrence, R. Elder, S. L. Mercer, K. M. Wilson, B. DeVinney, S. Melillo, M. 
Carvalho, S. Taplin, R. Bastani, B. K. Rimer, S. W. Vernon, C. L. Melvin, V. Taylor, M. 
Fernandez, and K. Glanz. 2012. “Effectiveness of interventions to increase screening for breast, 
cervical, and colorectal cancers: nine updated systematic reviews for the guide to community 
preventive services.” American Journal of Preventive Medicine 43(1): 97-118. 
 
Sanders, T. and S. Skevington. 2003. “Do bowel cancer patients participate in treatment 
decision-making? Findings from a qualitative study.” European Journal of Cancer Care (English 
Language Edition) 12(2): 166-75. 
 
Satin, J. R., W. Linden, and M. J. Phillips. 2009. “Depression as a predictor of disease 
progression and mortality in cancer patients: a meta-analysis.” Cancer 115(22): 5349-61. 
 
Seibaek, L., J. Blaakaer, L. K. Petersen, and L. Hounsgaard. 2013. “Ovarian cancer surgery: 
health and coping during the perioperative period.” Supportive Care in Cancer 21(2): 575-82. 
 
SGO. 2000. “Guidelines for referral to a gynecologic oncologist: rationale and benefits. The 
Society of Gynecologic Oncologists.” Gynecologic Oncology 78(3 Pt 2): S1-13. 
 
Shavers, V. L. and M. L. Brown. 2002. “Racial and ethnic disparities in the receipt of cancer 
treatment.” Journal of the National Cancer Institute 94(5): 334-57. 
 
Shea, C. M., R. Teal, L. Haynes-Maslow, M. McIntyre, B. J. Weiner, S. B. Wheeler, S. R. 
Jacobs, D. K. Mayer, M. Young, and T. C. Shea. 2014. “Assessing the feasibility of a virtual 
tumor board program: a case study.” Journal of Healthcare Management 59(3): 177-93. 
 
Sherbourne, C. D. and A. L. Stewart. 1991. “The MOS social support survey.” Social Science 
and Medicine 32(6): 705-14. 
 
Sherwood, P. R., H. S. Donovan, M. Rosenzweig, R. Hamilton, and C. M. Bender. 2008. “A 
house of cards: the impact of treatment costs on women with breast and ovarian cancer.” Cancer 
Nurs 31(6): 470-7. 
 169 
 
Siesto, G., R. Cavina, F. Romano, and D. Vitobello. 2016. “Primary Debulking Surgery Versus 
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched 
Analysis.” American Journal of Clinical Oncology. [Epub ahead of print] 
 
Siminoff, L. A., A. Zhang, C. M. Saunders Sturm, and N. Colabianchi. 2000. “Referral of breast 
cancer patients to medical oncologists after initial surgical management.” Medical Care 38(7): 
696-704. 
 
Stavraky, K. M., A. P. Donner, J. E. Kincade, and M. A. Stewart. 1988. “The effect of 
psychosocial factors on lung cancer mortality at one year.” Journal of Clinical Epidemiology 
41(1): 75-82. 
 
Stewart, D. E., F. Wong, A. M. Cheung, J. Dancey, M. Meana, J. I. Cameron, M. P. McAndrews, 
T. Bunston, J. Murphy, and B. Rosen. 2000. “Information needs and decisional preferences 
among women with ovarian cancer.” Gynecologic Oncology 77(3): 357-61. 
 
Stewart, S. L., D. Cooney, S. Hirsch, L. Westervelt, T. B. Richards, S. H. Rim, and C. C. 
Thomas. 2014. “Effect of Gynecologic Oncologist Availability on Ovarian Cancer Mortality.” 
World J Obstet Gynecol 3(2): 6. 
 
Stewart, S. L., S. H. Rim, and T. B. Richards. 2011. “Gynecologic oncologists and ovarian 
cancer treatment: avenues for improved survival.” J Womens Health (Larchmt) 20(9): 1257-60. 
 
Stricker, C. T. and M. O'Brien. 2014. “Implementing the commission on cancer standards for 
survivorship care plans.” Clinical Journal of Oncology Nursing 18 Suppl: 15-22. 
 
Stypulkowski, K., S. Uppaluri, and S. Waisbren. 2015. “Telemedicine for postoperative visits at 
the Minneapolis VA Medical Center. Results of a needs assessment study.” Minnesota Medicine 
98(2): 34-6. 
 
Su, S. C., N. Kanarek, M. G. Fox, A. Guseynova, S. Crow, and S. Piantadosi. 2010. “Spatial 
analyses identify the geographic source of patients at a National Cancer Institute Comprehensive 
Cancer Center.” Clinical Cancer Research 16(3): 1065-72. 
 
Sun, C. C., D. C. Bodurka, C. B. Weaver, R. Rasu, J. K. Wolf, M. W. Bevers, J. A. Smith, J. T. 
Wharton, and E. B. Rubenstein. 2005. “Rankings and symptom assessments of side effects from 
chemotherapy: insights from experienced patients with ovarian cancer.” Support Care Cancer 
13(4): 219-27. 
 
Taplin, S. H., R. Anhang Price, H. M. Edwards, M. K. Foster, E. S. Breslau, V. Chollette, I. 
Prabhu Das, S. B. Clauser, M. L. Fennell, and J. Zapka. 2012. “Introduction: Understanding and 
influencing multilevel factors across the cancer care continuum.” Journal of the National Cancer 
Institute. Monographs 2012(44): 2-10. 
 
 170 
 
Taplin, S. H., S. Weaver, V. Chollette, L. B. Marks, A. Jacobs, G. Schiff, C. T. Stricker, S. S. 
Bruinooge, and E. Salas. 2015. “Teams and teamwork during a cancer diagnosis: 
interdependency within and between teams.” Journal of Oncology Practice 11(3): 231-8. 
 
Tariman, J. D., D. L. Berry, B. Cochrane, A. Doorenbos, and K. Schepp. 2010. “Preferred and 
actual participation roles during health care decision making in persons with cancer: a systematic 
review.” Annals of Oncology 21(6): 1145-51. 
 
Terplan, M., N. Schluterman, E. J. McNamara, J. K. Tracy, and S. M. Temkin. 2012. “Have 
racial disparities in ovarian cancer increased over time? An analysis of SEER data.” Gynecologic 
Oncology 125(1): 19-24. 
 
Terplan, M., E. J. Smith, and S. M. Temkin. 2009. “Race in ovarian cancer treatment and 
survival: a systematic review with meta-analysis.” Cancer Causes and Control 20(7): 1139-50. 
Terplan, M., S. Temkin, A. Tergas, and E. Lengyel. 2008. “Does equal treatment yield equal 
outcomes? The impact of race on survival in epithelial ovarian cancer.” Gynecologic Oncology 
111(2): 173-8. 
 
Tew, W. P. and G. F. Fleming. 2015. “Treatment of ovarian cancer in the older woman.” 
Gynecologic Oncology 136(1): 136-42. 
 
Tew, W. P., H. B. Muss, G. G. Kimmick, V. E. Von Gruenigen, and S. M. Lichtman. 2014. 
“Breast and ovarian cancer in the older woman.” Journal of Clinical Oncology 32(24): 2553-61. 
 
Thewes, B., P. Butow, R. Zachariae, S. Christensen, S. Simard, and C. Gotay. 2012. “Fear of 
cancer recurrence: a systematic literature review of self-report measures.” Psycho-Oncology 
21(6): 571-87. 
 
Thorne, S., J. L. Oliffe, and K. I. Stajduhar. 2013. “Communicating shared decision-making: 
cancer patient perspectives.” Patient Education and Counseling 90(3): 291-6. 
 
Thrall, M. M., H. J. Gray, R. G. Symons, N. S. Weiss, D. R. Flum, and B. A. Goff. 2011. 
“Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.” 
Gynecologic Oncology 122(1): 100-6. 
 
U.S. Cancer Statistics Working Group (USCS). 2015. “United States Cancer Statistics: 1999-
2012 Incidence and Mortality Web-based Report.” U.S. Department of Health and Human 
Services, Centers for Disease Control and Prevention, and National Cancer Institute. Atlanta, 
GA. [accessed on January 5, 2016].  Available at http://www.cdc.gov/uscs.  
 
Vergote, I., F. Amant, G. Kristensen, T. Ehlen, N. S. Reed, and A. Casado. 2011. “Primary 
surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced 
ovarian cancer.” European Journal of Cancer 47 Suppl 3: S88-92. 
 
 171 
 
Vernooij, F., P. Heintz, E. Witteveen, and Y. van der Graaf. 2007. “The outcomes of ovarian 
cancer treatment are better when provided by gynecologic oncologists and in specialized 
hospitals: a systematic review.” Gynecologic Oncology 105(3): 801-12. 
 
Vonlanthen, R., K. Slankamenac, S. Breitenstein, M. A. Puhan, M. K. Muller, D. Hahnloser, D. 
Hauri, R. Graf, and P. A. Clavien. 2011. “The impact of complications on costs of major surgical 
procedures: a cost analysis of 1200 patients.” Annals of Surgery 254(6): 907-13. 
 
Weber, J. J., D. C. Mascarenhas, L. S. Bellin, R. E. Raab, and J. H. Wong. 2012. “Patient 
navigation and the quality of breast cancer care: an analysis of the breast cancer care quality 
indicators.” Annals of Surgical Oncology 19(10): 3251-6. 
 
Weir, H. K., T. D. Thompson, A. Soman, B. Moller, and S. Leadbetter. 2015a. “The past, 
present, and future of cancer incidence in the United States: 1975 through 2020.” Cancer 
121(11): 1827-37. 
 
Weir, H. K., T. D. Thompson, A. Soman, B. Moller, S. Leadbetter, and M. C. White. 2015b. 
“Meeting the Healthy People 2020 Objectives to Reduce Cancer Mortality.” Preventing Chronic 
Disease 12: E104. 
 
Wells, K. J., T. A. Battaglia, D. J. Dudley, R. Garcia, A. Greene, E. Calhoun, J. S. Mandelblatt, 
E. D. Paskett, and P. C. Raich. 2008. “Patient navigation: state of the art or is it science?” Cancer 
113(8): 1999-2010. 
 
Williams, R. 2006. “Generalized ordered logit/partial proportional odds models for ordinal 
dependent variables.” Stata Journal 6(1): 58-82. 
 
Wisdom, J. and J. W. Creswell. 2013. "Mixed Methods:  Integrating Quantitative and Qualitative 
Data Collection and Analysis While Studying Patient-Centered Medical Home Models" 
[accessed on July 30, 2015]. Available at 
http://www.pcmh.ahrq.gov/sites/default/files/attachments/MixedMethods_032513comp.pdf. 
 
Woo, Y. L., M. Kyrgiou, A. Bryant, T. Everett, and H. O. Dickinson. 2012. “Centralisation of 
services for gynaecological cancers - a Cochrane systematic review.” Gynecologic Oncology 
126(2): 286-90. 
 
Wooldridge, J. M. 2009. Introductory Econometrics: A Modern Approach Edition 4e: Thomson-
Southwest Publishing. 
 
Yabroff, K. R., J. Lund, D. Kepka, and A. Mariotto. 2011. “Economic burden of cancer in the 
United States: estimates, projections, and future research.” Cancer Epidemiology, Biomarkers 
and Prevention 20(10): 2006-14. 
 
Zhang, W. and J. Creswell. 2013. “The use of "mixing" procedure of mixed methods in health 
services research.” Medical Care 51(8): e51-7. 
 
 172 
 
Ziebland, S., J. Evans, and A. McPherson. 2006. “The choice is yours? How women with 
ovarian cancer make sense of treatment choices.” Patient Education and Counseling 62(3): 361-
7. 
 
